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Abbreviations and symbols 
 
AbD  assay(s) by design (Applied Biosystems, available at 
https://www.store.appliedbiosystems.com) 
AGER  advanced glycosylation end-product-specific receptor (synonym RAGE) 
AoD  assay(s) on demand ( Applie d Biosystems, available at 
https://www.store.appliedbiosystems.com) 
ASP  affected sibling pair 
B7-1  B7-1 antigen 
BAC  bacterial artificial chromosome 
bp.  base pair(s) 
BTNL2 butyrophilin -like 2 (alternative symbol BTL-II) 
°C  degree Celsius 
CARD15 caspase recruitment domain family, member 15 (alternative symbol NOD2) 
CCR2  chemokine (C-C motif) receptor 2 
CD4+ T cells that recognise their specific antigens in association with major 
histocompatibility complex class II molecules 
CD8+ T cells that recognise their specific antigens in association with major 
histocompatibility complex class II molecules 
CD28  CD28 antigen 
CD80  CD80 antigen (B7-1 antigen)  
CEPH  Centre d’Etude du Polymorphisme Humain (cell lines) 
CTLA4 cytotoxic T-lymphocyte-associated protein 4 
DDW  double distilled water 
DNA(s) deoxyribonucleic acid(s) 
dNTP  2’-deoxynucleoside -5’-triphosphate 
DQA1  see HLA-DQA1 
DRA  see HLA-DRA 
DRB1  see HLA-DRB1 
dsDNA double stranded DNA 
e.g.  exempli gratia 
EM  expectation maximisation 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 
HLA-DRA major histocompatibility complex, class II, DR alpha 
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HLA-DRB1 major histocompatibility complex, class II, DR beta 1 
FAMTM 6-carboxyfluorescein 
Fig(s).   figure(s) 
HLA  human leukocyte antigen 
HWE  Hardy-Weinberg-Equilibrium 
i.e.  id est 
IgC  immunoglobulin constant domain 
IgV  immunoglobulin variable domain 
kb  kilo base(s) 
LD  linkage disequilibrium 
LTA  lymphotoxin alpha 
MB  mega base(s) 
MHC  human major histocompatibility complex  
MICA  MHC class I polypeptide-related sequence A 
MICB  MHC class I polypeptide-related sequence B 
µl  microlitre(s) 
mmol  millimole  
NCBI  National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov) 
nmol  nanomole(s) 
NOD  nucleotide oligomerisation domain 
NOTCH4 Notch homolog 4 (Drosophila) 
NPL  nonparametric linkage 
PAR  population attributable risk 
pmol  picomole(s) 
Rn  fluorescent emission of the normalised reporter dye 
RR  familial relative risk 
TAMRA 6-carboxytetramethylrhodamine  
TAP2  transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 
TaqMan®  commercial name for sequence variation detection assay, using 5’? 3’ 
exonuclease activity 
TaqMan® -MGB- commercial name for sequence variation detection assay, using 5’? 3’ 
exonuclease activity and 3’ minor groove binding probes 
TCR T cell receptor  
TDT  transmission disequilibrium test 
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TE  Tris-hydroxymethyl aminomethane buffer 
TET  tetachloro-6-carboxyfluorescein 
THP-1  myelomonocytic cell line 
Tm  melting temperature 
TNFa  tumor necrosis factor alpha (TNF superfamily, member 2) 
TSBP  testis specific basic protein 
SD  standard deviation 
SNP(s) single nucleotide polymorphism(s) 
SPSS  statistical package for the social sciences 
SSPCR sequence specific polymerase cyclic reaction 
STR  short tandem repeat(s) 
VIC®  Applied Biosystems trade name for fluorescent dye 
Yrs  years 
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Amino acid symbols 
 
A Alanine 
C Cysteine 
D Aspartic acid 
E Glutamic acid 
F Phenylalanine 
G Glycine 
H Histidine 
I Isoleucine 
K Lysine 
L Leucine 
M Methionine 
N Asparagine 
P Proline  
Q Glutamine 
R Arginine 
S Serine 
T Threonine 
V Valine 
W Tryptophan 
Y Tyrosine 
 
DNA bases 
 
A Adenine 
G Guanine 
C Cytosine 
T Thymine 
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1. Introduction 
 
1.1. Susceptibility gene finding in complex diseases 
 
Linkage and association studies represent the two major approaches that attempt to determine 
the genetic loci that confer susceptibility to diseases with a complex genetic background. 
Linkage studies attempt to identify the approximate genetic location of a disease trait. 
Association studies provide a method for the fine localisation. Association tests can be 
pedigree or singleton-based. A case-control study is population based and investigates the 
association between a disease trait and genetic markers using data (different genotype 
frequencies) from unrelated patients (singletons) and unrelated controls. Genetic linkage 
analysis tests for co-segregation between a marker (the most common used markers are short 
tandem repeats (STRs) which are often referred to as microsatellites) and a putative disease 
locus. Genotype association is useful to detect the precise location of disease susceptibility 
markers. Such positional candidates are then investigated to characterise their potential 
function in the context of the disease.  
 
1.1.1. Linkage analyses 
 
In complex diseases, linkage analysis tests are performed to detect a co-segregation between a 
marker and a putative disease locus. The traditional lod score approach 1 tests the likelihood 
of reduced recombination between a marker locus and disease gene versus independent 
segregation of the two loci. Generally, highly-polymorphic STRs, whose chromosomal 
locations are known, are genotyped using the polymerase chain reaction with the resulting 
fragments separated electrophoretically according to length. Such microsatellites are 
distributed throughout the genome at around 100kb intervals and the different alleles vary in 
repeat length 2. 
 
Parametric lod score analysis requires a considerable number of large families and a clear 
Mendelian mode of inheritance to be valid  to show genetic linkage. However, in complex 
diseases, pedigrees are generally small and the mode of inheritance tends to be unclear. This 
limitation has led to an emphasis on non-parametric linkage (NPL) analysis methods, which 
do not require the mode of inheritance to be specified. Such analyses determine if allele 
transmission in affected siblings pairs (ASP) deviate from Mendelian expectations 3. A 
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significantly increased level of allele sharing (alleles that are identical by descent) suggests 
the marker is linked to the disease locus 4. Multipoint linkage analysis is performed testing at 
the same time several markers located on the same chromosome. The closer the microsatellite 
is located to the disease gene, the higher LOD score value is expected because of rarer 
recombination. Successful location of linkage depends much on informativity of markers, 
sample size and phenotype complexity 5 
 
1.1.2. Linkage disequilibrium in the MHC and entire human genome  
 
Each new allele that arises by mutation in the sequence is initially associated with the 
particular chromosomal background on which it arose. A set of closely linked alleles (genes 
or DNA polymorphisms) inherited as a unit is called haplotype. Different combinations of 
polymorphisms are known as haplotypes. Coinheritance of haplotypes leads to associations 
between the alleles present on the haplotypes at the population level 6. This phenomenon of 
non-random association between alleles at different but adjacent loci is known as linkage 
disequilibrium (LD) 7. A common measure of LD is the absolute D’ value 8, which is a 
standardization of the LD coefficient D to an index between zero and one corresponding to no 
LD and complete LD respectively. D  is the difference between the observed and the expected 
haplotype frequencies at two diallelelic loci 9. 
 
Investigations of LD suggest that the genome consists of discrete haplotype blocks in which 
there is a little evidence of historical recombination 10-12.LD blocks may extend from a few 
kilobases (kb) to regions greater than 100 kb 13. A useful measure is  the ,,half-length’’ of LD 
(the distance at which the average ¦ D’¦  drops below 0.5). For example, LD in a United 
States population of northern-European has a half-length of about ~60 kb and in a Nigerian 
population extends markedly less far 13.  New haplotypes emerge through novel mutation 
events and through recombination between homologous sites in the paternal and maternal 
chromosomes 6. LD patterns are influenced not only by ,,hot’’ and ,,warm’’ spots of 
recombination but also by selective pressures and demographic events 7, 14, 15 . 
 
Haplotype-based methods offer a powerful approach to disease gene mapping, based on 
association between causal mutations and the ancestral haplotype 11. Newly introduced 
mutations are in LD with the alleles on the ancestral haplotype. Thus, genotyping effort and 
costs might be effectively reduced by genotyping only a small fraction of carefully selected 
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SNPs that tag common haplotypes 10, 16. Further steps would then include a fine mapping 
experiment in the region of strong LD 12. On the other hand, strong association between 
nearby alleles can make identification of the causal variant very difficult. The statistical 
power to detect an allelic association depends on specific properties of each marker, including 
its frequency and population history 10. 
 
The organization of the Human Major Histocompatibility Complex (MHC), which has been 
implicated in many immune disorders, appears to be well conserved. The regions encoding 
the class I and II molecules in most of the cases (~97%) are inherited without 
recombination17. Investigations into MHC evolution suggest that the region is derived from a 
single ancestral gene, which has expanded through serial duplications and has been modified 
by mutations and contracted by deletions. Selection pressures have accompanied all these 
processes 18,530. Although classical human-leukocyte-antigen (HLA) genes in this region 
represent good candidates for immune disorders, linkage disequilibrium makes it difficult to 
rule out the influence of neighbouring genes on disease susceptibility. The few studies that 
have analysed the haplotype structure of the MHC region have suggested that LD variation in 
the MHC, with the exception of the classical HLA  loci 19, is not essentially different from that 
in the rest of the genome 14, 20 -22.  
 
1.1.3. Association studies 
 
The main use of association tests in genetics is to identify genes that possibly influence 
disease susceptibility. Disease association tests are carried out using either a case-control or 
family-based study design.  Single numcleotide polymorphisms (SNPs) are used to localise 
disease susceptibility genes. 
 
Case-control studies use data from unrelated affected individuals and unrelated controls. 
Evidence for a statistically significant association between a marker and the disease is taken 
from a comparison of the genotype ( and thus allele) frequencies in both samples. A major 
limitation with case-control association studies is that an association may arise if cases and 
controls were drawn from genetically different populations even though no disease gene 
association exists. Admixture in populations lead to a potential excess of both false positive 
and false negative associations. The possibility of false associations depends on the 
population sampled, the trait being studied and the marker being tested 23, 24. 
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Family-based association studies use data from within families. Limiting analysis to familial 
genetic information helps to avoid the matching problems experienced in case-control studies. 
Sampling families is generally more difficult than cases and controls, but this methodology is 
still possible in a sarcoidosis study because sarcoidosis typical has an onset in early-adulthood 
and thus both parents of the proband may be available 24. The association test in pedigrees is 
performed measuring distorted transmission of alleles 25. 
 
Sarcoidosis literature is replete with case-control association studies. However, the findings 
often conflict with one another. One potential explanation for inconsistent results is that the 
same phenotype can be caused by damage of different genetic mechanisms 26. Discrepancies 
among studies can also arise due to differing sampling methodologies 24. Ideally, in the 
functional candidate gene approach, associations found through case-control studies should be 
confirmed in family-based studies 27. 
 
1.1.4. Candidate gene analyses 
 
The selection of candidate genes includes a large number of potential factors that are most 
likely to be involved in the phenotype. Knowledge about biology, disease pathophysiology, 
biological plausibility are evaluated. Functional effects of single nucleotide polymorphisms 
(SNPs) on the protein are considered. Multiple SNPs can contribute to association, thus the 
ones with strongest association are identified. Dose effect is evaluated in cases, when numbers 
of variant copies contribute to a greater risk 24, 28. 
 
Information about the location and type of the sequence variants in a gene can be used to 
prioritize polymorphisms 28. Nonsense, missense, splice site mutations, and deletions in the 
coding sequence can affect protein structure. Synonymous changes do not primarily affect the 
protein structure. However, they may influence the mRNA splicing, if the polymorphism is 
located in an exonic splicing enhancer 29, 30. Mutations affecting gene expression levels are 
usually localised in promoter, intronic and intergenic regions. Interpretation of the latter 
mutations is more complex. As polymorphisms are frequent in the human genome 
(approximately 1 in 1,000 bp), it is important to select carefully a limited number of SNPs to 
genotype from the set that is often available in a particular candidate gene28, 31. 
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Replication of association is another critical aspect. Inconsistency of results between 
different studies and different populations might point to the need for more studies in certain 
populations or more detailed study of the function of a candidate gene 28. However, 
population diversity may also be a reason of lack of replication 32 (e.g. CARD15 is associated 
with Crohn’s disease in European population, but not in Asians) 26 
 
1.2. Sarcoidosis 
 
1.2.1. The disease 
 
Sarcoidosis is a systemic inflammatory disease of unknown aetiology, characterized by T-
lymphocyte and mononuclear phagocyte infiltration leading to granuloma formation 33, 34. The 
hallmark of the disease is the presence of noncaseating granulomas in affected organs. These 
granulomas can occur with varying rates in any organ system, but most commonly are found 
in the lung and lymph nodes 33. A range of 30-60% of reported cases of sarcoidosis are 
asymptomatic and have been discovered by the presence of characteristic findings on routine 
health screening chest radiographs 35-37. For symptomatic patients, the most common 
problems include respiratory symptoms e.g. dry cough, dyspnea, chest pain and systemic 
symptoms e.g. fever, night-sweats, fatigue and malaise. The characteristic granuloma found in 
sarcoidosis is discrete and compact, composed of multinucleated giant cells, mononuclear 
phagocytes and lymphocytes surrounded by tightly organized fibroblasts, mast cells and an 
extracellular matrix 38. The finding of noncaseating granulomas in biopsy specimens requires 
the presence of correlating clinical symptoms consistent with sarcoidosis and the exclusion of 
alternative diseases like tuberculosis to establish confidently the diagnosis. 
 
Clinical presentation of the disorder varies widely, with two main phenotypes: acute and 
chronic sarcoidosis. Acute sarcoidosis resolves within two to three years, often disappearing 
spontaneously and leaving no residual effects. A subset of acute patients exhibit Löfgren’s 
syndrome, which is chacterised by a combination of fever, bilateral hilar lymphadenopathy, 
erythema nodosum and arthritis, often at the ankle joints. Approximately one-quarter of 
sarcoidosis patients have permanent lung damage because of scarring, and some may suffer 
from chronic sarcoidosis. In about five percent of patients, the damage from sarcoidosis 
progresses enough that organ transplantation (such as lungs, heart, liver) is required or death 
occurs 39-42.  
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Despite of evidence suggesting that sarcoidosis results from a complex interaction of multiple 
genes with environmental exposures or infection, no specific aetiologic agent has yet been 
identified. Disease presentation in certain seasons supports the idea of an infective trigger, 
possibly microbial in origin. The initiating agent responsible for sarcoidosis is likely to be 
airborn since the lungs are the most commonly affected organ in this complex disease 43, 44.  
The seasonal peak occurs during spring 45. Investigations of bacteria (e.g. mycobacteria), 
viruses (e.g. herpes, Epstein -Barr, retrovirus, cytomegalovirus) and environmental organic 
(e.g. pine tree pollen, clay) or inorganic (e.g. aluminium, zirconium, talc) antigens have not 
consistently demonstrated an association with sarcoidosis 46-50. 
 
Many individuals with sarcoidosis are characterised as asymptomatic. Therefore, estimates of 
the reported prevalence may depend on the way in which the epidemiological data is 
generated. The reported prevalence varies significantly by sex, racial group, and country. 
Nevertheless, sarcoidosis appears to be one of the most frequent interstitial lung diseases 51.  
There are up to 64 patients per 100,000 individuals in Sweden to 9 per 100,000 in Italy. 
Intermediate numbers are observed in Denmark (53 per 100,000), Germany (43), Ireland (40), 
Norway (27), UK (20) and France (9). Within the United States, the prevalence for the 
Caucasian population of North America is 3 and for Afro-Americans 47 per 100,000 34, 52.  
Sarcoidosis is found in all races, affecting slightly more females than males. It most 
commonly affects individuals aged 20 to 40 years. Initial presentation of sarcoidosis is also 
related to race- African-Americans are at greater risk of morbidity and mortality 36, 53. 
 
1.2.2. Familial aggregation of sarcoidosis 
 
Numerous reports on the familiar occurrence of sarcoidosis suggest a genetic component to 
disease predisposition 54, 55. Data from a nationwide chest radiography screening program 
indicated a recurrent risk in siblings of affected patients of approximately one in 100, which is 
20 times higher than the prevalence rate of sarcoidosis in Germany 56. A familial relative risk 
observed in American whites (RR=18.0) was markedly higher compared with African-
American (RR=2.8) cases 54. Monozygotic twins are 2-4 times more concordant for disease 
than dizygotic twins 57. From these studies, it is clear, that family members have a several-
fold increased risk of disease compared with the general population. The familial sarcoidosis 
studies clearly exclude a simple mode of inheritance, suggesting a more complex genetic 
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background. Genetic mechanisms such as single gene effects with greatly reduced 
penetrance, polygenic inheritance or a multifactorial background with interactions between 
genetic make-up and environmental agents could be characteristic features of sarcoidosis 58.  
 
1.2.3. Sarcoidosis and other hereditary granulomatous disorders 
 
Sarcoidosis demonstrates remarkable overlap with other chronic inflammatory disorders. Blau 
syndrome and Crohn’s disease are complex disorders that show overlap with sarcoidosis in 
the spectrum of involved organs and their immunopathophysiology. 
 
Enhanced immune response to a yet unknown target with monocyte and T-cell activation and 
granuloma formation in affected tissues are characteristic features of both sarcoidosis and 
Crohn’s disorders 33, 34, 59. Although the primary sites of inflammation differ (lung in 
sarcoidosis and intestine in Crohn’s disease), affection of skin, joints and other organs is 
common in both disorders. Coincidence of sarcoidosis and Crohn’s disease in families or even 
in one individual is more common than expected by chance alone 42. 
 
Blau syndrome demonstrates clinical similarities with sarcoidosis. The disease is 
characterised by granulomatous arthritis, uveitis and erythema 60. Blau syndrome is caused by 
a single dominant gene mutation and has onset in early childhood. Based on clinical 
similarities with saroidosis, Blau syndrome might be a monogenic early -onset variant of 
sarcoidosis.  
 
1.2.4. Sarcoidosis linkage studies 
 
In order to localize sarcoidosis susceptibility genes, several linkage studies and many 
association studies have been performed in different populations. A linkage study of seven 
polymorphisms spanning the MHC region in 55 German sarcoidosis families gave an 
estimated maximum NPL score of >2.5 for the entire MHC region, with a maximum value of 
3.2 at marker locus D6S1666 (panel A of fig.1) 61(see NPL definition in chapter 1.1.1). Later, 
a detailed genome-wide linkage study of 63 German sarcoidosis families with 225 
microsatellite markers identified seven peaks of linkage evidence located on six 
chromosomes. The most prominent peak was still located on chromosome 6 at the 
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microsatellite marker D6S1666 with an NPL score of 2.99 (p=0.0001) (panel B of fig.1). 
Other minor peaks (p<0.05) were found on chromosomes 1, 3, 7, 9 and X 58.  
 
Fig.1. Chromosome 6 multipoint NPL results. 
A. Chromosome 6p multipoint NPL results based on 55 German sarcoidosis families. 
B. Multipoint NPL results of the entire chromosome 6 based on 63 German families with 
siblings suffering from sarcoidosis. 
A. and B. as published by M.Schurmann et al., in 200061 and 200158. In both figures x-axis: 
microsatellite markers; y-axis: NPL score. 
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located 3.9Mb centromeric from the marker D6S1666 which was implicated as indicating a 
susceptibility region in German families. 
 
1.2.5. Human Major Histocompatibility Complex 
 
The human Major Histocompatibility Complex (MHC) is located on chromosome 6p21 and is 
composed of three classes: (see fig.2) MHC class I, II and III. MHC class I mainly includes 
the HLA-A, HLA-B and HLA-C genes, MHC class II contains the HLA-DR, HLA-DQ  and 
HLA-DP subclasses. The primary immune relevant genes in the MHC class III region (located 
between the class I and class II regions) encode TNF-alpha , TNF-beta, the complement 
proteins (C4A, C4B, C2 and Bf), enzymes involved in steroid synthesis (CYP21A and 
CYP21B) and heat-shock proteins (HSPA1A; HSPA1B and HSPA1L) 63.  
 
Fig.2. The Major histocompatibility complex (published by 63). Upper panel: classification of 
the region into three classes. Lower panel: HLA gene content in every subclass. 
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The products of the Human Leucocyte Antigen (HLA) genes play a fundamental role in the 
regulation of immune processes by antigen presentation to T cells. The HLA genes and their 
products are grouped into two classes according to their chemical structure and biological 
properties. Class I molecules contain one heavy chain (45 kD) and a light chain called ß2-
microglobulin (12 kD) that contributes to the overall structure of the protein. Class II 
molecules do not contain ß2-microglobulin and consist of two (alpha and ß) chains of similar 
size (34 and 30 kD). Both classes differ according to their peptide-binding groove, which 
accommodates 8-9 amino acids in class I but is open-ended in class II. MHC class I molecules 
present endogenously amplified antigens, e.g. viral proteins, to CD8+ T-cells. MHC class II 
molecules present exogenously derived proteins, e.g. bacterial products or viral capsid 
proteins, to CD4+ T cells. However, if the immune mechanism malfunctions and T-cells react 
against “self”-peptides, an autoimmune disease may arise. MHC class I molecules are widely 
expressed, although the level varies between different cell types. MHC class II molecules are 
constitutively expressed only by certain cells involved in immune responses, though they can 
be induced in a wider variety of cells. All HLA  alleles are expressed co-dominantly. In about 
97% of individuals, the entire MHC haplotype is inherited without recombination. Each HLA 
gene has an unusual number of alleles (for instance HLA-DRB1 gene has over 200 different 
alleles) caused by high levels of polymorphism in the region.176, 177 
 
1.2.6. Sarcoidosis associations with HLA genes 
 
Many HLA genes have been tested for association with sarcoidosis; investigating the theory 
that disease-associated HLA molecules present specific antigenic peptides in such a way that 
the recognizing T-lymphocytes initiate an inflammatory response with peculiar pathological 
consequences 64. Originally, associations with sarcoidosis were attributed to the MHC-I 
alleles. A positive association between HLA-B7 and HLA-B13 was found in Moravian 
Czechs 65. However, the HLA-B7 was significantly decreased in Japanese patients 66. 
 
Recently, many studies have concentrated on MHC-II typing sustaining the hypothesis that 
sarcoidosis is triggered by exogenous antigene. HLA-DR allele typing have provided 
comprehensive results for numerous populations, although reports of risk alleles were 
conflicting. HLA-DR5, HLA-DR8 and HLA-DR9 were risk alleles in Japanese 66-68. HLA-
DR5 has been found significantly associated with chronic form of sarcoidosis in Germans 69, 
70. HLA-DR3 was associated with acute disease in Germans and Scandinavians, whilst the 
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chronic form in Scandinavians was associated with HLA-DR14 and HLA-DR15 69-72. A 
study in Asian Indians reported two risk alleles: HLA-DRB*11 and HLA-DRB1*14 73.  
Recently, significant association with HLA-DRB1*1101 alleles was found in American 
blacks and whites 74. More consistent results were achieved when evaluating ,,protective’’ 
HLA-DRB alleles in different populations. The HLA-DR alleles, which encode DR1 and DR4 
antigens, which share characteristic small hydrophobic residues at amino acid position 11, 
were negatively associated with Scandinavian, Japanese, British, Polish and Czech sarcoidosis 
cases 72. In this study, a previously reported association between sarcoidosis and single 
nucleotide polymorphisms of the TAP2 gene 75 was shown to be probably due to linkage 
disequilibrium with the HLA-DR locus. 
 
HLA-DQ locus analysis has provided fewer significant alleles. HLA-DQA1 0101/4 was 
significantly associated with sarcoidosis in Asian Indians 73. Alleles of the more centromeric 
gene HLA-DQB1*0201 and HLA-DQB1*0602 were over-transmitted in African-American 
sarcoidosis families 76. However, the HLA-DQB1*0201 was strongly ,,protective’’ against 
severe sarcoidosis in British, Dutch and Asian Indian patients, whereas HLA-DQB1*0602 
was associated with disease 73, 77. HLA-DQB1*0503 has been found associated with disease 
in Asian Indians. 
 
Despite only few reports about the HLA-DP locus, the HLA-DPB1  gene is interesting because 
of its association with berylliosis (a phenocopy of sarcoidosis characterised by accumulation 
of beryllium-specific CD4+ T lymphocytes). An allele-association study indicated that a 
glutamine located at position 69 of DPB1 confers susceptibility to chronic beryllium disease 
78. The immunopathologic and clinical similarities between chronic beryllium disease and 
sarcoidosis suggest that similar immune-response genes may be involved in susceptibility to 
both diseases. H owever, no association was found with the Glu69+ allele in sarcoidosis 
patients from the US 79 and from Europe 61, 75. Further HLA-DPB1 amino acids, Val36+ and 
Asp55+, which are involved in antigen binding have been shown to be significantly 
associated with sarcoidosis risk in African-American cases79. 
 
1.2.7. Autoimmune and chronic inflammatory disease mapping to the human MHC 
 
Numerous studies have indicated a role for the peri-MHC in susceptibility to chronic 
inflammatory and autoimmune diseases. Most studies have focused on the allelic variants of 
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the HLA genes, as the products of these genes are primarily involved in immune processes. 
Autoimmune responses involve T-cells, which respond to a particular MHC genotype-
dependent antigen. Thus, the associations are supported by the hypothesis that susceptibility 
to autoimmune disease could be caused by certain HLA allelic variants through their 
presentation of auto-antigenic peptides to autoreactive T-cells. However, there are many other 
inflammatory response related genes in the MHC region (for gene content in the peri-MHC 
region see fig.3), which have not been tested for disease association. Therefore, the MHC 
region is still one of the main targets for association studies for autoimmune disorders. 
  
22 
Fig.3. Gene content in peri-MHC region (published by 80) 
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Linkage and association studies on chromosome 6p have been performed on patients with 
inflammatory bowel disease 81, psoriasis 82, systemic lupus erythematosus 83, insuline-
dependent diabetes 84, rheumatoid arthritis 85 and multiple sclerosis 86. All these studies 
indicated the presence of genetic factors located in the MHC.  
 
Many association studies have investigated non-HLA genes as well that map to the MHC. 
However, association results obtained fr om investigations of Caucasian sub-populations or 
different populations often do not overlap or are even contradictory. Thus, in only a few 
successful studies an initial association between a typical HLA gene and a disease been 
excluded by finding a nearby locus possessing a causative mutation. Mutations in the 
CYP21A2  gene were found in patients suffering from congenital adrenal hyperplasia 87, 88.  
Defects of the HFE gene were assigned to the iron storage disorder referred as hereditary 
haemochromatosis 89. Sequence variants in the lymphotoxin-alpha (LTA) gene were indicated 
as risk factors for myocardial infarction 90. 
 
1.2.8. Sarcoidosis candidate genes in the entire genome 
 
Numerous reports have implicated angiotensin-converting enzyme (ACE) in the 
pathophysiology of sarcoidosis. The gene has a 300bp insertion/deletion (I/D) polymorphism, 
which influences serum ACE levels. ID and DD genotypes were found to be associated with 
the disease in several studies 91-93. However, in later studies no co-segregation was found with 
familial sarcoidosis 94 and no associations with the various sub-phenotypes of the disease was 
detected in a case-control study in two European populations95. Therefore, it seems that ACE 
polymorphisms do not represent a major hereditary cause of the disease, but rather, they 
modify the course of the disorder 94. 
 
The inflammatory response in sarcoidosis is characterised by an increased production of 
several pro-inflammatory cytokines and chemokines at the sites of disease 34. Therefore, it is 
plausible that polymorphisms in these genes may contribute to differences in the regulation of 
cytokine release 96. In sarcoidosis major mediators are released by both T-lymphocytes (IL-2, 
IFN-gamma, LT) and alveolar macrophages (IL -1beta, IL -12, TNF-alpha). Tumor necrosis 
factor –alpha (TNFa) is thought to play a key role as a mediator of inflammation and cellular 
response. TNFa production is increased in the sarcoid lung and its role in the formation of 
granulomas has been widely studied 97-99. Biallelic polymorphisms at position -308 in the 
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promoter region of the TNFa gene and in the first intron of the LTA gene have been 
associated with variation in TNFa production and with susceptibility to infectious and 
autoimmune diseases 98. Association studies on genetic polymorphisms in promoter region 
have raised the possibility that this cytokine might influence the predisposition or severity of 
sarcoidosis 70, 98. Except for a higher allele frequency of a rare TNFa allele found in patients 
suffering from acute sarcoidosis, other studies have not found significant association of either 
polymorphism with sarcoidosis 98, 100. Among the chemokines, many association studies have 
focused on gene polymorphisms in CC chemokine receptor 2 (CCR2) and CC chemokine 
receptor 5 (CCR5) because the products of these genes are expressed on the surface of CD4+ 
T cells. The CCR2 valine to isoleucine substitution at amino acid position 64 appears to have 
a protective effect 101, whereas the 32 bp deletion in the promoter of the CCR5  gene increases 
susceptibility to sarcoidosis 102. A haplotype study indicated that variations in the CCR2 gene 
are associated with different sarcoidosis phenotypes 103.  
 
Clinical similarities between Blau syndrome, Crohn’s disease and sarcoidosis suggest the 
presence of shared susceptibility genes. Linkage on chromosome 16 has been established for 
both Blau syndrome and Crohn’s disease 104-107. Later, several independent association studies 
have demonstrated that distinct alleles of the CARD15  gene contribute to susceptibility for 
Crohn’s disease 108-110. The CARD15  gene resides on the long arm of chromosome 16 
(16q12). The protein is composed of two caspase recruitment domains (CARD), a nucleotide 
oligomerisation domain (NOD) and a stretch of leucine rich repeats (LRR). The putative 
function of the CARD15 protein also contributes to the hypothesis of shared susceptibility 
genes. CARD15 may be involved in activation of the nuclear regulatory factor kappa B 
(NFkB) pathway, which is activated after stimulation with microbial lipopolysaccharides. 
High NFkB activity is characteristic feature of both disorders 111, 112. Furthermore, mutations 
in the CARD15  gene could influence the regulation of immune cell apoptosis 113.  
 
Blau syndrome mutations were found in the NOD domain of the CARD15, while mutations 
associated with Crohn’s disease are located in the LRR region. Thus, alterations in different 
regions of the gene could cause or contribute to different granulomatous disorders. 
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1.3. Aims of the study 
 
1. Identification of HLA-independent susceptibility marker for sarcoidosis in the chromosome 
6 linkage region. 
 
2.  Evaluation of CARD15  as a candidate gene for sarcoidosis. 
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2. Materials and methods 
 
2.1. Materials and equipment 
 
Table 1. Part 1: materials 
Material Manufacturer/Supplier, Country 
100bp DNA ladder Invitrogen, Karlsruhe, Germany 
2.2 ml storage plate (96 well) ABgene, Epsom, UK 
384 deep well storage plate ABgene, Epsom, UK 
Agarose Eurogentec; Köln, Germany 
Taq® DNA polymerase Qiagen, Hilden, Germany 
AmpliTaq® Gold DNA polymerase Applied Biosystems; Darmstadt, Germany 
Bacilol® Bode Chemie, Hamburg, Germany 
BigDye Terminator Ready reaction kit Applied Biosystems, Darmstadt, Germany 
Bromphenol blue Sigma, München, Germany 
dNTP set (100mM solutions- each 100µM) Amersham Biosciences; Freiburg, Germany  
Ethanol  Merk; Darmstadt, Germany 
Ethidium bromide solution (10mg/ml) Invitrogen; Karlsruhe, Germany  
GeenAmp PCR buffer system (10x buffer 
w/o MgCl2; 25mM MgCl2) 
Applied Biosystems, Darmstadt, Germany 
Invisorb Blood Giga Kit Invitek; Berlin, Germany 
MgCl2 Merck; Darmstadt, Germany 
MicroAmp®optical 96-well reaction plate  Applied Biosystems, Darmstadt, Germany 
MicroAmp®single strips  Applied Biosystems, Darmstadt, Germany 
MicroAmp® single tubes Applied Biosystems, Darmstadt, Germany 
Microtiter 384-well plates Sarstedt; Nürnberg, Germany 
Microtiter 384-well plates Greiner Bio -One GmbH, Frickenhausen, 
Germany 
Microtiter 96-well plates Sarstedt; Nürnberg, Germany 
Microtiter 96-well plates Costar Corning Incorporated; Cambridge, 
MA, USA 
Microtiter plates, 96 well, round bottom with 
lid 
Sarstedt; Nürnberg, Germany 
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Table 1. Part 2: materials 
Material Manufacturer/Supplier, Country 
PicoGreen® Molecular Probes Europe BV; Leiden, The 
Netherlands 
Pipette (serological, sterile with filter 
5/10/25ml) 
Sarstedt; Nümbrecht, Germany 
Pipette tips with filter (10/200/1,000µl) Sarstedt; Nürnberg, Germany 
SAP shrimp alkaline phosphatase Amersham Biosciences; Freiburg, Germany 
Sephadex powder (G50 superfine) Amersham Biosciences; Freiburg, Germany 
Sepahdex spin column plates MAHVN 4550 Amersham Biosciences; Freiburg, Germany 
SmartLadder DNA marker Eurogentec; Köln, Germany 
TAE Buffer 25x ready pack Amresco; Solon, OH, USA 
TaqMan® Universal PCR Master Mix Applied Biosystems; Darmstadt, Germany 
TBE Buffer 10x ready pack Amresco; Solon, OH,USA  
Tubes (0.5 / 1.5 / 2.0 ml) Eppendorf; Köln, Germany 
Tubes (0.5 / 1.5 / 2.0 ml) Eppendorf; Köln, Germany 
Tubes, flat bottom (60 ml)  Sarstedt; Nümbrecht, Germany 
Tubes, sterile (15 ml) Sarstedt; Nümbrecht, Germany 
Tubes, sterile (50 ml) BD Biosciences; Heidelberg, Germany 
Xylene Cyanol FF Sigma; München, Germany 
 
  
28 
Table 2. Equipment  
Equipment Manufacturer/Supplier, Country 
10/100/300/1000 µl single/multi-channel 
pipettes 
Eppendorf; Hamburg, Germany 
7900HT Sequence Detection Systems Applied Biosystems; Darmstadt, Germany 
ABI PRISM®7700 Sequence Detector Applied Biosystems; Darmstadt, Germany 
Biometra® T Gradient Whatman Biometra GmbH; Göttingen, Germany 
Biometra® T1 Termocycler Whatman Biometra GmbH; Göttingen, Germany 
GeneAmp®PCR system 9700 Applied Biosystems; Darmstadt, Germany 
Gibco BRL Electrophoresis Power Supply™ 
250 EX 
BioRad; München, Germany 
Gibco BRL Horizontal Gel Electrophoresis 
Apparatus™ 
BioRad; München, Germany 
Heraeus Kelvitron®t Kendro; Hanau, Germany 
Heraeus Labofuge 400 Kendro, Hanau, Germany 
High Performance Ultraviolet 
Transilluminator 
VWR; Hamburg, Germany 
Horizontal Electrophoresis Apparatus BioRad; München, Germany 
Hydra™384 Robbins Scientific® Dunn Labortechnik GmbH; Asbah, Germany 
Hydra™96 Robbins Scientific® Dunn Labortechnik GmbH; Asbah, Germany 
Platesealer ALPS-300 Abgene, Epsom, UK 
Power Pack 300 Electrophoresis Power 
Supply 
BioRad; München, Germany 
TECAN Genesis RSP 150 Tecan Deutschland GmbH; Crailsheim, 
Germany 
TECAN GENESIS Workstation 150 Tecan Deutschland GmbH; Crailsheim, 
Germany 
TECAN GENESIS Workstation 200 Tecan Deutschland GmbH; Crailsheim, 
Germany 
TECAN Spectrafluor Plus Tecan Deutschland GmbH; Crailsheim, 
Germany 
Vortex-GENIE 2® G-560E Scientific Industries, Inc., Bohemia, N.Y., USA 
 
 
  
29 
2.2. Electronic data bases 
 
Applied Biosystems http://www.appliedbiosystems.com/ 
BLAST http://www.ncbi.nlm.nih.gov/BLAST/ 
Celera Discovery Systems http://www.celera.com/ 
dbSNP http://www.ncbi.nlm.nih.gov/SNP/index.html 
Gene Cards  http://bioinfo.weizmann.ac.il/cards/ 
HLA database http://www.ebi.ac.uk/imgt/hla/align.html 
Locus Link http://www.ncbi.nlm.nih.gov/LocusLink/ 
MAP viewer http://www.ncbi.nlm.nih.gov/mapview/ 
NCBI http://www.ncbi.nlm.nih.gov/ 
PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed 
Repeat Masker http://repeatmasker.genome.washington.edu/cgi-bin/RepeatMasker 
UCSC Genome Browser http://genome.ucsc.edu/ 
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2.3. Participants 
 
2.3.1. Sarcoidosis population for the chromosome 6 association study 
 
Sarcoidosis patients and close relatives were contacted between years 1996 and 2003 through 
specialised hospitals and general practitioners, or through the German sarcoidosis patient 
organisation (Deutsche Sarkoidose-Vereinigung e. V., www.sarkoidose.de). Others were 
enrolled after calls for participation in the study that were forwarded by health insurance 
institutions. Diagnoses were made on the basis of the International Consensus Statement on 
Sarcoidosis 33, 114. Patients from sarcoidosis families were interviewed by telephone about 
their individual and familial sarcoidosis history. All patients (families and single affected 
patients) completed a questionnaire about the course of their disease. Physicians were 
contacted to confirm the diagnosis, and the presence of sarcoidosis was additionally verified 
by biopsy in 78% of cases from the “exploratory” sample, 90% of patients from the 
“extension” sample, and in 88% of patients from the “replication” sample. For the remainder, 
the clinical course and the radiology and laboratory data were regarded as sufficiently 
consistent with the diagnosis of sarcoidosis 114. 
 
Observed sarcoidosis phenotypes were grouped into ten classes in the entire sample presented 
in this study (for detailed sarcoidosis phenotype classification and description see supplement 
information 9.1.2.). 31% of all affected individuals had an acute form of sarcoidosis (mainly 
with Loefgren syndrome) and 61% were classified as chronic patients. Both acute and chronic 
patients had involvement of the lung.  
 
All patients were of German origin. All participants gave written informed consent for 
participation in the study. The protocols were approved in writing by the institutional ethics 
and data protection authorities. An overview of the patient samples is given in table 3.  
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Table 3. Sarcoiodosis sample for the chromosome 6 association mapping study. Upper 
part: non-overlapping categories of sampling units (families, trios, singleton cases); lower 
part: summary of case/patient numbers. The total number of independent cases equals the sum 
of the sampling units in the upper part. The experiments performed in different combinations 
of patient samples are depicted in the lower part of the table. 
 
 Patient sample 
Sampling unit exploratory extension replication  Full 
Affected sib pairs 
(ASP) – 2 sibs 
 
70 
 
9 
 
10 
 
89 
ASP – 3 sibs 8 -- -- 8 
Complex families 11 5 -- 16 
Trios (complete) 153 72 203 428 
Trios (one parent 
missing) 
10 79 62 151 
Single patients 13 65 177 255 
Total number of  
independent cases 
265 230 452 947 
Total number of 
patients 
(male/female) 
372 (163/209)  248 (123/125) 462 (175/287) 1082 (461/621) 
Average age at 
diagnosis (SD) in 
years 
34.7 (10.3)  37.2 (11.4) 37.3 (11.3) 36.4 (11.1) 
Experiment Initial SNP screen    
 SNP fine mapping Replication  
    Differentiation 
of DRB1 -
BTNL2  effects 
 
 
2.3.2. Control group individuals 
 
A group of 517 age- and sex-matched healthy blood donors of German origin were included 
as control group in the association analysis. 
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2.3.3. Sequencing patients for association mapping experiment on chromosome 6  
 
Only for a minority of sequence variations annotated in databases, SNP allele frequency is 
indicated. Even more, part of annotated SNPs derive from mismatches by comparing 
sequences of overlapping clones. Such mismatches can arise due to mutations introduced in 
the clone sequence so that the variation in reality does not exist as an SNP. In regions where 
no SNPs in databases are annotated but for a higher density of a map more SNPs are needed, 
variations can be detected trough resequencing of genomic DNA. For all these reasons, 
resequencing of genomic DNA of 47 unrelated individuals was used. To not overlook specific 
sequence variations that could be the disease causing mutations and thus have a very low 
frequency in sample of healthy individuals, sarcoidosis patients have been chosen. 
 
2.3.4. CARD15 gene analysis samples 
 
The CARD15 gene was investigated in the following two sarcoidosis populations: i) families 
with two or more members suffering from sarcoidosis (henceforth referred to as "sarcoidosis 
families"), ii) unrelated sarcoidosis patients without a family history of sarcoidosis, together 
with their healthy parents (henceforth referred to as ,,sarcoidosis trios’’). For the case-control 
analysis, a sample of healthy control individuals was used. The complete families panel 
comprised 302 patients (135 males, 137 females; average age at inclusion (mean±SD) 
51±13.1 yrs, average age at diagnosis 35±11.3 yrs, range 12-73 yrs) and 153 close relatives 
without sarcoidosis (64 males, 89 females). The trios sample consisted of 127 patients (49 
males, 78 males; average age at inclusion 34±6.8 yrs, average age at diagnosis 33±6.9 yrs, 
range 11-51 yrs) and 254 parents without sarcoidosis. The control groups comprised 265 
healthy German Caucasian blood donors recruited through the Dept of Trasnfusion Medicine 
at the Kiel University Hospital, Kiel, Germany (118 males, 147 females: average age at 
inclusion 51±8,2 yrs). 
 
The sample of 138 German families of Caucasian origin included 66 families with two or 
three affected sibling pairs, 41 families with affected parent-offspring pairs, 19 families with 
two more distantly related patients and 12 families with a more complex structure involving 
more than two patients. The sarcoidosis trio sample comprised 127 spontaneous cases with 
unaffected parents. (see the detailed CARD15 study family sample information in 9.1.3.). All 
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CARD15 study patients were a subset of the chromosome 6 association mapping study 
sample. 
 
2.4. DNA samples 
 
2.4.1. Isolation of genomic DNA from blood 
 
Genomic DNA was extracted using a slightly optimised Invisorb®Blood Giga Kit for DNA 
isolation (Invitek, Germany). 10ml of whole blood were incubated with 30ml of cold Buffer I 
for 10 minutes at a room temperature to achieve lysis of erythrocytes and centrifuged at 3000 
rpm for 3 minutes. After the supernatant was carefully removed, the procedure was repeated 
with 20ml of Buffer I to achieve a better purification of leucocytes from erythrocytes. The 
cells were centrifuged at 3000 rpm for 3 minutes. The cell pellet containing leucocytes should 
be white, if this was not the case then the second step was repeated. The pellet was then 
resuspended in 3ml of Buffer II and 50µl of Proteinase K and incubated overnight in a 60°C 
water bath with continuous shaking. During this step, the reagents lyse the leucocytes and the 
DNA becomes free from nuclei. For protein lyses, 1,8ml of Buffer III was added, the mix was 
vigorously shaken and incubated on ice for 5 minutes. After incubation, the mix was 
centrifuged for 15 minutes at 5000rpm. The cleared supernatant was transferred into a 15ml 
centrifuge tube. For the precipitation of the genomic DNA, 10ml of 96% Ethanol was added 
and the tube was carefully inverted several times. The precipitated DNA was collected w ith a 
pipette tip and transferred into 2ml eppendorf tubes containing 1 ml of 70% ethanol. The 
DNA pellet was rinsed with ethanol, vortexed and then centrifuged at 13000rpm for 2 
minutes. In cases where no DNA pellet was present, patients were contacted for an additional 
blood sample. After the rinsing step, the ethanol was removed by pipette and samples were 
dried for 10 minutes at a room temperature. The purified genomic DNA was resuspended in 
500µl of 1xTE buffer and stored at +4°C for a short time or at -20°C for longer periods.  
 
2.4.2. Plates for genotyping with TaqMan assays 
 
The DNA samples for di-allelic genotyping were arrayed into 96- and 384-well format plates. 
Every 96 well plate contained not more than 92 DNA samples leaving the rest of space for 
controls. Complete families were included in the same plate. There were at least two wells 
with CEPH (Centre d’Etude du Polymorphisme Humain, Paris, France) cell line samples in 
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each plate as positive amplification controls. One to four wells were left empty for a 
negative amplification control. Every 96 well plate received a unique identifier and was 
entered into the laboratory data base system. 384 well format plates were designed by 
arraying four 96 well plates. A barcode system has been implemented for the identification of 
each individual plate. Samples were pipetted into 96 and 384 deep-well plates (Abgene, 
Epsom, UK) and the DNA concentration adjusted through two steps of dilution to 10ng/µ and 
0,5ng/µl using a TECAN Genesis RSP 150 multipipetting robot (Tecan Deutschland GmbH; 
Crailsheim, Germany). The aliquots of DNA (5µl of 0,5ng/µl DNA-TE aliquot) were 
distributed via either a 96- or 384-channel Robbins Scientific Hydra microdispener into the 
96-well and 384-well plates (Costar Corning Incorporated; Cambridge MA, USA, Greiner 
Bio-one GmbH; Frickenhausen, Germany) and dried at 60°C (~2 hours). Dry DNA plates 
were covered with Plate Sealer (AB Gene, Hamburg, Germany ) and stored at room 
temperature until use. 
 
2.4.3. HLA-DRB1 typing plate design 
 
Standard 96-well format dry DNA plates with sarcoidosis patients and control sample DNA 
(as described in the chapter above) were used for genotyping the multiallelic marker HLA-
DRB1. Additional DNA samples with known HLA-DRB1  genotypes were used as positive 
controls for typing of HLA alleles (see table 4). 
 
1µl of the 2.5ng/µl positive control DNA was pipetted into two empty (no-template) positions 
on each 96-well plate. Amplification of a positive DNA sample precluded false interpretation 
of amplification results: i) if both positive controls were successfully amplified but no patient 
was amplified, then the plate was still recorded as working; ii) if positive amplification was 
achieved in patients but not in both controls then the plate was discarded, since the result 
could be obtained from mixed-up primers. Allele -groups 6 and 7 had ambiguous positive 
DNAs ( DRB1*03,*09 for amplification group 6 and DRB1*03,*10 for amplification group 
7) because the alleles DRB1*09 and *10 are rare there was little likelihood that homozyotes 
would be observed. Results of these two amplification groups were accepted based on a 
comparison of the number of positive amplifications in the plate and the expected population 
allele frequency. Contamination with DNA carrying the frequent HLA-DRB1*03 allele or 
usage of amplification group 3 primers by mistake, would have given up to a 20 times higher 
frequency of positive amplification. Consistency of CEPH (positive controls for TaqMan 
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assays) final genotypes in all plates was checked after all allele -groups were amplified and 
final genotypes were defined.  
 
The remaining no-template wells served as controls of negative amplification for the PCR 
reagents. 
 
Table 4. Known HLA-DRB1 genotypes of patients used as positive controls for 
amplification of HLA-DRB1 allele-groups 1 to 7. Positive DNA: patient DNA with known 
genotype used as positive control for respective HLA-DRB1  allele-group. 
 
HLA-DRB1 
allele 
amplification 
group 
HLA-DRB1  alleles amplified by corresponding 
allele group 
Positive DNA 
genotypes 
1 DRB1*01 DRB1*01 
2 DRB1*15,*16 DRB1*15,*16 
3 DRB1 *03,*08,*11(not *1122/30),*12,*13,*14 
(not *1410/39) 
DRB1*08,*12 
4 DRB1*04,*1122,*1410 DRB1*04 
5 DRB1*07 DRB1*07 
6 DRB1*09 DRB1*03,*09 
7 DRB1*10 DRB1*03,*10 
 
2.5. Di-allelic genotyping 
 
To determine the genotype at known SNPs, di-allelic genotyping was performed using a 
TaqMan 5’ nuclease fluorogenic assay 115. An oligonucleotide probe that is specific for the 
target (SNP) to be amplified is labeled with the fluorescent reporter dyes FAM™, VIC® or 
TET at the 5’end and a quenching molecule TAMRA at the 3’ end. During the extension step 
of a PCR the AmpliTaq Gold® polymerase digests the probe bound to the target and separates 
the fluorescent tag from its quencher molecule thus permitting fluorescence. Consequently, 
the fluorescence signal(s) generated by PCR amplification indicate(s) the alleles that are 
present in the sample (see fig.4). 
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-Fig. 4. Schematic view of TaqMan® assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluorescence results of diallelic genotyping were visualized using laser scanning technology 
(ABI Prism® 7700 Sequence Detection System for 96-well format plates or ABI 
Prism®7900HT Sequence Detection System for 384-well format plates). The laser light is 
targeted into 96 or 384 wells via a multiplexed array of optical fibres. The fluorescent 
emission returns via the fibres and is directed to a spectrograph with a charge-coupled device 
camera. Possible results of allelic discrimination are as following: i) TET (VIC® for 
TaqMan® -MGB assays) fluorescence only for allele 1 homozygosity, ii) FAM™ 
fluorescence only for allele 2 homozygosity, ii) both fluorescent signals for heterozygosity.  
 
Diallelic genotyping of individuals plated on 96-well and 384-well plates was performed 
using TaqMan® and TaqMan®-MGB assays. The TaqMan®-MGB probe 116 is an alternative 
probe for TaqMan® (demonstrated in fig.4). These probes differ in the following features: i) 
there is a non-fluorescent quencher attached to the 3’end, which allows the fluor escence of the 
reporter dye to be measured more precisely against a lower background fluorescence, ii) the 
3’ end has a minor groove binder (MGB) ,which increases the melting temperature of the 
probes and thus permits shorter probes. Short probes exhibit greater differences in annealing 
temperature values between matched and mismatched probes. That feature provides a higher 
quality of allelic discrimination.  
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2.5.1. Di-allelic assay design and genotyping  
 
TaqMan® and TaqMan®-MGB assays were utilised for the genotyping of SNPs in a panel of 
sarcoidosis and control DNAs. Some pre-optimised assays for allelic discrimination were 
available from the ABI company (Assay-on-Demand, Assay-by-Design, Applied Biosystems 
Inc., Foster City, CA, USA) and from laboratory resources built up for other projects 117, 118.  
Several assays in more complicated sequence regions were self-designed by hand as 
TaqMan® -MGB assays.  
 
To design a TaqMan®-MGB assay the genomic region of interest has to be analysed in detail. 
It is essential that the target region be first analysed for repetitive elements 
(http://repeatmasker.genome.washington.edu/cgi-bin/RepeatMasker). Probes can only be 
designed for a unique sequence with one SNP. The sequence should contain no repetitive 
elements or additional SNPs. Non-repetitive sequence is not obligatory, but is certainly 
desirable for primers. The presence of other SNPs is not permitted at the primer binding sites. 
If the sequence had many repetitive elements and the positioning of bot h primers on unique 
sequence was not possible, at least one of the primers was positioned on non-repetitive 
sequence (for detailed sequencing and mutation detection description, see chapter 2.7.). 
 
TaqMan® -MGB diallelic assays were designed using the software Primer Express 2.0 
(Applied Biosystems Inc., Foster City, CA, USA). Probes and primers were designed 
according to the criteria of the supplier. Accordingly, the melting temperature of the probe 
must be 7°C higher than the primer melting temperature and range between 65°C and 67°C. 
The melting temperatures of both probes have to be as close as possible with a maximum 
difference of 1°C. The C and G nucleotide content should be 20-80%. The probe must be 13 
to 20 base pairs in length and contain less than four contiguous G nucleotides. The total 
number of G nucleotides should not exceed the number of C nucleotides in the probe. The 
probe must not have a G at the 5’ end. The polymorphism has to be located in the interval 
between the middle and 3’ end of the probe, but not at the last 2 nucleotides. The primers 
were designed to match the probes. The primer sequence was selected to as to meet the 
criterion of a 7°C lower Tm difference than the probe. The Tm interval therefore was between 
58°C and 60°C with a less then 2°C difference between the two primers. The CG content 
ranged between 30% and 80% with a maximum of 2 out of 5 C nucleotides at the 3’ end. 
Primers with high nucleotide variation at the 3’end were preferred. Primer length varied 
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between 9 and 40 base pairs. The amplicon length varied between 50 and 150bp. The 3’ 
end of the forward primer (located on the same strand as the probe) had to be positioned as 
close to the probe as possible, but without overlapping. As the reverse primer only amplifies 
the target sequence, this may overlap with the probe (but not with the SNP). If the assay 
design did not meet the described conditions the complement strand was examined to 
facilitate the best choice of assay. 
 
A special design was applied to the measurement of  sequence variation at the BTNL2_M286I 
site. The target SNP was flanked by another two SNPs and hence a standard probe could not 
be designed. Therefore, a special four probe combination was chosen. For each allele at the 
target SNP two FAM and two VIC labelled probes were designed such that each allele at an 
adjacent SNP would be targeted by both FAM and VIC probes and have no impact on the 
discrimination at the target SNP (see fig.5).  
 
Fig.5. TaqMan® assay using four-probe combination. Two probes labelled with FAM™ 
had a T nucleotide at the BTNL2_M286I variation site, but both C and T nucleotides at 
another variation site located eight nucleotides upstream. The same was applied for the probes 
labelled with VIC® fluorescentic dye. 
 
 
 
 
 
 
 
 
 
Self-designed TaqMan®-MGB assays were optimised for annealing temperature. The 
experiment was performed on 96-well plates with 2.5ng control sample DNA. Two annealing 
temperatures were tested: 60°C and 62°C (for standard cycling protocol, see next page). 
Supplied probes and primers were adjusted to 100µM storage concentration with double 
distilled water. Working dilutions were 10µM for probes and 20µM for primers. The final 
reaction mixture volume was 5µl and contained 200nmol of each probe and 900nmol of each 
primer. 2.5µl of 2-times TaqMan® Universal MasterMix (Applied Biosystems Inc., Foster 
City, CA, USA) and DDW were added into reaction up to the 5µl final volume. The 
Termocycler GeneAmp®PCR System 9700 (Applied Biosystems Inc., Foster City, CA, USA) 
GAAGAGCA GCTGCATTTCTCACCCATC
A
C
T
C ATC
T
G
BTNL2_M286I
FAM™-CATCTGAAGAGCATATC
VIC®-CATCTGAAGAGCACATC
VIC®-ATCCGAAGAGCACATC
FAM™-ATCCGAAGAGCATATC
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was employed for TaqMan®-MGB assay optimisation. Standard cycling conditions with 
alternative annealing temperatures were applied. After cycling, plates were visualised in the 
ABI Prism®7700 Sequence Detector (Applied Biosystems Inc., Foster City, CA, USA). The 
assay had to meet the following quality criteria. For diallelic assays, only a maximum of 3 
clouds of dots corresponding to the 3 different genotypes (two homozygotes and one 
heterozygote) was satisfactory. One additional cloud located at the cross of the x- and y-axis 
had to contain only no-template control samples (represented as genotype “0/0” - see fig.6). 
The observed genotypes of the positive controls (the CEPH cell line DNA) had to be the same 
across all plates genotyped for that assay. Missing genotype data was not allowed to exceed 
5% of the sample. The genotype frequency distributions in the independent control samples 
had to satisfy Hardy-Weinberg Equilibrium. 
 
Fig.6. Schematic representation of fluorescent measurement of TaqMan® assay. The assay 
measures fluorescence of biallelic variations. A maximum of three genotype clouds and one 
negative control cloud are detectable in the view. 
 
 
 
 
 
 
 
 
 
 
96 and 384 platforms were employed for the genotyping of all diallelic SNPs in the 
sarcoidosis sample and the healthy controls. The PCR reaction mastermix was prepared for at 
least one plate. For the 96-well reactions, primers and probes were mixed with the 2.5µl 2-
times concentrated TaqMan® Universal PCR Master Mix (Applied Biosystems; Darmstadt, 
Germany) and diluted w ith DDW to achieve a 5µl reaction volume. Optimal final 
concentrations for primers and probes in all assays of this study varied from 50nmol to 
900nmol and from 100nmol to 200nmol respectively (see supplement 9.1.5.). The mix was 
applied to the plates containing 2.5ng dried DNA. The amplification step was performed in 
the GeneAmp®PCR system 9700 (Applied Biosystems Inc., Foster City, CA, USA). The 
thermal cycle had the following profile: a 2min hold step for optimal AmpErase uracil-
FAM
TET
1/1
1/2
2/20/0
Legend
0/0- negative controls and 
unidentified genotypes
1/1 homozygote for allele 1
1/2  heterozygote
2/2 homozygote for allele 2 
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N.glycosylase activity followed by a 10min hold step at 95°C for AmpliTaq Gold DNA 
Polymerase activation (both are components of the TaqMan® Universal PCR Master Mix). 
This was followed by 45 PCR cycles consisting of a denaturation step at 95°C for 15sec and 
then a 1min annealing step at the optimal temperature (which ranges between 58°C and 64°C 
-see supplement 9.1.5). The plates were read in the 7900HT Sequence Detection System 
(Applied Biosystems; Darmstadt, Germany). The resulting fluorescence was analysed using 
an integrated software to manually call the genotypes on each plate. Plates were repeated or 
the assay was excluded from analysis, if the performance rate was lower than 95%. Other 
quality criteria were the same as applied for the assay optimisation. 
 
For higher automation, a 384-well platform was employed. Reaction mix was applied to the 
plates with the aid of The TECAN GENESIS Workstation 150 (Tecan Deutschland GmbH; 
Crailsheim, Germany) and thermal cycling was performed in Biometra® T1 Termocyclers 
(Whatman Biometra GmbH; Göttingen, Germany). Fluorescence was evaluated in the ABI 
PRISM®7700 Sequence Detector (Applied Biosystems; Darmstadt, Germany).  
 
The resulting genotype scoring was integrated into an internal data base and linked with the 
patient information (i.e., pedigree information, patient identification number, gender and 
affection status). 
 
2.5.2. SNP selection for chromosome 6 mapping 
 
The interval for association mapping on chromosome 6 was selected based on the linkage 
result in the genome scan 58. Defined by a decrease in LOD score by 1.5 units or less, this 
interval represented an approximate 99% confidence region for linkage. 69 biallelic markers 
for the initial screening of the region were selected largely from the ,,peri-HLA SNP set’’ that 
was previously evaluated for association studies on chromosome 6 117. The SNP set covered 
the target region located at 27.80 – 44.14 Mb (NCBI release 32) on chromosome 6. 
 
2.5.3. Typing of the CARD15 gene 
 
In total, 1101 individuals were genotyped for the three Crohn’s disease associated CARD15 
polymorphisms: SNP8 (2104C>T; R702W; nomenclature according to ref.119), SNP12 
(2722G>C; G908R), SNP13 (3020insC; 1007fs) and SNP5 (802C>T; P268S) were selected as 
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the susceptibility haplotype tagging SNP. Furthermore, SNP5 is located in exon 4 of the 
CARD15 gene, the exon where the mutations causing Blau syndrome reside. The TaqMan™ 
system was used for the genotyping. In this thesis, the rarer alleles of these polymorphisms 
are annotated as allele 1. For detailed primer and probe information see supplement 9.1.4., 
and for genotyping conditions supplement 9.1.5.  
 
2.6. Multi-allelic genotyping  
 
2.6.1. The Problem of multi-allelic genotyping 
 
Current HLA genotyping methodologies include group-specific PCR 120, genomic or cDNA 
sequencing 121 , and hybridisation 122 methods, employed either individually or in combination. 
The standard methods of SNP genotyping for non-HLA loci, for example the TaqMan™ 
system, face significant problems in highly polymorphic regions such as the informative HLA 
molecule exon sequences. There is an extremely high density of SNPs in the HLA region, 
which makes probe and primer design very difficult. This high diversity is further 
complicated by a complex haplotype structure that makes successful allele resolution, even 
with multiple probes, impossible. The standard techniques require a universal and stable 
underlying PCR. For many HLA loci, the design of such primers is impossible, because either 
undesirable co-amplification of pseudogenes or lack of amplification of the relevant alleles at 
the locus of interest occurs. 
 
The DRB1 locus has all these – from a genotyping point of view – undesirable characteristics. 
123, 124. (HLA Database at www.ebi.ac.uk/imgt/hla ). Therefore, an appropriate method that 
genotype this multi-allelic locus had to be employed. 
 
2.6.2. Genotyping of HLA-DRB1 by allele -group PCR 
 
High resolution typing of specific HLA-DRB1  alleles was not required in our situation, 
because we were interested in tagging of “risk haplotypes” and differentiation of the genetic 
effect from the BTNL2  gene. Therefore, a system of non-overlapping allele groups was 
exploited in order to amplify the basic alleles of the DRB1 gene. 
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Primers for the detection of the seven major DRB1 allele groups were adopted from 
published reports 125, 126 and are listed in table 5. Specific HLA-DRB1  alleles were merged into 
allele groups: DRB1*01 (allele-group 1); DRB1*15,*16 (2); DRB1 *03,*08,*11(not 
*1122/30),*12,*13,*14 (not *1410/39) (3), DRB1*04,*1122,*1410 (4), DRB1*07 (5), 
DRB1*09 (6) and DRB1*10 (7) (see table 5). 
 
Table 5. Primers used for the amplification of HLA-DRB1 allele groups. Allele group-
specific primers were adapted according to ref 127, 128. Specific seven forward primers and one 
common reverse primer 5’ -CCGCTGCACTGTGAAGCTCT-3’ were used for all 
amplifications 129. Primers were selected for use in a Caucasian sample. Certain rare DRB1 
alleles will not be amplified with these primers, but their combined frequencies are below 
0.05% and thus not relevant for the application needed in this context.  
 
Amplification 
group 
Primer DRB1  alleles detected 
1 5’-TTCTTGTGGSAGCTTAAGTT-3’ DRB1*01 
2 5’-TTCCTGTGGCAGCCTAAGAGG-3’ DRB1*15, *16 
3 5’-CACGTTTCTTGGAGTACTCTAB-3’ DRB1*03, *08, *11( not 
*1122/30), *12, *13, *14 (not 
*1410/39) 
4 5’-GTTTCTTGGAGCAGGTTAAAC-3’ DRB1*04, *1122, *1410 
5 5’-CCTGTGGCAGGGTAARTATA-3’ DRB1*07 
6 5’-CCCAACCACGTTTCTTGA-3’ DRB1*09 
7 5’-AGACCACGTTTCTTGGAGG-3’ DRB1*10 
 
To acheive optimal PCR conditions, MgCl2 (1,0;1,5;2,0;2,5;3.0;3,5;4,0µl) and Taq 
polymerase (0,02;0,03;0,06;0,09;0,12µl) concentrations were titrated for all seven PCR 
reactions. PCR optimisation was performed in a 25µl reaction mixture. In each case, optimal 
PCR conditions were established using a panel of human DNAs of known genotype taken 
from the German HLA quality control panel. These DNAs were used in all allele -group 
amplification experiments as a quality controls for positive amplification (for control DNA 
panel see table 4).  
 
All allele-group genotyping reactions were carried out in 10µl reaction mixtures with 
1µl(10x) buffer, 0.2mM dNTPs (each), 0.2µM primer (each) and the MgCl2 and Taq 
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polymerase concentrations listed in table 6. All reactions employed AmpliTaq Gold® with 
Gene Amp, Applied Biosystems, USA. 
 
Table 6 .PCR conditions used for DRB1 allele-group amplifica tion. Optimal MgCl2 and Taq 
DNA polymerase concentrations varied between amplification groups. 
 
Amplification 
group 
MgCl2 
mM 
Taq DNA 
polymerase 
U/µl 
1 2 0.024 
2 2 0.030 
3 3.5 0.036 
4 2 0.024 
5 2 0.018 
6 3 0.036 
7 2 0.036 
 
Touchdown PCR programs wer e used for all primer pairs (performed with the GeneAmp PCR 
System 9700, Applied Biosystems, USA). Optimal annealing temperatures for each primer 
pair were identified via a temperature gradient (employing a Biometra® T Gradient, 
Whatman Biometra GmbH; Göttingen, Germany). Optimal annealing temperatures was 
identified through inspection of the intensity of the amplicon bands when visualised on 1.5% 
agarose gel (Agarose, Eurogentec; Köln, Germany). Electrophoresis conditions were 30min at 
110V. The PCR cycle conditions used for the genotyping of the entire sarcoidosis sample and 
controls are listed in table 7. 
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Table 7. PCR temperature profiles used for DRB1 allele-group amplification.  
 
Allele-amplification group  
7 1/3 6 2/4/5 
Time Number 
of cycles 
Process 
95°C 95°C 95°C 95°C 12 min  Hot start 
95°C 95°C 95°C 95°C 30 sec Denaturation 
56°C 61°C 63°C 65°C 30 sec 
(touchdown -
0.5°C ) 
Annealing 
72°C 72°C 72°C 72°C 30 sec 
 
 
16 
Extention 
95°C 95°C 95°C 95°C 30 sec Denaturation 
48°C 53°C 55°C 57°C 30 sec Annealing 
72°C 72°C 72°C 72°C 30 sec 
 
19 
Extention 
10°C 10°C 10°C 10°C Pause  Hold 
 
2.6.3. Development of a non-electrophoretic method for high-throughput DRB1  allele-
group identification  
 
The majority of methods for the visualisation of HLA allele amplification products employ an 
electrophoretic approach. However, this technique does not scale well in a high throughput 
setting. Thus, for the characterisation of PCR products a non-electrophoretic method was 
adapted. The method was previously described for genotyping a G/A transition in the p53 
proto-oncogene of Chinook salmon 125. The methodology is based on ability of the fluorescent 
dye PicoGreen® (Molecular Probes Europe BV; Leiden, The Netherlands) to bind 
specifically to dsDNA and thus to identify amplified product by its increased fluorescence.    
 
Initially, the validity of the non-electrophoretic measurement assay was tested by comparing 
PicoGreen® measurement results with those obtained by agarose gel assay. One 96-well 
format plate with ninety individuals was genotyped for all seven allele groups. 5µl of the PCR 
products were visualised on an agarose gel stained with ethidium bromide (1.5% agarose gel 
(Agarose, Eurogentec; Köln, Germany); electrophoresis conditions were 30min at 110V). 
Another 5µl of PCR products were incubated with PicoGreen® and the fluorescence was 
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measured. Results of both methods coincided for all ninety samples through all seven 
amplification groups. 
 
Five microliters of PCR product were transferred into 96 well plates (Microtiter plates, 96 
well, round bottom with lid, Sarstedt; Nürnberg, Germany) containing 45µl of PicoGreen® 
diluted 1:400 with 1xTE buffer. The plates were vortexed, incubated for 5 min, and then read 
in a TECAN Spectrafluor plus Fluorometer (TECAN, Männedorf, Switzerland) with 
excitation wavelength 485nm. The raw data files were exported for each plate separately.  
 
PCR plates were read in a TECAN Spectrafluor plus (Tecan Deutschland GmbH; Crailsheim, 
Germany), which generated “device-specific artificial units”. Analysis of raw data was 
performed in Microsoft Excel®. Measurements were automatically arranged based on signal 
intensity. A clear, sudden increase in intensity in the ,,positive’’ samples (samples that contain 
the amplified allele) corresponded to the dsDNA of a PCR product (see fig. 7).  
 
Fig.7. Fluorescence reading of a 96-well plate for the amplification group 1. The y-axis 
denotes the signal intensity of the fluorescence measurement of the TECAN Spectrafluor plus 
in device-specific artificial units. Based on the signal intensity, measurements 1 to 96 of a 96-
well plate are ordered on the x-axis. The positions of the positive and negative controls on the 
graphic are denoted with solid and open arrows, respectively.  
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In this example, samples that had a fluorescence more than 600 units were assigned as  
,,positives’’ ,i.e., containing that allele. The ,,negative’’ samples contained only original DNA 
that was not amplified, because the allele was not present in their genotype. In this example, 
all samples that had fluorescence lower than 400 fluorescence units where assigned as 
,,negatives’’. Negative amplification of blank controls , a positive signal in control DNA wells  
and clear peak of ,,positive’’ samples were basic quality criteria. 
 
For the analysis of raw fluorescence a specialised software was created (available from 
http://www.mucosa.de/neu/index_bioinformatics.html.). The software allows manual entering 
of cut-off values for the scoring of each PCR reaction. Negative, unknown and positive cut-
offs were defined based on the signal intensity of the allele -specific positive and negative 
controls included in each plate as described previously. Where the signal intensity did not 
allow assignment of the result to either a positive or negative amplification, the sample was 
marked as unknown.  
 
After all seven PCRs were performed and cut-offs for ,,positive’’ and ,,negative’’ samples 
were defined, final genotypes were assigned by software (see fig.8). In this example, the 
sample located at the position A1 has the genotype ,,3/5’’. This result comes from positive 
amplifications in the amplification groups 3 and 5 and negative amplifications in groups 
1,2,4,6 and 7.  
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Fig.8. Screenshot of the "DRB tool" software. The software displays the final composite 
genotypes for a 96-well plate. Discrepancies that occur during the verification of Mendelian 
inheritance, positions of positive and negative controls are highlighted automatically in red.  
 
 
 
Finally, the data was tested for inconsistencies (e.g. false positive amplifications creating the 
final ,,genotype’’ with three or more chromosomes) and Mendelian segregation (possible only 
in pedigrees). The software facilitated import of the data into the laboratory information 
system 130. 
 
This method was applied to the entire sarcoidosis sample and the healthy unrelated 
individuals. A genotyping success rate of 94.11% was achieved. Genotyping failure was 
recorded in situations where signal intensities could not be clearly assigned either to the 
positive or negative groups. A percentage of 1.3 of the data had to be discarded from the 
family data due to violations of Mendelian inheritance within the families. This error rate 
compares favorably to other genotyping methodologies, for example Matise et al. 131 reported 
recently a 1.6% error rate for SNP data. The analysis of genotype and allele frequencies in the 
DRB1 allele-group genotyping data revealed no departures from Hardy-Weinberg-
Equilibrium. 
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2.7. SNP verification and mutation detection 
 
The successful design of TaqMan™ assays for an association study requires detailed analysis 
of the DNA sequence in a set of individuals. This typically consists of a gene content analysis 
in the region and a search for annotated sequence variations in the genomic sequence data 
bases (in http://www.celera.com/; http://genome.ucsc.edu/ and 
http://www.ncbi.nlm.nih.gov/SNP/index.html ). Known SNPs may then have to be 
validated and/or patient DNA screened for novel polymorphisms. 
 
2.7.1. SNP selection 
 
SNP selection criteria depend on the aims of the study. The purpose of screening the 
chromosome 6 linkage region with biallelic markers was to identify the association region. 
16.34Mb of linkage region were screened with 69 SNPs from the marker set developed for 
identification of disease-susceptibility genes located in the peri-HLA region 117 (for marker 
set see table 8). The average density of the markers in the screening region was one per 
240kb. The highest marker density was achieved in the linkage peak region (e.g. four SNPs 
were located in the TNFa promoter region), whereas more distant regions had lower marker 
density (e.g the maximal distance was between markers rs943461 and rs755658 located at 
33.77 Mb and 35.55Mb respectively).  
 
The 69 used assays for the I stage chromosome 6 screen were already optimised and typed on 
at least two 96 well plates with unrelated individuals from control sample for assay quality 
validation and Hardy-Weinberg equilibrium testing (Hardy-Weinberg equilibrium was re-
estimated later in the entire sample of controls). Two candidate association regions were 
identified, one at MICB-IkBL (demonstrating only case-control association) and one at 
BTNL2 -DRA (demonstrating consistent results in both TDT and case-controls analyses). 
These loci were analysed for gene content and sequence variation. A set of pre-available 
Assays -on-Demand and Assays -by-Design ( both from Applied Biosystems Inc., Foster City, 
CA, USA) was checked for available markers covering the both regions  and adding one 
flanking gene upstream and downstream: MICA-TNFa  (rs1063635-rs1799964) and AGER-
DQA1 (rs1035798-rs707952). A high density map was established at the AGER-DQA1 locus 
by selecting 48 markers covering 440kb ( 32.177Mb to 32.616Mb in NCBI release 32). 
Because of the complex patterns of haplotype structure and high sequence variation in the 
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HLA region, densely located biallelic markers were established in the genomic sequence 
between the AGER  (rs2070600) and HLA-DRA (rs2395182).  The average distance between 
these 47 markers in that region was 5.6kb. Distance to the las t marker of the high-density LD 
map, HLA-DQA1  (rs707952), varies according to individual HLA haplotype structure.  
 
In addition to pre-available Assays-on-Demand and Assays-by-Design (Applied Biosystems 
Inc., Foster City, CA, USA), additional SNPs were established through de novo mutation 
detection and through verification of annotated sequence variations. A targeted SNP search 
was performed on the candidate BTNL2  gene and the flanking intergenic sequences, where a 
higher density of markers was required. Non-synonymous SNPs found in the BTNL2 coding 
sequence had a priority. In cases where only synonymous or non-coding polymorphisms were 
found, SNPs with a higher frequency and therefore informativity were selected for the further 
typing. 
 
SNP markers were genotyped in the CARD15 gene, a candidate gene for sarcoidosis 
association. Selection of these markers was based on the association findings in Crohn’s 
disease. The CARD15 sequence variations in the NOD domain, which is responsible for Blau 
syndrome, were investigated by sequencing 47 sarcoidosis DNA samples.  
 
2.7.2. Primer design and PCR 
 
The primers for mutation detection were designed for sequencing the exons and flanking 
intronic sequences in candidate genes, known SNP verification or searching for new SNPs in 
intergenic regions at loci of interest. Primers for exonic sequences were generally located in 
introns, covering the exon itself, splice site and 20-50bp of intronic sequence. Typically, 
amplicon length was 500-700bp. For longer exons, overlapping primer pairs were designed. 
Both chromosomes were always sequenced to avoid sequencing artefacts and verify the SNP 
on both the forward and the reverse strand. Primers were designed using the Primer Express 
2.0 software (Applied Biosystems Inc., Foster City, CA, USA). If the program has failed to 
find optimal primers automatically, the oligonuleotide sequences were selected manually and 
tested for self-annealing loops and dimers. 
 
PCR optimisation was carried out according to manufacturer’s protocols (Qiagen GmbH; 
Hilden, Germany). Primers were diluted with DDW to a storage concentration of 100pmol/µl 
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and a working concentration of 20pmol/µl. The reaction solution contained the following 
reagents: 2.5µl Qiagen Buffer (10x), 0.5µl MgCl2 (25mmol), 0.5µl dNTP (10mmol each), 
0.25 forward primer (20pmol/µl), 0.25 reverse primer (20pmol/µl), 0.2µl Taq polymerase 
(Qiagen GmbH; Hilden, Germany) and DDW to a final volume of 25.0µl per reaction. 2.5ng 
dried or liquid human DNA was amplified. MgCl2 was titrated for problematic amplifications. 
The reaction solution was set up for 13 reactions (of which 12 were used) and pipetted into 
the MicroAmp®single strips (Applied Biosystems, Darmstadt, Germany) or Microtiter 96-
well plates (for testing up to eight primer pairs) (Costar Corning Incorporated; Cambridge, 
MA, USA) in the T1 Gradient (Whatman Biometra GmbH; Göttingen, Germany). An 
annealing temperature gradient was used to select the optimum annealing temperature for 
each primer pair. A two step touchdown program was employed with denaturation at 95°C for 
10 min followed by 16 cycles of denaturation at 95°C for 30 sec, annealing at 66°C (the 
middle annealing temperature of the gradient; reduced by 0,5°C with every following cycle) 
for 30 sec, and extension at 72°C for 30 min . This was continued by 19 cycles of denaturation 
at 95°C for 30 sec, annealing at 58°C (the middle annealing temperature of the gradient) for 
30 sec, extension at 72°C for 30 sec and final extension at 72°C for 10 min. The gradient 
covered annealing temperatures 5°C lower and higher than the given conditions. 5µl of PCR 
amplification product together with 5µl of 2-times loading buffer (0.25% bromphenol blue, 
0.25% Xylene Cyanol FF, 30% Glycerol in Water) were loaded into a 2% agarose gel (300ml 
TBE (Tris borate EDTA), 3µl ethidium-bromide). A 100bp ladder (Invitrogen, GmbH; 
Karlsruhe, Germany) was run to size the PCR products. PCR products were run at 150V for 
50 min. The gel was analysed under UV light. A single clear band of expected size and only a 
low amount of primer-dimer indicated optimal PCR conditions. As necessary, optimisation 
was repeated with either a modified PCR mix (MgCl2 concentration gradient ranging from 
0.5µl to 3.0µl per reaction) or modified cycle conditions ( changing annealing temperature). 
 
2.7.3. Sequencing  
 
For SNP identification, DNA from mutation detection patients (see chapter 2.3.3. for patient 
information) was amplified using the reaction conditions optimal for each primer-pair. The 
reaction was performed in the GeneAmp®PCR system 9700 (Applied Biosystems; 
Darmstadt, Germany) and visualized on a 2% agarose gel as described in the chapter 2.7.2. 
The criteria for the PCR quality were a single band of amplified product with a low amount of 
primer-dimer, a low number of failed reactions in the patient samples and no visible 
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amplification in the blank control well. Following PCR an enzymatic digestion step 
removed primer-dimers and free dNTPs from the samples. If the band on the gel was very 
intense, the amplified PCR product was diluted with the DDW (1:5). For weak bands, the 
original PCR product was used. The digestion reaction contained 0.30µl SAP (Shrimp 
Alkaline Phosphatase; 1U/µl), 0.15µl ExoI (Exonuclease I; 10U/µl) and 1,55µl DDW mixed 
with 8µl of PCR product (either concentrated or diluted) and was transferred to a new plate. 
The samples were incubated for 15min at 37°C followed by 15min at 72°C. Sequencing was 
performed using BigDye™ chemistry (BigDye Terminator Kit, Applied Biosystems, USA) 
according to the manufacturer’s protocol. Next, in a separate plate, 2µl of the digested product 
was mixed with 1.0µl forward primer (1.6pmol/µl), 1.0µl of Big Dye Ready Reaction Mix 
and 6.0µl DDW. The same reaction was prepared with the reverse primer. The samples were 
incubated at 95°C for 5min followed by 25 cycles at 95°C for 1min, 50°C for 45sec and 60°C 
for 4 min. The thermal cycle was completed with a 5min extension at 60°C. After sequencing, 
samples were purified using Sephadex spin columns. The Sephadex powder (G50 Superfine; 
Amersham Biosciences; Freiburg, Germany) was measured with a 96 well format Multiscreen 
Column loader and applied to special filter plates (MAHVN 4550). 300µl of DDW were 
added into each well. The filter column plates were then incubated for ~3 hours at a room 
temperature followed by centrifugation at 910xg for 5min to eliminate excess water. The 
columns were then washed with 150µl of DDW and again centrifuged at 910xg for 5min. 
Finally, the sequencing product was mixed with 20µl of water and applied to the columns. 
The plate was centrifuged at 910xg for 5min the purified sequencing product collected in a 
MicroAmp® Optical 96-Well Reaction Plate (Applied Biosystems Inc., Foster City, CA, 
USA). Sequence detection was performed with an automated, high-throughput, 96-capillary 
fluorescence detection system ABI PRISM®3700DNA Analyzer (Applied Biosystems Inc., 
Foster City, CA, USA ). The sequences of both strands were analysed and compared to the 
consensus sequence using the Sequencher program (Version 4.0.5. Gene Codes Corporation, 
Ann Arbor, MI, USA). 
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2.7.4. SNP verification and mutation detection in the association region and in 
sarcoidosis candidate genes 
 
2.7.4.1. The BTNL2 locus on chromosome 6 
 
Taking the consistency of the TDT, case-control results and significa nce levels into account, a 
~15kb region at the 3-prime end of the BTNL2 gene (from marker hCV2488476 to 
hCV2488463) yielded results two to three orders of magnitude more significant than the other 
regions. The BTNL2  gene is located within the linkage region and within the associated region 
identified in the association mapping experiment. BTNL2 therefore qualified as a candidate 
gene based on this data. Consequently, mutation detection of all exon sequences and the 
adjacent intron boundaries of BTNL2  was performed in 47 sarcoidosis patients. Alignment of 
the revised cDNA sequence (see sequence information in the supplement 9.1.8.) with the 
genomic sequence (AL935032) was performed to determine the exact positions of the exons. 
Sequencher (version 4.0.5 created by Gene Codes Corporation, Ann Arbor, MI, USA) was 
employed for the analysis of all experimental sequences. Annotated sequence variations were 
compared to the experimental sequences and new SNPs were recorded. The coding sequence 
was located between 32. 43Mb and 32.45Mb on chromosome 6p21 in the NCBI (release 32).  
 
The DRA promoter, which in contrast to the coding region of this HLA molecule has not been 
hitherto investigated for polymorphisms, was sequenced in the same group of patients. To 
achieve a high map-density, markers in the genomic sequence between BTNL2  and the TSBP 
were established either by direct sequencing or retrieved from the databases. The 
oligonucleotide primer sequences and reaction conditions used for amplification and 
sequencing of genomic DNA are listed in the supplement 9.1.6. 
 
2.7.4.2. CARD15 on chromosome 16 
 
Based on haplotype information from a genome-wide linkage analysis in 63 families 58, 39 sib 
pairs or trios were identified as sharing at least one parental chromosome 16. One patient 
representing each of these families, together with eight patients who represent seven complex 
families and do not share the parental chomosome 16, were selected for DNA sequence 
analysis of CARD15 exon 4. In order to cover 1175 bp of exon 4, including the sites of 
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missense mutations responsible for susceptibility to Blau syndrome 132, 133 , two overlapping 
primer pairs were used: 
5’-TCCCTTCAGTTATGTCAGCGTC-3’ / 5’-CAGAGAAGCCCTTGAGGTTGA-3’ 
and 
5’-AAACCACTCTCTGTGCGGACTC-3’ / 5’ -AGAACGCGGCAAAGAAGCA-3’. 
 
2.8. Internal data bases 
 
An integrated internal data base system 130 , with data entry and retrieval tools, was employed 
to store patient, genotype and assay information. All samples were entered into a patient data 
tables of the data base and received a unique identification number. Pedigrees contained all 
available information about probands and their relatives: phenotypic trait (affection status), 
date of birth and gender.  
 
Plate layouts were also stored in the data base. Information about the sample positions on 96- 
and 384-well format plates was stored and plates were identified with unique numbers and 
labelled using a barcode system. Samples were assigned to certain positions in the plate 
layout.  
 
Genotype data and assay information was also stored. After the assay was run, the resulting 
genotypes were entered into the data base and the data linked to the barcode on the plate. If 
families were genotyped, internal software checked for Mendelian inheritance errors. In cases 
were inconsistencies were found, genotypes for that entire pedigree at the assay in question 
were excluded from the data base. Primers and probes data were also stored in the database 
along with the assay reaction conditions. The data base tools also permitted the construction 
of user-defined marker maps, and marker sets for data export and further analysis. 
 
A multiallelic-genotype information tool was developed for the DRB1 allele -group 
genotyping experiment. This tool was developed for definition of allele -group positive and 
negative amplification in samples, genotype construction and checking of genotyping 
inconsistencies. Information was linked to the main genotype data base described above thus 
enabling the concurrent export of multiallelic and diallellic genotypes.  
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All regions of the data base were relationally linked to each other thus integrating all 
available sample information. Additional software programs were used for the controlling of 
robots used in processing DNA and assay preparation. The genotype data base was facilitated 
the production of export files with sample genotype information for detailed statistical 
analysis programs running under UNIX. 
 
2.9. Statistical analysis 
 
Prior to detailed genetic analyses, each marker was tested for Hardy-Weinberg equilibrium 134, 
135 in the control population using a c 2 test.  
 
Many analyses utilized utility scripts implemented in the GENEDIGGER software 
environment (www.genedigger.de) for genetic analysis using the principles outlined below.  
 
Single point and haplotype transmission disequilibrium tests 136 -138 were performed for 
association analysis using TRANSMIT 139 and GENEHUNTER 2.1 140. In cases of families 
with multiple af fected individuals, analyses were performed by random selection of single 
trios from those families (as implmented by both programs). Haplotype frequency estimates 
of singletons were obtained using an implementation of the expectation maximisation (EM) 
algorithm (HAPMAX, www.uwcm.ac.uk\uwcm\mg\download) 141. Significance testing of 
haplotype frequency differences was performed with HAPMAX, making use of the fact that 
twice the log-likelihood ratio between two nested data models approximately follows a c2 
distribution with k degrees of freedom, where k is the difference in parameter number 
between the two models. Significance assessment of associations with or between single locus 
genotypes was performed with c2 or Fisher's exact test for 2 x 3 contingency tables 
(http://home.clara.net/sisa/fishrhlp.htm). Allele and genotype frequency differences between 
cases and controls were calculated using Pearsons c 2 (http://home.clara.net/sisa/two2hlp.htm ). 
 
In order to assess the relative importance of the MICB and BTNL2 leads, logistic regression 
analysis was used. Genotypic regression analysis was performed with SPSS analysis 
(http://www.spss.com/). Individual SNP genotypes were coded as categorical variables and 
the affection status was used as a binary outcome measure. Forward likelihood ratio inclusion 
was used in the program. 
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Standardized coefficients r2 and D’ 8, 26 were computed for pair-wise LD estimation 
between markers. To this end, haplotype frequencies were estimated using the EM 
implementation in HAPMAX, excluding markers that frequency was below 1% 141. Breslow-
Day test (http://www.cochrane.dk/cochrane/handbook/hbookBreslowDay_test.htm) for 
homogeneity of odds ratios of genotypes was used to stratify the BTNL2 rs2076530 effect 
from the DRB1 gene allele -groups. 
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3. Results 
 
3.1. Association study in the peri-MHC 
 
3.1.1. Identification of the association lead on chromosome 6 
 
For the association study of sarcoidosis susceptibility genes on chromosome 6 we defined the 
27.8-44.1 Mb region on the basis of linkage as identified in a whole genome scan (fig. 9A 
according to published information by Schürmann et.al. 58). The ,,exploratory’’ sample of 
sarcoidosis patients was genotyped for 69 SNP markers covering the linkage region that  was 
defined by a decrease in LOD score by 1.5 units or less, representing an approximate 99% 
confidence region for linkage  in the original genome screen 58 (see marker details in 
supplement 9.1.1.). In order to maximise the informativity of the data, three-locus SNP 
haplotypes were analysed in the TDT (fig. 9B) and case-control (fig . 9C) designs. A P-value 
less than 0.001 was selected as a cut-off for our association mapping study. According to this 
criterion, only the BTNL2 -HLA-DRA locus (marker rs2076523 to rs7192) demonstrated a 
consistent association signal in both study designs. A second putative peak was detected in the 
MICB–IkBL sub-region. This region was significant only in the case- control analysis. 
Nevertheless, the peak was further investigated by typing additional markers (rs1063635, 
rs3134900, rs3130062, rs1041981 and rs1799964) in the ,,extended’’ sample of sarcoidosis 
patients (see table 3 for patient information). In the same sample set, markers rs2076523, 
hCV2455668, hCV2455646, rs7192 were genotyped to verify the association signal in the 
BTNL2 -HLA-DRA region. Genotype logistic regression analysis with likelihood ratio-based 
forward inclusion at the p<0.05 level resulted in a model that included only two markers from 
the BTNL2– DRA region (rs2076523, rs7192), but none of the MICB markers. Furthermore, 
long range LD with D’ values up to 0.94 was observed between markers of the two loci (see 
fig.10). Thus, further association study was pointed only to the BTNL2-HLA-DRA locus. 
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Fig.9. Graphical representation of the stage I SNP screen on chromosome 6p21. Panel A 
illustrates the NPL- score curve from the original genome scan 58. Approximately 99% of the 
confidence interval for linkage is marked in grey. Panel B: results of a three-locus haplotype 
TDT, using TRANSMIT 139. Panel C: results of a three-locus haplotype case -control analysis, 
using HAPMAX 141. In panels B and C, the black dots represent markers; the P-value is 
plotted against the physical map position (NCBI coordinates; release 32) of the most 
telomeric marker of each haplotype. Using a cut -off of p-value 0.001, two potential lead 
regions (MICB and BTNL2  regions) were identified (marked by arrows). 
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Table 8.Part 1: Analysis of 69SNP marker covering chromosome 6 linkage region typ ed 
in the ,,exploratory’’ sample. Three-locus haplotype analysis: haplotype TDT, using 
TRANSMIT 139. and three-locus haplotype case-control analysis, using HAPMAX 141. 
Meaning of the headers- Marker: name of the first marker in the analyzed three-marker 
haplotype; Position: map position of this marker in NCBI release 32; Gene: gene name is 
provided, if the marker was assigned to the gene; GLOBAL_P: global P-value (using 
tabulated chi-squared values) of the TRANSMIT analysis , (represented graphically in the B 
panel of fig.9) LR_P: likelihood ratio P-value in HAPMAX analysis (represented graphically 
in the panel C of fig.9). Using a cut-off of P-value 0.001, two potential lead regions (MICB 
and BTNL2  regions) were identified. Three-locus analysis results are represented at the first 
marker, thus no separate information can be provided for the last two SNPs. 
 
Nr Marker Gene Position 
MB 
GLOBAL_P  LR_P 
1 rs126007  27,80 0.66272 0.33685 
2 rs929042 RFP 28,95 0.31158 0.35774 
3 rs53161  29,56 0.00439 0.02515 
4 rs404240 UBD 29,59 0.60590 0.24800 
5 rs362536 UBD 29,59 0.28863 0.18665 
6 rs1805057 GABBR1 29,64 0.38716 0.25904 
7 rs3130253 MOG 29,73 0.06654 0.32363 
8 rs1569315 HLA-G 29,85 0.30168 0.73116 
9 rs8347 HCG-V 30,10 0.06731 0.03672 
10 rs1264457 HLA-E 30,52 0.06068 0.04346 
11 rs2074510 GTF2H4 30,94 0.07043 0.00569 
12 rs3095318 CDSN 31,15 0.44813 0.03073 
13 rs2073721 SC1 31,19 0.59125 0.02606 
14 rs1050393 HLA-C 31,30 0.14277 0.08974 
15 rs1051488 HLA-B 31,38 0.62729 0.11985 
16 rs1063635 MICA 31,44 0.17855 0.00031 
17 rs3134900 MICB 31,53 0.14103 0.00011 
18 rs3130062 IkBL 31,59 0.24477 0.00631 
19 rs1799964 TNFa  31,60 0.65624 0.17068 
20 rs1799742 TNFa  31,60 0.02797 0.36793 
21 rs1800629 TNFa  31,60 0.01595 0.26435 
22 rs361525 TNFa  31,60 0.04533 0.34753 
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Table 8.Part 2: Analysis of 69SNP marker covering chromosome 6 linkage region typed 
in the ,,exploratory’’ sample.  
Nr Marker Gene Position 
MB 
GLOBAL_P  LR_P 
23 rs707916 DDAH2 31,76 0.23426 0.13348 
24 rs707926 VARS2 31,81 0.59715 0.42364 
25 rs2075800 HSP70-HOM 31,84 0.64525 0.36278 
26 rs539689 HSPA1B 31,86 0.03912 0.57590 
27 AF019413_C89532G C2 31,96 0.46907 0.20283 
28 rs1035798 AGER 32,18 0.21567 0.00011 
29 rs2076523 BTNL2 32,40 0.02512 0.00005 
30 rs7192 HLA-DRA 32,44 0.00068 0.00008 
31 rs707952 HLA-DQA1  32,62 0.19542 0.02065 
32 X66401_G48629A TAP2  32,80 0.28180 0.07202 
33 rs1042337 HLA-DMB 32,91 0.78721 0.13677 
34 rs1063478 HLA-DMA 32,92 0.64879 0.06935 
35 rs3918143 RING3 32,95 0.89879 0.58044 
36 rs2581 HLA-DNA 32,98 0.29726 0.74512 
37 rs926424 RXRB 33,16 0.39056 0.35662 
38 rs1547387 HKE4  33,17 0.23682 0.04729 
39 rs466384 BING4 33,26 0.18172 0.85135 
40 rs2071888 TAPBP 33,27 0.24968 0.32265 
41 rs999942 ITPR3  33,63 0.06519 0.89534 
42 rs943461 MLN 33,77 0.20307 0.86884 
43 rs755658 FKBP5 35,55 0.48398 0.72043 
44 rs992105 FKBP5 35,56 0.15834 0.72385 
45 rs1320991 FKBP5 35,56 0.01655 0.57041 
46 rs1326752 SRPK1 35,83 0.97381 0.14943 
47 Z95152_G57723A  36,03 0.69303 0.09150 
48 Z95152_T58784G  36,08 0.79999 0.16206 
49 Z95152_T106861C  36,08 0.39651 0.90485 
50 rs763096 MAPK13 36,10 0.44718 0.31687 
51 rs2007683 MAPK13 36,10 0.48579 0.51913 
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Table 8.Part 3: Analysis of 69SNP marker covering chromosome 6 linkage region typed 
in the ,,exploratory’’ sample.  
Nr Marker Gene Position 
MB 
GLOBAL_P  LR_P 
52 rs881648 TEL2  36,35 0.39159 0.24957 
53 rs881647 TEL2  36,35 0.52845 0.43205 
54 rs916287 TEL2  36,35 0.45249 0.66488 
55 rs1885205 TEL2  36,35 0.60848 0.39376 
56 rs2055272 FLJ20337  37,29 0.32889 0.71445 
57 rs1004279 GLP1R 39,03 0.23950 0.16773 
58 rs1541816 KCNK5 39,16 0.25399 0.91441 
59 rs1014737 APOBEC2  41,02 0.22457 0.36773 
60 rs2234246 TREM1 41,25 0.45006 0.00228 
61 rs1817538 TREM1 41,25 0.69467 0.03263 
62 rs1351835 TREM1 41,25 0.32326 0.15618 
63 rs2234237 TREM1 41,25 0.95560 0.60305 
64 AL391903_C88694T TREM1 41,26 0.33000 0.52120 
65 rs742735 MDFI 41,62 0.39961 0.55194 
66 rs1410492 CCND3 41,91 0.19828 0.16327 
67 rs1160867 TNRC5 42,90 0.32091 0.85330 
68 rs9395 SRF 43,15   
69 rs1418488 CAPN11 44,14   
 
 
3.1.2. Analysis of LD in the screened region 
 
Due to linkage disequilibrium between genes, a distortion of the true location of a 
susceptibility gene is likely. Therefore, pair-wise LD analysis in the control population was 
performed on the set of markers employed for the screening experiment. Generally, the lower 
is the frequency of an SNP, the further extended LD around such alleles is expected, because 
such alleles are generally young and there has been less historical opportunity for 
recombination to break down ancestral haplotypes 142. Markers with a higher frequency than 
1% were included into analysis of LD structure in this study. D’ values were calculated for all 
pair-wise inferred two-locus haplotypes for the 69 SNPs covering a 16,34 Mb region. The LD 
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in this region was found to vary greatly, with strongly correlated regions of sequence 
forming so called LD blocks interspersed with regions of low LD. D’ values grater than 0.5 
were considered as evidence of linkage disequilibrium between markers 13 (see fig.10) . In the 
analysed fragment, six such blocks were discovered. In general, the telomeric end of the 
region presented higher LD values which are represented by ,,LD block 1’’ (29.55Mb-
29.84Mb) and ,,LD block 2’’(31.14Mb-31.85Mb). The strongest LD was observed between 
markers in the second region, which is bordered by rs3095318 and rs539689. This region 
includes the MICB and IkBL  genes that exhibit high LD values over long physical distance 
reaching the BTNL2-HLA-DRA region. Interaction between the two putative association 
regions was of a special interest because both regions demonstrated significant results in the 
case-control analysis. The size of LD blocks 3 to 6 was notably smaller, ranging from 253bp 
(LD block 5) to 91kb (at LD block 3). These blocks represented densely located markers. The 
LD analysis results in our sample set in the peri-MHC region agree with previous studies that 
have asserted that apart from the classical HLA loci 19, the LD patterns in this region are no 
different from those found in other studies in the rest of the genome 13, 14, 20, 21. 
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Fig10. Linkage disequilibrium between 69SNP markers typed for association screening 
on chromosome 6. 16,34Mb sequence of 517 unrela ted individuals of German origin were 
tested for LD between markers. The 69 SNPs are plotted against each other (from left to right 
and from top to bottom). The colour squares code D’ values. LD values from 0.00 to 1.00 are 
colour-coded as following: light blue - blue (0.0-0.34), green (0.35-0.49) and red (³0.5). 
,,Blocks’’ formed by D’ values ³0.5 were designated as ,,LD blocks1-6’’, formed by markers 
3-8, 12-26, 37-39, 47-50, 52-54 and 60-63 respectively. 
 
 
 
3.1.3. High density SNP mapping in the association region 
 
Further investigation of the BTNL2 -HLA-DRA region comprised genotyping 48 additional 
markers (NCBI release 32, map coordinates 32,177 – 32,616 Mb) in the ,,fine mapping’’ 
sample. This sam ple consisted of the combined ,,exploratory’’ and ,,extension’’ samples (see 
table 3. for sample information).  
 
To establish a dense SNP map in the locus and to identify the disease-associated marker, 47 
sarcoidosis patients were sequenced for mutation detection screening (see fig.11). The 
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sequencing experiment covered all BTNL2  gene exons and adjacent intronic sequences. 
Seven non-synonymous polymorphisms were identified: BTNL2_W94R ( tryptophan 
changed into arginine at amino acid position 94 of the revised BTNL2 transcript see 
sequences in supplement 9.1.7. ); BTNL2_S240L; rs2076530; BTNL2_P285L; 
BTNL2_M286I; BTNL2_P299Q; BTNL2_E360Amb. Two synonymous SNPs were 
identified: BTNL2_H60H; rs2076529. Seven intronic sequence variations were identifed: 
BTNL2_i1_G1717T (G nucleotide is change d into T at position 1717 of intron 1 of the 
BTNL2 gene); BTNL2_i3_A1837G; rs2076523; BTNL2_i3_C1900T; rs2076524; 
BTNL2_i4_A239T; rs2294878. These SNPs were selected for high density SNP mapping (see  
marker details in supplement 9.1.1.). Further SNPs were established in the intergenic 
sequence between the BTNL2 and TSBP  genes: AL034394_C16965T (C changed to T at 
nucleotide position 16965 of sequence AL034394 from the BAC clone RP5-1077I5); 
AL034394_C20283T; hCV248876; AL034394_A26270C and AL034394_T26355G (see 
fig.11). The remaining markers were located in the AGER , NOTCH4, TSBP and HLA-DRA 
genes and were obtained from Assays-on-Demand and Assays -by-Design (Applied 
Biosystems Inc., Foster City, CA, USA) or sequencing experiment. 
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Fig.11. Fragment of the high density SNP map established in the association region.  
Upper panel: SNP markers (marked in green) identified through ABI and dbSNP databases. 
Lower panel: SNP markers established through mutation detection experiments. Central 
panel: SNP marker locations in the revised BTNL2 gene; e: exon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional assays were obtained either from the ABI ,,Assay on Demand’’ database 
(www.store.appliedbiosystems.com), or from the dbSNP web page (www.ncbi.nlm.nih.gov). 
Single point TDT and case-control analyses were performed to evaluate the contribution of 
individual markers to the significant signal detected at the locus. Taking the consistency of 
results from both the family- and population-based analyses into account, markers at the 3’  
end of the BTNL2 region (rs2294878 to hCV2488476) demonstrated the strongest and most 
robust association (see fig.12.). Average rate of the P-values for these markers were two to 
three orders of magnitude smaller than for other significant markers. The human BTN gene 
cluster consists of seven genes (BTN1A1, BTN3A3, BTN2A1, BTN3A1 , BTN2A3 , BTN3A2  and 
BTN2A2) and is located on chromosome 6p22 80, 143 approximately 6 Mb telomeric of BTNL2. 
For completeness, six markers (rs2073528, rs2072803, hCV2474907, hCV2474883, 
hCV9804528 and rs3736781) covering ~130kb of the BTN cluster were also genotyped in the 
combined “exploratory” and “extended” samples of the present study. There was no evidence 
for disease association (data not shown). 
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Fig.12.High density mapping in the association region. SNP markers comprising 440 kb 
region of chromosome 6p21 were typed in the combined ,,exploratory’’ and ,,extension’’ 
samples. Table: results of disease-association tests. fcontrols: allele frequency in controls; TDT: 
P-values from a single point TDT calculated by GENEHUNTER 2.1, Case-control: single 
point P-values from a genotype -based c2 test of case-control data. Colour intensity-code was 
used to mark decreasing P-values. Right panel: revised intron-exon structure of the BTNL2 
gene. The most disease-associated BTNL2  markers P299Q, M286I, P285L (located in exon 6) 
and rs2076530 (located in exon 5) are indicated with arrows.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
marker gene fcontrols TDT Case_control
rs2070600 AGER 0.03 0.5637 0.547556261
rs1800624 AGER 0.70 0.8932 0.888288117
rs2071287 NOTCH4 0.43 0.4857 0.471723107
rs384247 NOTCH4 0.13 0.7797 0.615679814
rs915894 NOTCH4 0.38 0.7963 0.050395291
rs436845 0.75 0.8282 0.170348756
rs560505 TSBP 0.57 0.1203 0.001818197
rs485774 TSBP 0.56 0.0872 0.001808805
rs552339 TSBP 0.44 0.1351 0.004321214
rs761187 TSBP 0.56 0.1482 0.003243398
rs2073044 TSBP 0.75 0.0107 0.000155551
rs2050190 TSBP 0.67 0.0993 0.019714402
rs2073045 TSBP 0.36 0.9468 0.038608552
AL034394_T26355G 0.93 0.3770 0.513599058
AL034394_A26270C 0.26 0.1509 0.000115550
AL034394_C20283T 0.03 0.7237 0.355508299
AL034394_C16965T 0.15 0.0066 0.001426440
hCV2488476 0.41 0.0001 0.000000021
AL034394_C12339T 0.15 0.0025 0.001453209
AL034394_T10552C 0.86 0.0027 0.002117374
BTNL2_E360Amb BTNL2 0.99 0.4142 0.999962285
BTNL2_P299Q BTNL2 0.15 0.0013 0.000565354
BTNL2_M286I BTNL2 0.85 0.0008 0.001159376
BTNL2_P285L BTNL2 0.85 0.0001 0.000186665
rs2076530 BTNL2 0.58 0.0009 0.000000103
BTNL2_S240L BTNL2 0.98 0.2008 0.532618389
rs2076529 BTNL2 0.59 0.0001 0.000000044
rs2294878 BTNL2 0.56 0.0012 0.000000700
BTNL2_i4_A239T BTNL2 0.97 1.0000 0.900004549
rs2076524 BTNL2 0.74 0.0588 0.000076997
BTNL2_i3_C1900T BTNL2 0.92 0.5876 0.727167218
rs2076523 BTNL2 0.35 0.1385 0.000907369
BTNL2_i3_A1837G BTNL2 0.08 0.3173 0.843149836
BTLIIW94R BTNL2 0.08 0.9068 0.908877597
BTLIIH60H BTNL2 0.92 0.7255 0.829924141
BTNL2_i1_G1717T BTNL2 0.98 0.8084 0.993204521
hCV2455668 0.42 0.2359 0.041676362
DRAp_231 HLA-DRA 0.30 1.0000 0.451078993
DRAp_224 HLA-DRA 0.30 0.7400 0.492950227
DRAp_196 HLA-DRA 0.31 0.8435 0.490587034
DRAp_127 HLA-DRA 0.98 0.4927 0.984228521
rs14004 HLA-DRA 0.42 0.1761 0.058413905
hCV2455646 HLA-DRA 0.39 0.7622 0.937496596
rs8084 HLA-DRA 0.44 0.0083 0.000183610
rs7192 HLA-DRA 0.58 0.0014 0.000094646
rs2213584 HLA-DRA 0.59 0.0010 0.000176354
rs2395182 HLA-DRA 0.79 0.2626 0.000847780
rs707952 HLA-DQA1 0.28 0.0115 0.025177725  
1 
2 
3 
4 
5 
6 
8 
7 
BTNL
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Fig.13. The matrix of pair-wise r2 values estimated at the locus AGER-HLA-DQA1 (from 
rs1035798 through rs707952, as used in the stage II chromosome 6 screening). Left panel: 
gene map of the analysed 440 kb region on human chromosome 6p21. Equidistance plot of 
pair-wise LD (r2) between all markers in the analysed region. 69 SNPs are plotted against 
each other (from left to right and from top to bottom). The left panel presents the physical 
map of the analysed region. The colour squares in the plot code r2 values.r2 values that range 
from 0.00 till 1.0 (no LD and complete LD respectively) are colour-coded according to LD 
strength (indicated in r2 value legend). The most disease-associated marker positions in the 
LD plot indicated by arrows. 
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To investigate the association signal in more detail, the haplotype structure of the high 
density mapping region was analysed. According to our experience, D’ values are of little 
utility between markers in close proximity, therefore a r2 value of LD measure were  
investigated (see fig.13). The four potentially functional and with disease mostly associated 
markers rs2076530, P285L, M286I, P299Q had r2 values ranging from 0.88 till 0.99 
indicating high LD between markers.  
 
From the 15kb segment, four  SNPs (rs2076530, P285L, M286I, P299Q) in the BTNL2 gene 
were the most strongly associated with sarcoidosis. Combined in a four marker TDT 
haplotype analysis they yielded a P-value of 1.9x10-7, and a P-value of 6.2x10-7 in the 
equivalent case-control analysis. Most of the association was due to rs2076530, leaving 
P=0.03 for the inclusion of the other three markers in a case -control haplotype regression 
model. The strong association of rs2076530 with sarcoidosis was verified by typing a 
,,replication’’ sample containing 452 independent cases (see table 9.). Both TDT and case-
control analyses demonstrated increased significance in the ,,full’’ sarcoidosis patient sample , 
which represents the entire sample of 947 affected individuals (single affected individual per 
family). Transmission disequilibrium tests and case-control tests returned Ptdt = 3.0x10-5and 
Pcase-control = 6.7x10-8 values respectively. 
 
Table 9. Significance of disease-associated BTNL2 markers in the replication sample. The 
markers were analysed in the ,,SNP fine mapping’’ and ,,replication ‘’ samples separately and 
combined. TDT p-value: single point TDTs were calculated by GENEHUNTER 2.1. Case 
control genotype p -value: single point genotype-based c 2 test in the population study design. 
Homozygotes: odds of ratio between wild type homozygote genotype,,2/2” and mutated type 
homozygote ,,1/1’’; heterozygotes: odds of ratio between wild type homozygote ,,2/2” and 
mutated type heterozygote ,,1/2’’. Marker rs2076530 demonstrated consistent results in both 
samples and had the highest odds ratio in homozygotes for allele ,,A’’. Colour intensity 
indicated the decreasing P values. 
 
Sample 
SNP fine mapping Replication Full 
Genotype odds 
ratio 
Marker 
TDT 
p-value 
Case 
control 
genotype 
p value 
TDT 
p-
value 
Case 
control 
genotype 
p value 
TDT 
p-value 
Case control 
genotype 
p value 
Homo 
zygotes 
Heteroz
ygotes 
BTNL2_P299Q 0.00175  0.00056535 0.1118 0.644517 0.000631 0.024066193  0.61 0.71 
BTNL2_M286I 0.00175  0.00115938 0.2752 0.429132 0.001963 0.008748047  1.65 1.11 
BTNL2_P285L 0.00085  0.00018667 0.1129 0.269000 0.000322 0.006999268  1.86 1.26 
rs2076530 0.00052  0.00000010 0.0019  0.000059  0.000003 0.000000067  2.59 1.53 
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The underlying allele transmission rates in the transmission disequilibrium tests and the 
allele and genotype frequencies in the case-control analyses of the marker rs2076530 are 
listed in table 10. The disease susceptibility allele, allele “1” (corresponding to the nucleotide 
A), was over-transmitted in families. 256 alleles were transmitted from heterozygous parents 
to affected children against 161 un-transmitted (a ratio of 1.59). Case-control statistics agreed 
with the TDT results with the following distribution of frequencies for genotypes AA, AG and 
GG in controls and cases respectively: 0.32; 0.53; 0.16 and 0.46; 0.44; 0.09. 
 
Table 10. Association of the rs2076530 with susceptibility to sarocoidosis. Table A: 
transmission disequilibrium test. Trans: number of transmitted alleles; untrans: number of un-
transmitted alleles. Table B: case -control analysis test. Frequencies of alleles and genotype 
frequencies are presented for various samples (see table 3 for detailed sample information). 
Allele1 denotes nucleotide A and allele 2 denotes nucleotide G of the rs2076530 marker. 
A. 
Sample 
SNP fine mapping Replication Full 
Allele  
Trans Untrans Trans Untrans Trans Untrans 
1 158 102 98 59 256 161 
2 102 158 59 98 161 256 
 
B. 
Sample Alleles 
Controls SNP fine 
mapping 
Replication Full 
1 0.58 0.70 0.68 0.69 
2 0.42 0.30 0.32 0.31 
Genotypes     
11 0.32 0.50 0.44 0.46 
12 0.53 0.40 0.47 0.44 
22 0.16 0.10 0.09 0.09 
 
3.1.4. Separation of the genetic effect of BTNL2 and the HLA-DRB1  genes 
 
The marker rs2076530 demonstrated high significance in family-based and population-based 
study designs. Thus, BTNL2 could be regarded as a sarcoidosis susceptibility gene. However, 
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it is located in the vicinity of the HLA-DRB1 gene (~200kb) (see fig.14), which has been 
previously implicated in the aetiology of the disease 72, 74. 
 
Fig.14. Gene content in the fragment of the chromosome 6p21. The BTNL2  gene maps 
~200kb (indicated by black arrow) telomeric from HLA-DRB1  gene. Grey arrows indicate 
gene direction. 
 
 
 
 
 
 
 
To investigate the association signal and possible effect of linkage disequilibrium in the 
association region, the HLA-DRB1 gene was genotyped. To differentiate the BTNL2 genetic 
effect from the HLA marker, a low -resolution typing approach for non-overlapping HLA-
DRB1 allele groups was applied (see chapter 2.6.2. for experiment design details). Allele 
group genotyping results in the full sarcoidosis sample plus controls confirmed that a group of 
alleles confers an increased risk of sarcoidosis. Amplification group 3, comprising alleles 
DRB1*03, *08, *11(not *1122/30), *12, *13, *14, (not*1410/39), demonstrated a significant 
signal (see table 11). To evaluate the relative genetic effect of both markers, a stratification 
analysis of the respective HLA-DRB1  and BTNL2 genotypes was employed. However, a 
stratified analysis of the respective DRB1 and BTNL2  genotypes (see table 12)  was 
insignificant throughout (Breslow -Day test for homogeneity of odds ratios: c 2=0.12, 1 d.f., 
p>0.5 for both stratifications). Therefore, DRB1 amplification group 3 and rs2076530 allele A 
represent independent risk factors for sarcoidosis. 
BTNL2 AGER  NOTCH4 TSBP 
HLA-DRA 
HLA -DRB1 
HLA-DQA1 
~200kb 
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Table 11: Association between BTNL2 and DRB1 risk alleles and sarcoidosis (based on 
947 cases and 517 controls). fcase, fcontrol: allele frequency in cases and controls. P (global): 
error probability of a global c2 test for allelic association. tdt (obs./exp.) ratio between 
observed and expected number of transmissions; P (allele): allele group-specific TDT error 
probability, as reported by the TRANSMIT program 139. 
Locus allele fcase fcontrol P (global) tdt (obs./exp.) p (allele) 
BTNL2 (rs2076360) A 0.69 0.58  1303/1239 3.1*10-7 
 G 0.31 0.42 3.3*10-9 605/669 3.1*10-7 
       
DRB1  (allele groups) 1 0.067 0.112  124/155 1.1*10-5 
 2 0.193 0.169  344/330 n.s. 
 3 0.551 0.461  1010/947 7.4*10-7 
 4 0.100 0.146  186/217 0.0001 
 5 0.082 0.103  145/156 n.s. 
 6 0.003 0.005  10/4 n.s. 
 7 0.004 0.004 7.1*10-8 7/3 n.s. 
 
Table 12. Differentiation between BTNL2 and DRB1 effects. ,,x’’ denotes DRB1  alleles 
other than allele group 3. 
 
rs2076530 DRB1 case control 
any 3-3 282 125 
any 3-x 481 227 
any x-x 184 165 
AA any 445 170 
AG any 414 261 
GG any 88 86 
AA 3-3,3-x 388 137 
AA x-x 57 33 
AG,GG 3-3,3-x 375 215 
AG,GG x-x 127 132 
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3.1.5. BTNL2 structural analysis 
 
Originally, Stammers et al. 144 described the structure of the BTNL2 gene. . The complete 
mRNA sequence was described as consisting of 6 exons ( see exon accession numbers in 
supplement 9.1.8.). However, a problem of contiguous cDNA amplification between primers 
in exons 1-4 and exons 5 and 6 was indicated 144. This raised the possibility that the non-
overlapping transcripts belong to two different genes. A cDNA experiment was developed to 
verify the tissue specific expression and gene structure (see method description in appendix 
9.2.2.). Successful amplification of overlapping transcripts confirmed the presence of a single 
transcript. The original exon 3 was removed from the gene model. The excuded exon did not 
affect the open reading frame. One additional exon was detected at the 5’ untranslated region 
and two exons at the 3’ end of the gene ( see supplement 9.1.8. for sequence information).  
 
The expression of BTNL2 was investigated in order to verify the presence of the transcript in 
the lung - the organ which is most commonly affected by sarcoidosis. Gene expression was 
detected in myelomonocytic (THP-1) cells activated with TNFa and in bronchoalveolar 
(BAL) lavages from sarcoidosis patients (fig.15; see detailed description of BAL lavages 
extraction in appendix 9.2.1.). No BTNL2 expression was found in bronchoalveolar lavage 
extracted from control individuals or in naive THP-1 cells.  
 
Fig.15. Expression pattern of the BTNL2 gene (experiment performed in collaboration with 
Dr.K.Huse). Nested PCR amplification products are viewed on an agarosis gel (for detailed 
experiment information see supplement 9.2.2.). BTNL2 transcript amplification products in 
THP-1 cells (native and after a 4 hour incubation with 10ng/µl TNF-a) and in cDNA prepared 
from BAL cells of sarcoidosis patients and controls. 
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3.1.6. Functional exploration of BTNL2 mutations 
 
The association mapping experiments indicated four potentially functional SNPs in the 
BTNL2  gene that are associated with sarcoidosis. Three SNPs are located in exon 6 and cause 
a proline change to leucine at amino acid position 285, methionine to isoleucine at 286 and 
proline to glutamine at 299 (denoted P285L, M286I and P299Q respectively). According to 
the original gene model, the A to G mutation at rs2076530 causes a serine to be replaced by 
glycine 144. However, in the revised gene model, the SNP is located at position -1 of the splice 
donor site, where guanine is conserved in 77% of donor splicing sites 145, 146. Thus, the 
substitution of this conserved nucleotide could influence exon splicing and alter the gene 
transcript.  
 
To investigate the hypothesis of alternative splicing, DNA/cDNA pairs from lymphoblastoid 
cell lines and peripheral blood samples were compared by rtPCR (see method description in 
appendix 9.2.2.). Indeed, a four base deletion in the cDNA was observed in cases where the 
genomic DNA contained allele A at the -1 splice donor site (see fig.16). The loss of four bases 
in the BTNL2 transcript causes a frameshift and generates a premature stop codon in exon 6. 
In splice variants with frameshift and premature stop codon, the 118 amino acids at the C-
terminus are then replaced by 5 different residues.  
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Fig.16. Alternative splicing of the BTNL2 transcript at exon 5 (experiment performed in 
collaboration with Dr.K.Huse and Dr.P.Rosenstiel ). Alternative splicing is introduced 
through an A to G transition at rs2076530. Top panel: reference genomic sequence around the 
mutation site. Central panel: consensus splicing in the presence of the G allele. Bottom panel: 
alternative splicing in the presence of the allele A. The GT of the active donor is underlined in 
both panels. 
 
The BTNL2  gene belongs to the bur yrophilin family. Butyrophilin genes are members of the 
immunoglobulin superfamily 143, 147. According to sequence and structure homology, the 
entire butyrophilin family shares similarity with the B7 proteins 147 which are important in the 
regulation of previously activated T-cells 147-150. Structurally, the BTNL2  gene is organised 
into domains marked by the separate exons 144. The revised BTNL2 protein consists of an N-
terminal signal peptide encoded by exon 1 and 2, two N-terminal homologous IgV 
(immunoglobuline-like variable) domains encoded by exons 3 and 5, an heptad domain in 
exon 4 and a C-terminal IgC (immunoglobuline-like constant) domain encoded by exon 6. In 
the resulting protein model, a truncation of the protein at the site of the premature stop is 
introduced through rs2076530, just before the start of the IgC domain and the attached 
transmembrane helix. The variants P285L, P299Q and M286I are located in b-strands on the 
protein surface of the IgC domain (for details see appendix 9.2.4. and 9.2.5.).  
GATCTGAAGGTGGTARGTAAGAATTCTAGAT 
GATCTGAAGGTGGTAGGTAAGAATTCTAGAT  
GATCTGAAGGTGGTAAGTAAGAATTCTAGAT 
rs2076530 
gatctgaaggtggta g . . . 
ga t c tgaagg tg… 
Reference sequence 
cDNA 
Genomic sequence 
cDNA 
Genomic sequence 
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3.2. Results of the CARD15 gene analysis 
 
3.2.1. CARD15 mutations in sarcoidosis 
 
Allele and genotype frequencies for all four CARD15 SNPs in cases from the families and 
trios sample s were compared to controls using chi-squared statistics. One patient per family 
was randomly drawn from the sarcoidosis families for this case–control analysis. Related 
patients were excluded to avoid over-representation of specific alleles from multi-case 
families. In addition to the population-based analysis, family -based analyses were performed 
by evaluating transmission disequilibrium. In total, 1011 individuals from the sarcoidosis 
families, the sarcoidosis trios and controls were genotyped for four Crohn’s disease associated 
CARD15 polymorphisms: SNP5, SNP8, SNP12, and SNP13. All genotyped SNPs were 
consistent with expectations of the Hardy-Weinberg law in controls. 
 
Three different types of data analysis: case-control comparisons, genetic linkage ana lyses and 
family based association studies were performed to investigate the influence of CARD15 
mutations in sarcoidosis families and trios. In order not to overlook a possible effect, because 
of the relatively small sarcoidosis family and sarcoidosis trio sample sizes, both samples were 
also analysed together. Comparisons of allele frequencies for each SNP in 265 cases (138 
cases from 138 sarcoidosis families, one patient at random chosen from each family, and 127 
cases from 127 sarcoidosis trios) and 265 matched controls, revealed only two significant 
(p<0.05) results. The frequency of allele 1 in both SNP5 and SNP12 was increased in cases. 
For SNP12 this effect was observed both in cases from sarcoidosis families and cases from 
sarcoidosis trios. However, only cases from sarcoidosis families showed a significant increase 
of SNP5 allele 1. Furthermore, a significant difference in genotype frequencies was observed 
only in SNP12 for the sarcoidosis trios and the combined cases from trios and families. All 
case-control comparisons are listed in table 13.  
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Table 13. CARD15 allele (A) and genotype(B) frequencies in sarcoidosis patients and 
healthy controls. Numbering of CARD15  mutations according to ref. 119 . The rare allele of 
each SNP refers to allele 1.  
 
A. 
CARD15  
Alleles 
Controls  
 
(n=265) 
Sarcoidosis 
families  
(138 patients) 
Sarcoidosis 
 trios 
(127 patients) 
Sarcoidosis 
families + trios 
(265 patients) 
SNP5   1 
SNP5   2 
 
144 (27,2%) 
386 (72,8%) 
97 (35.1%) 
179 (64.9%) 
p=0,019 
80 (31.5%) 
174 (68.5%) 
p=0.21 
177 (33.4%) 
353 (66.6%) 
p=0.027 
SNP8   1 
SNP8   2 
 
25 (4.7%) 
505 (95.3%) 
15 (5.4%) 
261 (94.6%) 
p=0.66 
19 (7.5%) 
235 (92.5%) 
p=0.12 
34 (6.4%) 
496 (93.6%) 
p=0.23 
SNP12   1 
SNP12   2 
 
4 (0.8%) 
526 (99.2%) 
8 (2.9%) 
268 (97.1%) 
p=0.017 
8 (3.2%) 
246 (96.8%) 
p=0.011 
16 (3.0%) 
514 (97.0%) 
p=0.007 
SNP13   1 
SNP13   2 
19 (3.6%) 
511 (96.4%) 
11 (4.0%) 
265 (96.0%) 
p=0.78 
8 (3.2%) 
246 (96.8%) 
p=0.75 
19 (3.6%) 
511 (96.4%) 
p=0.99 
B. 
CARD15 genotypes Controls  
(n = 265) 
Sarcoidosis families  
(138 patients) 
Sarcoidosis trios 
(127 patients) 
Sarcoidosis families + 
trios 
(265 patients) 
SNP5   1 / 1 
SNP5   1 / 2 
SNP5   2 / 2 
 
18 (6.8%) 
108 (40.7%) 
139 (52.5%) 
17 (12.3%) 
63 (45.7%) 
58 (42%) 
p=0.06 
11 (8.7%) 
58 (45.7%) 
58 (45.7%) 
p=0.43 
28 (10.6%) 
121 (45.7%) 
116 (43.8%) 
p=0.083 
SNP8   1 / 1 
SNP8   1 / 2 
SNP8   2 / 2 
 
0 
25(9.4%) 
240 (90.6%) 
0  
15 (10.9%) 
123 (89.1%) 
p=0.65 
1 (0.8%) 
17 (13.4%) 
109 (85.8%) 
p=0.17 
1 (0.4%) 
32 (12.1%) 
232 (87.5%) 
p=0.37 
SNP12   1 / 1 
SNP12   1 / 2 
SNP12   2 / 2 
 
0 
4(1.5%) 
261 (98.5%) 
1 (0.7%) 
6 (4.3%) 
131 (95.0%) 
p=0.08 
0 
8 (6.3%) 
119 (93.7%) 
p=0.01 
1 (0.4%) 
14 (5.3%) 
250 (94.3%) 
p=0.034 
SNP13   1 / 1 
SNP13   1 / 2 
SNP13   2 / 2 
0 
19 (7.2%) 
246 (92.8%) 
0 
11 (8.0%) 
127 (92.0%) 
p=0.77 
0 
8 (6.3%) 
119 (93.7%) 
p=0.75 
0 
19 (7.2%) 
246 (92.8%) 
p=0.99 
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Family based association studies were performed to determine if there was any deviation 
from random expectation in the transmission of SNP alleles from heterozygote parents to 
affected offspring using the transmission disequilibrium test. 109 complete trios were 
extracted from the sarcoidosis families sample in addition to the 127 trios of the sarcoidosis 
trios set. No transmission disequilibrium was observed in trios taken from the sarcoidosis 
families sample, neither for single SNPs nor for 4 marker haplotypes. By contrast, significant 
increased transmission of SNP5 allele 1 as well as significantly decreased transmission of 
SNP allele 2 was detected in the sarcoidosis trios sample. Allele 1 was more often transmitted 
from heterozygote parents to affected offspring. Haplotype analysis demonstrated the same 
results, including significantly decreased transmission of haplotypes carrying SNP5 allele 2. 
Results of transmission disequilibrium tests are listed in table 14. 
 
Table 14. Results of transmission disequilibrium test. The analysis use 109 complete trios 
extracted from the sarcoidosis families sample and 127 trios of the sarcoidosis trios set. Only 
the results of the rarer allele 1 of individual single nucleotide polymorphisms (SNP) are listed. 
For allele 2 of the biallelic polymorphisms, the number of transmitted and untransmitted 
alleles (denoted as trans and untrans respectively) is inverse, with identical P values. 
Haplotypes are formed by alleles of SNP5-SNP8-SNP12-SNP13. P - P value. 
 
 Families Trios Families and trios 
SNPs trans untrans  p trans untrans p trans untrans P  
SNP5   1 31 33 0.8 60 39  0.034 91 72 0.13 
SNP8   1 8 8  18 10 0.13 26 18 0.23 
SNP12   1 5 5  8 3 0.13 13 8 0.28 
SNP13   1 8 7 0.8 8 8  16 15 0.86 
Haplotypes          
1  1  2  2 8 7 0.8 14 7 0.13 22 14 0.18 
1  2  1  2 5 4 0.74 6 2 0.16 11 6 0.23 
1  2  2  1 3 6 0.32 8 6 0.59 11 12 0.83 
1  2  2  2 18 19 0.87 31 23 0.28 49 42  0.46 
2  1  2  2 0 0  1 3 0.32 1 3 0.32 
2  2  1  2 0 0  0 0  0 0  
2  2  2  1 4 1 0.18 0 0  4 1 0.18 
2  2  2  2 25 26 0.89 33 52 0.039 58 78 0.086 
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3.2.2. Sequence analysis of the CARD15 gene NOD domain 
 
In 39 patients (from 39 families) sharing at least one parental chromosome 16 (identical by 
descent) with their affected sibling(s), none of the reported Blau syndrome mutations and no 
new mutations of exon 4 were detected. No new mutations were found in eight patients 
representing 7 complex families and sharing no parental chromosome 16. Sequence analysis 
of these 47 patients revealed only the known sequence variations denoted SNP5, SNP6, and 
SNP7 in ref 119. The frequencies of these alleles in 47 sequenced individually did not differ 
from the frequencies reported for larger samples of healthy individuals of German origin 110. 
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4. Discussion 
 
4.1. Association of the BTNL2 mutations with sarcoidosis  
 
4.1.1. Experimental design 
 
A three-stage SNP mapping experiment with mutation detection in the linkage region was 
performed on chromosome 6p21 in order to loca lise genetic variants that may generate a 
predisposition to sarcoidosis. Because allele/genotype frequencies depend heavily on the 
genetic background and history of a population, families, trios and incomplete pedigrees were 
collected in addition to single  affected cases so that both population- and family-based 
association study designs could be implemented. Such an experimental strategy, with both 
family and case-control analyses, was chosen so that the case-control studies, which can be 
prone to false positive (or false negative) results due to possible population admixture/sub-
structure, could be validated. For population based analyses, unrelated controls were matched 
to cases according to ethnic background, age and gender ratio. In the family-based analyses, 
families with both parents were preferentially collected (if available) to obtain the maximum 
number of informative trios for the transmission disequilibrium tests. 
 
A high throughput SNP typing method was applied to the association mapping experiment. It 
is an enabling technology that is useful for the identification of susceptibility genes by linkage 
disequilibrium mapping in large samples like in our study 140, 151. The method utilizes the 5’ 
exonuclease activity of Taq polymerase and employs a combination of PCR and competitive 
hybridization 152. The TaqMan genotyping results, as well as pedigree, patient phenotype, 
plate layout and marker information were stored and analysed in an integrated database 
system, which enabled to achieve the required throughput and to ensure the quality of the data 
130. 
 
4.1.2. Identification of the association region on chromosome 6p 
 
The genotyping strategy involved screening the linkage region, fine mapping in the resulting 
association region and then verifying the disease-marker association in an independent sample 
set. The linkage region had previously been identified in a study of 55 sarcoidosis families 61 
and was further supported in an extended sample set containing 63 families 58. The linkage 
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was consistent with numerous reports on associations between gene variants in the region 
and the risk of sarcoidosis. The linkage region was screened with 69 SNP marker in a 
combined sample set of families, trios and single patients containing 265 independent cases in 
total (refered as ,,exploratory’’). Three marker haplotypes in case-control and transmission 
disequilibrium tests were analyzed to maximize the informativity of the SNPs. Only the 
BTNL2 -HLA-DRA locus showed significance and demonstrated consistent results in both 
analyses. The association region peak was located at the HLA-DRA marker rs7192 
(P TDT(global)=0.00068; P case-control(LR)=0.00008), decreasing at BTNL2  marker rs2076523 
pTDT(global)=0.02512 pcase-control(LR)=0.00005. Another region located around the MICB-IkBL 
genes was significant only in the case-control analysis (rs3134900 Pcase-control(LR)=0.00011. 
PTDT(global)=0.14103). This locus also demonstrated long range LD with the markers from the 
previous region, exhibiting D’ values as large as 0.94. This indicates that the significance in 
the case-control analyses at MICB-IkBL may be influenced by the haplotype structure of the 
MHC locus. To resolve this problem, a genotype-based logistic regression analysis was 
performed that included markers from both regions. This analysis excluded the MICB-IkBL 
region and indicated that the disease susceptibility locus maps to the BTNL2 -HLA-DRA locus. 
Consequently, the BTNL2-HLA-DRA  region was selected for further fine mapping 
experiments. In order to verify the significant findings from the first screening experiment, 
and to test the validity of final mapping experiment result, an additional sample set containing 
trios and single cases (referred as the ,,extension’’sample) was added to the ,,exploratory’’ 
sample. The resulting set of patients contained 495 independent cases, representing a larger 
population affected by sarcoidosis.  
 
4.1.3. Sarcoidosis candidate genes on chromosome 6p 
 
The establishment of a high density LD map in the association region involved a detailed 
analysis of the sequence in the on-line databases. The chromosomal sequence was analysed 
for its gene content, the function of the genes and possible functional mutations. At the 
beginning of this study, there were five known genes in the region covered by the SNP 
screening experiment. The  AGER gene (located at 32.22Mb of chromosome 6) belongs to the 
immunoglobulin superfamily of cell-surface molecules and is an important receptor for the 
amyloid beta peptide. Expression of this receptor has been found to be increased in 
Alzheimer’s disease 153. The gene is also involved in inflammatory processes 154. The product 
of the NOTCH4 gene (at 32.25Mb) functions as a receptor for membrane-bound ligands and it 
  
80 
may play a role in vascular, renal and hepatic development. This gene has been found to be 
associated with susceptibility to schizophrenia in a fraction of cases 155, 156. Two genes TSBP 
(at 32.37Mb)and BTNL2  (at 32.44Mb) had unknown function. However, it was known, that 
BTNL2 contains immunoglobulin domains144 and is related to the B7-CD28 superfamily: 
these molecules have a crucial role in regulating T-cell activation and tolerance 147.  
Centromeric to the BTNL2  gene lies in the HLA gene cluster. These play a central role in the 
immune system by presenting peptides derived from extracellular proteins 17. Although many 
investigators have reported associations between HLA-DRB1 and sarcoidosis, BTNL2 became 
an interesting positional and functional candidate gene. The 440kb region bordered by the 
AGER and HLA-DQA1 genes and containing the BTNL2  gene therefore represented a prime-
target for the establishment of a high-density SNP map. As HLA genes are highly 
polymorphic and TaqMan assay design is largely not possible in the region, the high-density 
SNP map covered HLA-DRA gene and finished at the 3-prime end HLA-DRA gene.  
 
Every exon of the positional candidate gene BTNL2  was sequenced in 47 sarcoidosis patients 
in order to verify the known sequence variations and to detect any not previously described 
mutations. 48 SNP markers were genotyped in the combined ,,exploratory’’ and ,,extension’’ 
sample set that contained 495 independent cases. As in the first screening experiment, both 
family and population based analyses were carried out on this data. A 15kb region at the 3’ 
end of the BTNL2  gene, containing the markers rs2076530, P285L, M286I and P299Q, 
demonstrated a strong and consistent signal in both case-control and TDT analyses. 
 
It is important that an association study finding should be replicable in independent sample 
sets. In this study, the initial association study results were verified in an independent sample 
set (referred to in our study as ,,verification’’). For this, an additional sarcoidosis sample 
consisting mostly of trios and single patients, and yielding 452 independent cases in total, was 
genotyped at the four disease -associated markers: rs2076530, P285L, M286I and P299Q. The 
SNP (rs2076530), in the downstream region of the BTNL2 gene, was most strongly associated 
with disease and this observation was replicated in the verification sample. This variant is 
common and has a minor allele (allele 2 that corresponds to nucleotide G) frequency of 0.42 
in the control population. The allele 1 (corresponds to nucleotide A) apparently contributes to 
disease susceptibility in a manner that is completely independently of the (known) disease-
associated alleles in the HLA-DRB1 gene. The susceptibility allele A of rs2076530 is 
characterised by an odds ratio of 1.55 in heterozygotes, and of 2.56 in homozygotes, 
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corresponding to PARs of 22% and 34%, respectively. Comparing this result to other 
complex diseases associated loci, for example CARD15 in Crohn disease, rs2076530 has only 
a moderate impact on an individual’s disease risk. This is particularly intriguing in light of its 
profound impact upon the BTNL2 protein structure and function. This apparent discrepancy 
may be in part explained by a highly redundant system of co-stimulatory molecules, including 
the products of the butyrophilin gene cluster, B7-1, plus other, as yet unknown, members of 
the same functional class of proteins. 
 
The revised BTNL2 transcript consists of eight exons. Experiments on cDNA indicated that 
the annotated BTNL2 gene transcript was incomplete in that it was missing one exon at the 5’ 
and two exons at the 3’ end. Exon 3, referred to as an IgC domain in the original reference 144 , 
was not identified in our transcripts, thereby rendering the hypothesis of two transcripts at this 
locus somewhat unlikely. Furthermore, the most significant variation, rs2076530, does not 
result in an amino acid exchange but rather appears to influence splicing through the 
replacement of the normally conserved G allele at the -1 donor site of exon 5 with an A.  
 
The BTNL2 expression experiments supported the hypothesis, that the gene is implicated in 
susceptibility to sarcoidosis. Expression was found only in the bronchoalveolar lavage of 
affected lungs and in myelomonocytic cell-lines stimulated with TNFa. It is known, that 
activated alveolar macrophages secrete increased amounts of TNFa in sarcoidosis patients 98.  
Therefore, it may be speculated that TNFa induces BTNL2 transcription in the sarcoid lung.  
 
Phylogenetic analyses and homology searches with the immunoglobulin domains of BTNL2 
indicated, that the gene is similar to five human butyrophilin ge nes and belongs to the 
extended butyrophilin family144. BTNL2  also shows similarity to mouse NG9  and NG10 genes 
144 and is homologous to the Zipper proteins, bg2, MOG, and B-G which, phylogenetically, 
appear to be members of extended B7 family 157. The immunopathogenesis of demyelination 
in multiple sclerosis involves an autoantibody response to the immunoglobulin superfamily 
member myelin oligodendrocyte glycoprotein (MOG) 158. Crystal structure analysis has 
demonstrated that the extracelular domain of MOG adopts an IgV like fold that harbours a 
cavity that is similar to the one used by the co-stimulatory molecule B7-2 to bind its ligand 
CTLA4 159. Based on amino acid homology and domain structure, BTNL2 is most similar to 
the B7-1 protein (for details see chapters 9.2.4. and 9.2.5.). B7-1 (CD80) is a co-stimulatory 
molecule with known anti-inflammatory activity that is mediated through an interaction with 
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CTLA-4 160, 161. Co-stimulatory pathways for T -cells are initiated when CTLA-4 and CD28 
engage B7 class molecules in the context of a primary signal delivered through the TCR-
MHC interaction 149, 162, 163. Deletion the IgC domain in the CD80 gene had a substantial pro-
inflammatory effect in a mouse plasmid vaccination model, suggesting that the constant-like 
domains are critically important for immune regulation during co-stimulation 164. It may be 
therefore hypothesised tha t BTNL2 potentially has a down-regulatory effect on T-cells and 
that this would be impaired by the truncating mutation at rs2076530. This leads to a loss of 
the IgC domain, thereby leading to inappropriate T-cell activation. This hypothesis would also 
be compatible with the clinical immunology of sarcoidosis, which is characterized by a 
dysregulated T -helper cell activation 165.  
 
The importance of co-stimulatory dysfunction is becoming increasingly recognized in many 
autoimmune disorders 166. Our findings also emphasize the importance of the costimulatory 
mechanism in the regulation of T-cell activity, since CTLA4, a prototype of a putative 
BTNL2 receptor, is a risk factor for such autoimmune disorders as type I diabetes, 
autoimmune hypothyroidism and Grave’s disease 166. The exact function of BTNL2 and its 
role in the co-stimulatory system remains to be elucidated. The identification of the BTNL2 
gene as a risk factor for sarcoidosis will give new impetus to the understanding of 
immunological co-stimulation. Functional studies of BTNL2  may provide a perspective for 
future therapeutic targeting of this disorder. 
 
4.1.4. Genotyping of the HLA-DRB1  
 
Linkage to the HLA region has been shown for many complex autoimmune diseases. Despite 
the primary function of HLA genes in the immune system, many other immune response 
related genes also map to the region and their role in disease aetiology can not be excluded. 
However, only a few non-HLA disease genes have been successfully implicated with disease 
in the MHC region 89, 90. In the search for disease genes in this region, HLA genotyping is 
essential either to differentiate the gene effect from a nearby HLA gene or to implicate the 
HLA molecule itself in the disease aetiology. However, in such situations, high-throughput 
methods are required and low-resolution is sufficient. Current HLA genotyping methods do 
not meet such requirements.  
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In this study, a method was developed that combined allele-specific PCR with non-
elecrophoretic scoring of amplification products; an approach that is useful for high-
throughput HLA-DRB1 allele-group genotyping. Seven, non-overlapping groups of HLA-
DRB1 alleles were genotyped in place of the actual alleles 127, 128. Because HLA-DRB1  is a 
multi-allelic system, all groups had to be typed for an individual in order to reconstruct the 
final genotype. The scoring of PCR amplification products usually involves agarose gel 
electrophoresis. However, this method does not scale well for high-throughput. A non 
electrophoretic detection method was therefore adapted 125. This method specifically measures 
dsDNA concentration and detects an increase in samples where the PCR targeted DRB1 allele 
is present. A specialized software was developed for the scoring of PCR amplification 
products, genotype assignment, Mendelian segregation checking and integration into the 
laboratory database system. This allowed flexible handling of the DRB1 allele -group 
genotype information.  
 
In general, multi-allelic systems demonstrate a higher rate of genotyping error when 
compared to biallelic SNP genotyping. An individual can be miscalled as a homozygote 
simply because of a single failed PCR reaction. In our method, DNA concentration is further 
critical parameter because the detection of PCR amplification products with the dsDNA-
specific dye PicoGreen® is based on an increase in the dsDNA concentration when the 
targeted allele is present. To achieve uniform and reproducible genotyping results, the initial 
DNA concentration was measured and adjusted to 2.5ng/well for all analysed samples. The 
approach was evaluated in 2,295 individuals and gave a genotyping success rate of 94.11%. 
Mendel error rates in the family sample (1.3%) compared favourably with other genotyping 
methodologies 131.  
 
The primary purpose of this study was to establish a high-throughput HLA-DRB1  allele -group 
typing method for disease gene finding in the MHC region and to facilitate the differentiation 
of the genetic effect of a disease gene from a nearby HLA gene. Nevertheless, the HLA-DRB1 
allele genotyping results were also compared with associations reported in the literature for 
other populations. In principle, the results obtained in the  current study were in agreement 
with previously described associations in distinct Caucasian ethnic groups. DRB1*01 and 
DRB1*04 were reported as ,,protective’’ alleles in case-control studies with UK, Czech, 
Polish, Scandinavian, Italian and US Caucasian patients (with the exception of DRB1*01 in 
the US Caucasians) 72, 74. Although the frequencies of the “protective” HLA alleles varied to 
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some extent among the control samples of these studies, the reduction in allele frequency in 
patients was consistent across all investigated populations 72. In the current study design, the 
DRB1*01 and DRB1*04 alleles were amplified in allele amplification groups 1 and 4 
respectively. For both these allele groups reduced allele frequencies in samples of affected 
individuals were detected. As expected, this result was in agreement with the pattern of 
observed and expected transmissions in TDT analyses. That DRB alleles carrying 
hydrophobic side -chain residues at position 11 of the HLA-DRB1 peptide may confer a 
protective effect remains open to exploration. As the disease causing antigenic stimulus is 
unknown, it is still unclear whether the possible protective effect of HLA-DRB1 alleles could 
be due to an altered binding of autoantigens or foreign antigens 72. 
 
In contrast to the consistent reports of ,,protective” HLA-DR alleles across a variety of 
populations, descriptions of alleles associated with sarcoidosis susceptibility demonstrate non-
overlapping results, and seem to appear to act in ethnicity-dependent manner, or to influence 
the course of disease. For example, the alleles carrying hydrophilic residues at position 11 
(HLA-DRB1*07, *08, *09) apparently influence disease susceptibility in different ways in 
UK, Polish, Czech, Scandinavian and Japanese patients.HLA-DR-14 and –15 were found to 
be more common in UK, Polish and Czech populations 72. HLA-DR17 was found to be 
particularly associated with an acute disease course in Scandinavian and German cases 70, 71.  
HLA-DRB1*1101 has been suggested to be the most important susceptibility factor for 
sarcoidosis among the HLA class II alleles on the grounds that this allele has been 
significantly associated with sarcoidosis in both people of African ancestry and Caucasians 74.  
In the current study, amplification group 3 alleles (DRB1*03, *08, *11(not *1122/30, *12, 
*13, *14, (not *1410/39)) appeared confer an increased risk of sarcoidosis. The frequency of 
group 3 alleles was significantly increased in sarcoidosis cases relative to controls. A 
significant over-transmissions of these alleles was also observed in the family sample, thus 
supporting the case-control finding. It was therefore possible that HLA alleles and not the 
sequence variation at rs2076530 in BTNL2  might be driving the association effect in the 
region and that the signal at rs2076530 resulted from linkage disequilibirum between the 
markers. However, separation of the gene effects via a stratification analysis of the respective 
HLA-DRB1  and BTNL2  genotypes using a Breslow -Day test for homogeneity of odds ratios 
has rejected this hypothesis. Therefore, it appears that HLA-DRB1  amplification group 3 and 
rs2076530 allele A represent independent risk factors for sarcoidosis.  
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4.2. CARD15 mutations in sarcoidosis 
 
Sarcoidosis and Crohn’s disease are multifactorial disorders, in which disease is caused by an 
inherited susceptibility and an additive influence of unknown exogenous agents 33, 34, 59. In 
contrast, Blau syndrome is caused by single dominant gene mutation that directly leads to 
Mendelian inheritance of the disorder, although yet unknown factors modify the expression of 
the disorder between and within affected families considerably 60, 104. The clear mode of 
monogenic inheritance helped to localise the Blau syndrome gene. It was mapped to the 
centromeric region of chromosome 16 by linkage analysis of only one extended family 104. In 
contrast to monogenic diseases, large numbers of affected families and repeated genome-wide 
linkage studies are necessary to locate disease genes in complex diseases 105-107. Such a 
strategy finally led to the successful identification of CARD15 mutations as a major 
contributory factor in Crohn’s disease susceptibility 108 -110. In sarcoidosis, genome-wide 
linkage information is so far limited to one report 58 showing a main peak at the MHC region 
on the short arm of chromosome 6 61, 167.The genetic mechanisms behind a predisposition to 
sarcoidosis are unclear, although the contribution and cooperation of several genetic factors in 
the development of sarcoidosis is likely. Therefore the peak at the MHC region cannot fully 
explain the increased familial recurrence risk found in different studies in European 
populations 42, 168, 169 and in the USA 54. 
 
In addition to a genome-wide search by linkage analysis in affected siblings, association 
studies with candidate genes are widely used for the study of complex diseases 28. However, 
heterogeneity in sarcoidosis aetiology is likely to be caused by variable influences from 
different genetic factors that depend on the ethnic background. This could be the reason for 
the many contrasting reports on associations between sarcoidosis and polymorphisms in 
candidate genes 61. Nevertheless, there is an on-going search for promising candidate genes 
that connects an inhaled microbial trigger to a balanced cellular immune response 77. 
 
Significant familial clustering of sarcoidosis and Crohn’s disease has been reported. 42 This 
suggests homologous mechanisms in the pathophysiology of both disorders. In Crohn’s 
disease, increased levels of NF kappa B play an important role in the development and 
maintenance of inflammation 111. Increased levels of NF kappa B have been also found in 
sarcoidosis 112. Since the function of the CARD15 protein includes the regulation of NF kappa 
B levels, mutations in the CARD15 gene in patients with Crohn’s disease seem to clarify an 
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important link in the pathway from a presumed exogenous agent to granulomatous 
inflammation process.  
 
Blau syndrome is a rare condition with a limited number of reports in literature. The first 
mutations were identified in four unrelated families 132. All patients from these families 
carried a mutation in the nucleotide oligomerisation domain (NOD) of the CARD15 gene. In 
three families the same amino acid of the NOD, arginine at amino acid position 334 of the 
protein, was substituted by glutamine or tryptophan (R334Q and R334W). Both mutations 
were confirmed in another 5 out of 10 unrelated families 133. According to these findings, 
Blau syndrome mutations appear to cluster strongly within the NOD, and mutations of the 
LRR seem to be linked with Crohn’s disease. Thus the mutations in different domains of the 
CARD15 protein cause different phenotypes within the spectrum of granulomatous disorders, 
leading to the development of Blau syndrome or to a significant increase in the risk of 
Crohn’s disease, respectively. Taking into account the considerable overlap of clinical 
features between Crohn’s diasease, Blau syndrome and sarcoidosis, the CARD15  gene could 
be considered an excellent candidate gene of sarcoidosis susceptibility. 
 
There was preliminary information concerning the Blau syndrome mutation region in the 
CARD15 gene of sarcoidosis patients 170. In a study of 33 African-American nuclear families 
with 67 sarcoidosis siblings, tested for co-segregation of the disease with eight highly-
polymorphic DNA markers from the centromeric region of chromosome 16, no evidence of 
linkage was found. However, the heterogeneity of disease between African-American and 
Caucasians 33, 55 suggests that the results from this study may not necessarily be valid in 
Caucasians.  
 
A subgroup of the study population used in this experiment has been analysed in a genome-
wide linkage study 58. The microsatelite marker D16S3396 analysed in the scan is located 
close to the CARD15 gene. The results did not provide any significant evidence (P = 0.21) 
that siblings suffering from sarcoidosis tend to be identical by descent for this region of 
chromosome 16. However, these linkage data do not rule out the possibility that CARD15 
mutations could play a role in a subgroup of sarcoidosis patients. Therefore, mutations of the 
CARD15 gene that could contribute to sarcoidosis in only a portion of families seemed likely. 
In the current study, we have analysed the sequence of the CADR15 gene region that is altered 
in Blau syndrome, in a selected panel of patients. We excluded the presence of Blau syndrome 
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mutations in sarcoidosis patients and detected no other sequence variations than the known 
polymorphic sites. This result from sarcoidosis families cannot exclude a minor influence of 
rare NOD sequence variants in sarcoidosis. However, it clearly implies that a major 
contribution of CARD15 NOD variants in Caucasian patients is unlikely because a major 
gene effect would be linked to the familial occurrence of sarcoidosis.  
 
In order to investigate a minor contribution of Crohn’s disease CARD15 mutations to the 
aetiology of sarcoidosis, extended panels of sarcoidosis families, sarcoidosis trios and controls 
were genotyped for four SNPs that are associated with an increased risk of Crohn’s disease.  
With the exception of SNP13 in the sarcoidosis families set, the rarer alleles of the four SNPs 
tended to be more frequent in cases than in controls, replicating the observations made in 
Crohn’s disease study 108-110. A significant difference was detected for SNP5 in sarcoidosis 
families and for SNP12 in sarcoidosis families and in sarcoidosis trios. The allele frequencies 
of SNP5, SNP8 and SNP12 in our controls were in agreement with the published frequencies 
for controls in an Europe-wide study of Crohn’s disease 119, however, the SNP13 minor allele 
frequency of our study was considerably higher (3.6% versus 2%). On the other hand, a 
German control sample created for the case-control study of Crohn’s disease had an even 
higher frequency of SNP13 allele 1 of 5.3% 110. Genotyping of our extended group of 
available German controls, who were excluded from this study because of young age, 
indicates that the SNP12 allele 1 frequency in the matched control group is relatively low. 
Therefore, significant differences between sarcoidosis cases and controls might be attributable 
in part to this control group related phenomenon.  
 
Taking into account the limitations of case-control comparisons in association studies of 
candidate gene polymorphisms in complex disorders, family-based strategies such as the TDT 
have been employed in this study to overcome control group related problems. Although 
sarcoidosis trios exhibited an over-transmission of SNP5 allele 1, this observation did not 
overlap with the case-control results for this marker in the same set of patients. In addition, 
further information about haplotype segregation extracted from families has been analysed. 
Strong linkage disequilibrium between the four SNPs has been observed in other studies 26, 
171, and can provisionally be derived from the haplotype proportions of the TDT analysis. As 
listed in table 14, the rare alleles of SNP8, SNP12 and SNP13 occur almost exclusively in 
combination with SNP5 allele 1.  
 
  
88 
In the trios, all haplotypes with the rare allele of at least one of the four SNPs are 
preferentially transmitted from heterozygote parents to affected offspring although this 
deviation does not reach significance. However, complementary haplotypes composed of the 
four common alleles demonstrates a significant under-transmission. Interestingly, 
transmission of alleles and haplotypes is almost perfectly balanced in the sarcoidosis families. 
This fact could point to heterogeneity in the genetic aetiology of sarcoidosis with respect to 
CARD15 gene variation. 
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5. Conclusions 
 
The chromosome 6 association study in this thesis uses an association mapping method for 
identification of a disease susceptibility gene. The experiment design included both family- 
and population-based study approaches. The basic criterion for the validity of association 
findings was consistency of results in both family- and population based study designs. Using 
a single nucleotide polymorphism typing method, 16.4 Mb of the chromosome 6p21 region 
that was implicated in the chromosome 6 linkage study 58 were scanned in order to identify 
primary association lead(s). Consistently significant results in both study designs were 
obtained for one peak located at the BTNL2 -HLA-DRA region. To map the disease-associated 
gene, a certain marker density had to be achieved in the lead region. A high-density SNP map 
in the primary association region was therefore established through a detailed analysis of the 
physical map and the identification of sequence variations. Using TDT and case-control 
analysis, a 15kb segment of the BTNL2  gene was identified as being strongly associated with 
sarcoidosis. The major disease-associated variant rs2076530, located in exon 5 of BTNL2 
represents a risk factor that is entirely independent of the previously reported association 
between sarcoidosis and alleles of the DRB1 gene. The risk allele A of rs2076530 leads to 
alternative splicing of the BTNL2 transcript, which introduces a premature stop codon and 
leads to the truncation of the protein. BTNL2 is a member of the immunoglobulin superfamily  
and has been implicated as a co-stimulatory molecule based on its homology to B7-1. 
 
The BTNL2  gene, containing the disease susceptibility allele (rs2076530), is located in the 
close vicinity (~200kb) of the HLA-DRB1  gene. Since the HLA gene has also been implicated 
in the aetiology of disease, a special method of allele group-specific PCR typing with a non-
electrophoretic method and novel software to support scoring have been developed for high-
throughput typing. By design, primers amplified non-overlapping groups of HLA-DRB1  
alleles and only limited resolution of DRB1 alleles was achieved. Separate PCR-reactions had 
to be performed for each allele group in order to construct the final genotype. The method has 
several advantages over the alternatives and will complement other approaches 126, 172, 173.  
dsDNA measurement was used instead of agarose gel electrophoresis that does not scale well 
for high-throughput applications. Measurement of dsDNA is much less expensive than 
TaqMan assays 174 or fluorescently labeled PCR products for automated sequencing. The low-
resolution HLA-DRB1 allele genotyping strategy developed in this study has been 
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successfully applied for 2,295 individuals. The method may facilitate the gene 
identification of complex, HLA linked autoimmune disorders. 
 
A candidate gene approach is a useful approach for association testing between a disease and 
positional or functional candidate genes. In this study, CARD15, which leads to the 
development of Blau syndrome or to a significant increase in the risk of Crohn’s disease has 
been selected as a sarcoidosis candidate gene. In a case-control analysis, SNP12 alele1 was 
more frequent in sarcoidosis cases comparing to the controls. From the TDT results, 
sarcoidosis trios but not families demonstrate significant result for SNP5. Thus, replication of 
the investigation is desirable. Nevertheless, the present association and sequence analysis 
results seem to rule out a major role of CARD15 mutations in the pathogenesis of sarcoidosis. 
Because Crohn’s disease, Blau syndrome and sarcoidosis significantly overlap with respect to 
their pathophysiology and clinical phenotypes, this finding demonstrates the genetic 
heterogeneity of granulomatous inflammatory disorders. 
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6. Summary: Identification of sarcoidosis susceptibility genes by 
association mapping and candidate gene approaches 
 
Sarcoidosis is a systemic immune disorder with predominant manifestations in the lung, 
lymph nodes, eyes and skin. The disease can lead to pulmonary fibrosis and chronic 
respiratory failure and is pathophysiologically characterized by an exaggerated T-helper cell 
response. Identification of a sarcoidosis susceptibility gene on chromosome 6 in this study has 
been performed using the association mapping approach. In a previous genome wide linkage 
analysis, the extended MHC region on chromosome 6p has been implicated in the aetiology of 
sarcoidosis. Here, a systematic three-sta ge single nucleotide polymorphism (SNP) scan of 
16.4 Mb on chromosome 6p21 was performed in up to 947 independent cases of familial and 
sporadic sarcoidosis. Using TDT and case-control analyses, a 15 kb segment located at the 3-
prime end of the BTNL2  gene could be identified as being strongly associated with 
sarcoidosis. The major disease-associated variant, rs2076530, represents a risk factor that is 
entirely independent of the previously reported association between sarcoidosis and alleles of 
the DRB1 gene, located within ~200kb of BTNL2. BTNL2 is a member of the 
immunoglobulin superfamily. Homology to B7-1 implicates the BTNL2 as a co-stimulatory 
molecule. The risk allele A of rs2076530 leads to alternative splicing of the BTNL2 
transcript, which introduces a premature stop. The resulting truncated protein lacks the C-
terminal IgC domain and transmembrane helix, thereby disturbing the putative co-stimulatory 
function of this molecule.  
 
Differentiating specific gene effects from the nearby HLA loci is a common problem in the 
mapping of susceptibility genes of disorders linked to the MHC region. The HLA molecules 
may be risk factors for the disease themselves or they may serve as markers tagging risk 
haplotypes. Since the BTNL2  gene with the disease-associated variant is located near HLA-
DRB1, which has itself previously been implicated as a risk factor for sarcoidosis, genotyping 
of the HLA was performed to evaluate the effects of both genes. In this situation, high-
throughput rather than detailed resolution of the HLA genotype was required. Current methods 
do not support to this kind of requirement. A method combining non-electrophoretic scoring 
and genotyping of non-overlapping allele -groups, instead of specific HLA-DRB1  alleles, has 
been developed for genotyping large patient samples. A specialized software facilitated the 
construction of the final DRB1 genotype, testing of Mendelian segregation and database 
import. The approach was practically evaluated in a sample of 2,295 individuals from nuclear 
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familie s and 538 unrelated control individuals. Genotyping success rate was 94.11% and 
only 1.3% of the data had to be discarded due to Mendel errors. The HLA-DRB1 allele 
genotyping strategy developed in this study may contribute to gene identification in other 
complex, HLA linked autoimmune disorders. 
 
Association studies of candidate genes are widely used for the study of complex diseases. 
Crohn’s disease, Blau syndrome and sarcoidosis significantly overlap in clinical phenotypes 
and pathophysiology. In our sarcoidosis study, a minor contribution of CARD15 SNP12 
cannot be excluded because allele 1 was significantly more frequent in cases than controls. 
TDT results indicated association in sarcoidosis trios but not in families, thus replication of 
the investigation is desirable. However, association and sequence analysis results rule out a 
major role for the CARD15 mutations that confer susceptibility to Crohn's disease and Blau 
syndrome in the pathogenesis of sarcoidosis in Caucasians. This finding demonstrates the 
genetic heterogeneity of granulomatous inflammatory disorders.  
 
The association mapping and candidate gene testing results in patients suffering from 
sarcoidosis should provide insights into the pathogenesis of this complex disease. 
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7. Zusammenfassung: Identifikation von Sarkoidose Krankheitsgenen 
durch Assoziationsstudien und Kandidatengen Ansätze 
 
Sarkoidose ist eine systemische Immunkrankheit mit vorwiegenden Manifestationen in der 
Lunge, den Lymphknoten, den Augen und der Haut. Die Krankheit kann zu Lungenfibrose 
und chronischem Atemwegsversagen führen. Pathophysiologisch wird Sarkoidose durch eine 
stark übertriebene T-Helferzellen Antwort charakterisiert. Mit Hilfe von Assoziationsstudien 
konnte ein Sarkoidose Empfänglichkeitsgen auf Chromosom 6 id entifiziert werden. Eine 
vorher durchgeführte, genomweite Kopplungsstudie belegt einen Zusammenhang zwischen 
der erweiterten MHC Region auf Chromosom 6p und der Ätiologie von Sarkoidose. 
Daraufhin wurde ein systematischer, dreistufiger Einzelnukleotid Poly morphismus (SNP) 
Scan der 16,4 Mb auf Chromosom 6p21 für 947 unabhängige Fälle von familiärer und 
spontaner Sarkoidose durchgeführt. Durch das Benutzen des TDT und von 
Patient -/Kontrollanalysen, konnte ein 15 kb grosses Segment in der Nähe des 3’ Endes des  
BTNL2 Genes identifiziert werden, welches stark mit Sarkoidose assoziert ist. Die am 
häufigsten mit der Krankheit assoziierte Variante, rs2076530, stellt einen Risikofaktor dar, 
welcher komplett unabhängig von der schon länger bekannten Assoziation zwischen 
Sarkoidose und DRB1 Allelen ist. DRB1 liegt ~200 kb entfernt von BTNL2. Letzteres ist ein 
Mitglied der Immunglobulin Superfamilie. Die Homologie zu B7-1 impliziert, dass BTNL2 
als co-stimulierendes Molekül fungiert. Das Risiko-Allel A von rs2076530 führt zum 
alternativen Splicing des BTNL2 Transkriptes, welches zu einem frühzeitigen Abbruch der 
Translation führt. Dem resultierenden gekürzten Protein fehlt die C-terminale IgC -Domäne 
samt transmembraner Helix, weshalb die vermutete co-stimulierende Funktion des Moleküls 
gestört wird. 
 
Es ist ein bekanntes Problem, spezifische Geneffekte von nahegelegenen HLA Loci zu 
unterscheiden, wenn man potentielle Krankheitsgene kartiert, welche mit der MHC Region in 
Verbindung stehen. Die HLA Moleküle können selber Risikofaktoren für die Krankheit 
darstellen bzw. Marker auf Risiko Haplotypen sein. Da das BTNL2 Gen mit der 
krankheitsassoziierten Variante in der Nähe von HLA-DRB1 liegt, welches zuvor schon als 
Risikofaktor für Sarkoidose identifiziert wurde, wurde die HLA Region genotypisiert, um die 
Effekte der beiden Gene abzuschätzen. An Stelle von detaillierter Auflösung des HLA 
Genotyps, wurde eine Hochdurchsatz Methode angewandt. Da aktuelle Methoden noch nicht 
die nötigen Anforderungen erfüllen, wurde eine Methode entwickelt, welche nicht-
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elektrophoretisches scoring mit Genotypisieren von nicht-überlappenden Allel-Gruppen 
kombiniert, um eine hohe Anzahl an Patienten zu genotypisieren. Dabei erleichterte eine 
spezielle Software die Konstruktion des endgültigen DRB1 Genotyps, den Test auf 
Mendelsche Vererbung, als auch den Datenbank Import. Der Versuch wurde mit einer Anzahl 
von 2.295 Individuen aus Kernfamilien und 538 nicht miteinander vewandten Kontroll-
Individuen durchgeführt. Die Erfolgsrate lag beim Genotypisieren bei 94,11%, und nur 1,3% 
der Daten mussten wegen auftretender Mendelfehler vernachlässigt werden. Die HLA-DRB1 
Allel Genotypisierungs-Strategie, welche in dieser Studie entwickelt wurde, könnte für die 
Genidentifikation bei anderen komplexen, HLA gekoppelten Autoimmunkrankheiten von 
grosser Bedeutung sein.  
 
Assoziationsstudien an Kandidatengenen werden generell für Studien von komplexen 
Krankheiten genutzt. Die Krankheiten Morbus Crohn, Blau Syndrom und Sarkoidose 
überlappen sich signifikant bezüglich klinischer Phänotypen und ihrer Pathophysiologie. So 
konnte in der Vergangenheit das Krankheitsgen CARD15 bei Morbus Crohn und beim Blau 
Syndrom identifiziert werden. In unser Sarkoidose Studie können wir nicht den geringen 
Einfluss von CARD15 SNP12 ausschliessen, da Allel 1 häufiger in Patienten als in 
Kontrollpersonen zu finden ist. Die Ergebnisse des TDT lassen auf eine Assoziation in 
Sarkoidose Trios aber nicht in Familen schliessen. Es wäre wünschenswert diese Ergebnisse 
durch erneute Studien zu festigen und zu verifizieren. Trotz allem schließen die CARD15 
Assoziations- und Sequenzanalysen eine grundlegende Beteiligung an der Pathogenese der 
Sarkoidose aus. Diese Ergebnisse demonstrieren die genetische Heterogenität von 
granulomatösen entzündlichen Krankhe iten.  
 
Die Ergebnisse der Assoziationsstudie und die Kandidatengen Testergebnisse sollten einen 
Einblick in die Pathogenese der komplexen Krankheit Sarkoidose geben. 
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9.1.1. Primer and probe information for chromosome 6 assays 
 
Table 15. Part 1: Primers and probes of SNP assays  
Marker hCV number*  Gene Posit
ion 
(NCBI
) MB 
Primers: 
Forward 5’-3’ 
Reverse 5’-3’ 
Probes Sample used 
rs2073528 hCV11255445 BTN3A2 26,44   Exploratory/exten
sion 
rs2072803 hCV2474923 BTN2A2 26,46   Exploratory/exten
sion 
- hCV2474907 BTN3A1 26,48   Exploratory/exten
sion 
- hCV2474883  26,50   Exploratory/exten
sion 
- hCV9804528  26,54   Exploratory/exten
sion 
rs3736781 hCV9804725 BTN1A1 26,57   Exploratory/exten
sion 
rs126007   27,80 TCCTTAACCAACCTCATCCTGG 
TGGTAACTCGACAGCTGATTCTTG 
FAM-AGAAGAGCAGCAACCAAAGGCTAACGTGA 
TET-AGAAGAGCAGCAAACAAAGGCTAACGTGAGA 
Exploratory-
screen 
rs929042  RFP 28,95 CGGACGTGTGGTTCACAGC 
CTCCGTGTACAATGTGTCCGTG 
FAM-CTGTAGCTGGCGAGGAAGGCAGGAGT 
TET-CTGTAGCTGGCGAGGAAGCCAGGAGT 
Exploratory-
screen 
rs53161   29,56 GGGCTGTCCACGTGCAC 
GCAGAGTTGAACCAGTATATAACCTTTC 
FAM-AAGGGGCAACATACACAATGTGTTTACCAAAATT 
TET-AAGGGGCAACATACACATTGTGTTTACCAAAATT 
Exploratory-
screen 
rs404240  UBD 29,59 CCACAAGAAACAAGGGCAGC 
GAACATGTCCGGTCTAAGACCAA 
FAM-TCTTGGAGCCCAGCGAAAGAACCTG 
TET-ATCTTGGAGCCCAGCAAAAGAACCTGG 
Exploratory-
screen 
rs362536  UBD 29,59 TGGAGAGAACCTGGAATTAAGGC 
GGACTATATCTAAGTCTTACTTCAATAGCTGGA 
FAM-ATTGGGAGAATATTTCTGAATGGAGTATGAGGGAG 
TET-TATCTAGATTGGGAAAATATTTCTGAATGGAGTATGAGGG 
Exploratory-
screen 
rs1805057  GABBR1 29,64 CCATCTGGGCCTTGGCA 
GGTAATGGTCTGGTTGTTGTAGTTGAA 
FAM-AGGAGGCGGCCGTTCTGGTGTG 
TET-TGGAGGAGGCAGCCGTTCTGGTGT 
Exploratory-
screen 
rs3130253  MOG 29,73 GTTCTCCTCGCGGTGCTG 
CCCACCCTCTGCCCTGTAC 
FAM-CACTCTTGGCCTCGTCTTCCTCTGCC 
TET-TCACTCTTGGCCTCATCTTCCTCTGCCT 
Exploratory-
screen 
rs1569315  HLA-G 29,85 CGCAGGTCCTCGTTCAGG 
AGTGGATGATTGGCTGCGA 
FAM-AGGAGGCGTCCGTCGGACCC 
TET-AGGAGGCGACCGTCGGACCC 
Exploratory-
screen 
rs8347  HCG-V 30,10 AGGAGACCTCAGAGCTCCCAG 
AAGTGACCAATCTCAAGCCAGC 
FAM-AAATGGAATAAGAAATAATCATATCCTTTCTTCCCACCC 
TET-AAATGGAACAAGAAATAATCATATCCTTTCTTCCCACC 
Exploratory-
screen 
rs1264457  HLA-E 30,52 CTCACACCCTGCAGTGGATG 
AGGGTGAGATAATCCTTGCCG 
FAM-CCCGACAGGCGCTTCCTCCG 
TET-CCCGACGGGCGCTTCCTCC 
Exploratory-
screen 
rs2074510  GTF2H4 30,94 GAGTGCAGCGTCTATTCTCATCC 
TTGGCTCCTGGAGATTGAGG 
FAM-CATTCTGGGCTCTTGCCTGTGAAATCTTTC 
TET-CCATTCTGGGCTCTTTCCTGTGAAATCTTTC 
Exploratory-
screen/extension 
rs3095318  CDSN 31,15 CGTCTCGGGCACCCTG 
AGACACACAGACTAGAGGTAGGTGTCA 
FAM-CACGGGATGATGGCACTGCTGCT 
TET-CACGGGATGTTGGCACTGCTGCT 
Exploratory-
screen 
rs2073721  SC1 31,19 GGTGGACCAAAGAGCCTGC 
CATCCAGTTCCGCCAACAC 
FAM-ACCTGGGGAAGTGGGGACCACG 
TET-ACCTGGGGAAATGGGGACCACG 
Exploratory-
screen 
rs1050393  HLA-C 31,30 GGAGTATTGGGACCGGGAG 
CGCTCTGGTTGTAGTAGCCG 
FAM-CCAGGCACAGGCTGACCGAGTG 
TET-CGCCAGGCACAGACTGACCGAGT 
Exploratory-
screen 
rs1051488  HLA-B 31,38 CTGGCCTGGCTGTCCTAGC 
CTTCCCAGTAATGAGGCAGGG 
FAM-AGCTGTGGTCGCTGCTGTGATGTGA 
TET-AGCTGTGGTCGCTACTGTGATGTGAGGAG 
Exploratory-
screen 
rs1063630  MICA 31,44 CCCAGAGCCCCACAGTCTT 
AGAAACCCTGACTGCACAGATC 
FAM-ATCCCCGGACAGCA 
VIC-CATCCCAGGACAGCA 
Exploratory/exten
sion 
rs1063635  MICA 31,44 CTTTGAGCCACGACACCCA 
GGCTCACCAGAGGGCACA 
FAM-ACCAGGATTTGCCAAGGAGAGGAGCA 
VIC-ACCAGGATTTGCCGAGGAGAGGAGC 
Exploratory-
screen/extension 
rs3828916 hCV3273671  31,53   Exploratory/exten
sion 
rs3131639  MICB 31,53 GCAGAAACGCAGGGCAAA 
TGTCAAGTCCTCGGTCTCTGTGT 
FAM-CAGGACATTTTCTG 
TET-AGGACATCTTCTGCC 
Exploratory/exten
sion 
rs3134900  MICB 31,53 CTTGGGTGGAAAGGTGATGG 
GGTTTTGGGAGAGGAAGAGCTC 
FAM-TCTGTGAGATCCATGAAGACAGCAGCACC 
TET-CTGTGAGATGCATGAAGACAGCAGCACC 
Exploratory-
screen/extension 
AC006046_G3
0156A 
 MICB 31,53 CTGGCTCTGCCCTTTCTTCTC 
CGGTGATGTTGCCCTCTGA 
FAM-TGCAGATGACATTCA 
TET-TGCAGGTGACATTC 
Exploratory/exten
sion 
rs3130062  IkBL 31,59 CGGGAACATGCCCAGAAGT 
GGCTGGAGCCCTCAGCA 
FAM-TCGACAGGATCCCTCTGCTTCTCG 
TET-TCGACGGGATCCCTCTGCTTCTC 
Exploratory-
screen/extension 
rs1800683 hCV7514865 LTA 31,60   Exploratory/exten
sion 
rs1041981  LTA 31,60 CCCGTCAGCACCCCAAGATG 
TGGGAGGTCAGGTGGATGTTTACC 
FAM-TGCCCACAGCAACCTCAAACCTGC 
TET-TTGCCCACAGCACCCTCAAACCTG 
Exploratory/exten
sion 
rs1799964  TNFa 31,60 GATGGGACTCACCAGGTGAGG 
CCAGAGGTCTCCTGTAACCCA 
FAM-AGCAAAGGAGAAGCTGAGAAGATGAAGGAAAAGTC 
TET-AGCAAAGGAGAAGCTGAGAAGACGAAGGAAAAG 
Exploratory-
screen/extension 
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Table 15. Part 2: Primers and probes of SNP assays  
Marker hCV number*  Gene Posit
ion 
(NCBI) 
MB 
Primers: 
Forward 5’-3’ 
Reverse 5’-3’ 
Probes Sample used 
rs1799742  TNFa 31,60 TCCAGGGCTATGAAAGTCGA 
TGCTGGTTTCAGTCTTGGCT 
FAM-AGTATGGGGACCCCCCCTTAATGAAGA 
TET-TATGGGGACCCCCCCTTAACGAAG 
Exploratory-
screen 
rs1800629  TNFa 31,60 CCTGCATCCTGTCTGGAAGTTAGAAG 
TGGGCCACTGACTGATTTGTGTGT 
FAM-AACCCCGTCCTCATGCCCCTC 
TET-AACCCCGTCCCCATGCCCCTC 
Exploratory-
screen 
rs361525  TNFa 31,60 CAGTGGCCCAGAAGACCC 
AGCATCAAGGATACCCCTCAC 
FAM-AATCAGAGCAGGGAGGATGGGGA 
TET-AATCGGAGCAGGGAGGATGGG 
Exploratory-
screen 
rs707916  DDAH2 31,76 CTGGAGCCGGGAGTAGTGC 
CGAGCCTAAGGAGTTAAGCATCC 
FAM-TTTATACTAGGTCGTGCTAGGGGCAGCGT 
TET-TTTATACTAGGTCGCGCTAGGGGCAGC 
Exploratory-
screen 
rs707926  VARS2 31,81 GGTGGAGTGGGAGCAGTCAG 
TCACGGCCGGAAGATGAG 
FAM-CCATAGATGACGTCCAGGGGATCGAT 
TET-CCATAGATGACATCCAGGGGATCGATG 
Exploratory-
screen 
rs2075800  HSP70-
HOM 
31,84 AACGAGCTCCTTTCGTGGCT 
CACATACCCTGTTCCGCAGG 
FAM-CATAAGAGAAAGGAATTGGAGCAGATGTGTAACCC 
TET-TCATAAGAGAAAGGAATTGAAGCAGATGTGTAACCC 
Exploratory-
screen 
rs539689  HSPA1B 31,86 CAAAGTCCTTGAGTCCCAACAGT 
AACCCCATCATCAGCGGA 
FAM-CCCGAAGCCGCCAGGCC 
TET-CCCCGAAGCCCCCAGGCC 
Exploratory-
screen 
AF019413_C8
9532G 
 C2 31,96 TGAGCGTTGCCATTATCACC 
TCCTCTCTCATCACCATCACGT 
FAM-TCCCGGGATATGACTGAGGTGATCAGC 
TET-CCCGGGATATGACTGACGTGATCAGC 
Exploratory-
screen 
rs1035798  AGER 32,18 CCAGGGTCTTCTCCAAGGC 
GCCGTGAGTTCAGAGGCAG 
FAM-TGGCCTCATTTCCACATACAGAGTTTGAGAAC 
TET-TGGCCTCATTTCCACACACAGAGTTTGA 
Exploratory-
screen 
rs2070600  AGER 32,18 AGGCCCCTGGGACAGTGT 
CCGACAGCCGGAAGGAA 
FAM-CCAACGGCTCCCT 
TET-CCAACAGCTCCCTC 
Exploratory/exten
sion 
rs1800624 hCV3293837 AGER 32,18   Exploratory/exten
sion 
rs2071287 hCV3293818 NOTCH4 32,20   Exploratory/exten
sion 
rs384247 hCV2412441 NOTCH4 32,21   Exploratory/exten
sion 
rs915894 hCV3293780 NOTCH4 32,22   Exploratory/exten
sion 
rs436845 hCV2412414  32,22   Exploratory/exten
sion 
rs560505 hCV2495657 C6orf10 32,29   Exploratory/exten
sion 
rs485774 hCV2495577 C6orf10 32,32   Exploratory/exten
sion 
rs552339 hCV2495574 C6orf10 32,32   Exploratory/exten
sion 
rs761187 hCV2234065 C6orf10 32,34   Exploratory/exten
sion 
rs2073044 hCV2488525 C6orf10 32,37   Exploratory/exten
sion 
rs2050190 hCV2488524 C6orf10 32,37   Exploratory/exten
sion 
rs2073045 hCV2488523 C6orf10 32,37   Exploratory/exten
sion 
AL034394_T2
6355G 
  32,37 AGAACTTCTTAGATGAGAGTGCAACTTC 
GGGAAAGAAAATGTCTATGGCAAAGG 
FAM-TGAGCGTAGTCGATTC 
TET-TGAGCGTAGTAGATTC 
Exploratory/exten
sion 
AL034394_A2
6270C 
  32,37 CCATAGACATTTTCTTTCCCTGATGATTTTTT 
CTTGAGACACAGATTCTGGAACCT 
FAM-CAAACACATTTTTCTTTC 
TET-CAAACACATGTTTCTTTC 
Exploratory/exten
sion 
AL034394_C2
0283T 
  32,38 GTAGGAGCTTAAGACACTGTGTACTG 
GCCAAGGCATCTGAACTAAGAGA 
FAM-AGGGCTATTGCTTATT 
TET-CAGGGCTATTACTTATT 
Exploratory/exten
sion 
AL034394_C1
6965T 
  32,38 GCAGCTCATCCCAACCTCATC 
GCAGCTCATCCCAACCTCATC 
FAM-TTCTTCAACGGAGAATG 
TET-TTCTTCAACAGAGAATG 
Exploratory/exten
sion 
- 
hCV2488476  32,38   Exploratory/exten
sion 
AL034394_C1
2339T 
  32,39 GTTCAGAGTGCTGTTCATGAGTGAT 
CAGGATGGCAGACGTCAGA 
FAM-CGCATGGGACCGC 
TET-CCGCATAGGACCGC 
Exploratory/exten
sion 
AL034394_T1
0552C 
  32,39 ACTGTAAAGAAAGAGAATCCATTCTGATAATTA
ATCAATAT 
GCTGTTTTGTGTGCTCTAGAAAGTG 
FAM-TTCCACTTTAAATTTCTTACGTC 
TET-CTTCCACTTTAAATTTCTTATGTC 
Exploratory/exten
sion 
BTNL2_E360A
mb 
 BTNL2 32,39 GCGAGGAGAAAATCGCAACTT 
TTTCCAAACCTGAAGGAACATAAGGAA 
FAM-TTTCTCTCTCATGTTGGTG 
TET-TTTCTCTCTCAGGTTGGTG 
Exploratory/exten
sion 
BTNL2_P299Q 
 BTNL2 32,39 GAGTCAGGGCCTGGGAAGA 
GGAGGGGCAAGAAGATGGA 
FAM-TGTCCCTCCACTGCA 
TET-ATGTCCCTCCATGGC 
Exploratory/exten
sion/replication 
BTNL2_M286I 
 BTNL2 32,39 ACCCTTAGCAATGTCTGCACGT 
GGTTCTTCCCCACTGATCACTG 
FAM-ATCCGAAGAGCATATC 
FAM-CATCTGAAGAGCATATC 
VIC-CATCTGAAGAGCACATC 
VIC-ATCCGAAGAGCACATC 
Exploratory/exten
sion/replication 
BTNL2_P285L  BTNL2 32,39 GTTCTTCCCCACTGATCACTGT 
TGAGTCAGGGCCTGGGA 
FAM-TGGAGAAATGCAGCTGA 
TET-ATGGAGAAATGCAGCCGA 
Exploratory/exten
sion/replication 
rs2076530  BTNL2 32,39 AGTACCGCTGCCTTTTTGAAAA 
GTGGCAGGAGCAGGTATTGAATA 
FAM-AAGGTGGTAGGTAAGAA 
TET-AGGTGGTAAGTAAGAAT 
Exploratory/exten
sion/replication 
BTNL2_S240L  BTNL2 32,39 AGACTGACCCTGCAGATACTCA 
TTTTCAAAAAGGCAGCGGTACTG 
FAM-TCGTCCAAAGGTCT 
TET-TCGTCCGAAGGTCT 
Exploratory/exten
sion 
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Table 15. Part 3: Primers and probes of SNP assays  
Marker hCV number*  Gene Posit
ion 
(NCBI) 
MB 
Primers: 
Forward 5’-3’ 
Reverse 5’-3’ 
Probes Sample used 
rs2076529  BTNL2 32,39 GGAGAGCAGATGGCAGAGTACAG 
CCTCGTCAATGGCGTCACT 
FAM-ACCAGCACAGTCCT 
TET-ACCAGTACAGTCCTC 
Exploratory/exten
sion 
rs2294878 hCV2488463 BTNL2 32,39   Exploratory/exten
sion 
BTNL2_I4_A2
39T 
 BTNL2 32,40 TTGCAGCTGTGTTACCTGACA 
CAGAGATGATGCCATGCTTCCT 
FAM-ATCAGATGGTCACCTAT 
TET-CATCAGATGGACACCTAT 
Exploratory/exten
sion 
rs2076524 hCV2488453 BTNL2 32,40   Exploratory/exten
sion 
BTNL2_i3_C1
900T 
 BTNL2 32,40 TCTGAGCATCGCATCCAAGAT 
AGACTCTGCAGAGGCGTTCCT 
FAM-TGGCTTCCACATAGA 
TET-CTTCCGCATAGAAC 
Exploratory/exten
sion 
rs2076523  BTNL2 32,40 CCAGAGCCCCAGGTGTATTG 
TGGACCAAGCAGGACACAGA 
FAM-CATCGCATCCAAGATAAAGATGGCCTGTT 
TET-CATCGCATCCAAGATGAAGATGGCCT 
Exploratory-
screen/extension 
BTNL2_i3_A1
837G 
 BTNL2 32,40 CAGAGCCCCAGGTGTATTGG 
ACACGGCCAGCAGCTTCT 
FAM-CTCCCCGGATGTC 
TET-CTCCCTGGATGTCT 
Exploratory/exten
sion 
BTNL2_W94R 
 BTNL2 32,40 GACTGAGATGCAGATGGAGGAGTAC 
CTTTGCAATGCCATTCTCTATCC 
FAM-AGAGGCTGGGTAGAGT 
TET-AGAGGCAGGGTAGAGT 
Exploratory/exten
sion 
BTNL2_H60H 
 BTNL2 32,40 TGCCAGCTACTCCCCAAGAG 
GGGCTCTGAGCGGTACCA 
FAM-AATGCATGTGGAGGTG 
TET-AATGCACGTGGAGGT 
Exploratory/exten
sion 
BTNL2_i1_G1
717T 
 BTNL2 32,40 GGAGCCAAGCCCATTTCAC 
CAGTCTTAGCAGAGAATCCACATCA 
FAM-ACCCCTGAACAGTC 
TET-CCCCTGCACAGTC 
Exploratory/exten
sion 
 hCV2455668  32,43   Exploratory/exten
sion 
DRAp_231 
 HLA-DRA 32,43 AATGTGCTTCAGGTATATCCCTGTCT 
AGTAAAGTTCTTAAACAAACAGGACAACAA 
FAM-TGTCCGTGATTGAC 
TET-TGTCCGTCATTGAC 
Exploratory/exten
sion 
DRAp_224 
 HLA-DRA 32,43 AATGTGCTTCAGGTATATCCCTGTCT 
AGTAAAGTTCTTAAACAAACAGGACAACAA 
FAM-ATTTAAGACTGTTAGTCAAT 
TET-TTAAGACTGTTGGTCAAT 
Exploratory/exten
sion 
DRAp_196 
 HLA-DRA 32,43 AATGTGCTTCAGGTATATCCCTGTCT 
CCGTTCATTGGATAAAGAAGTAAAGTT 
FAM-CAACAACAACAACAAA 
TET-ACAACGACAACAAAT 
Exploratory/exten
sion 
DRAp_127 
 HLA-DRA 32,43 TTATCCAATGAACGGAGTATCTTGTG 
ATGACGCATCTGTTGCTAGGG 
FAM-CCTGGACTCTTTG 
TET-CTGGACCCTTTGCA 
Exploratory/exten
sion 
rs14004  HLA-DRA 32,43 CCTCACTCCCGAGCTCTACTGA 
CCACTTATGGCCATTTTCTTCTTG 
FAM-CTCCCAACAGAGCG 
TET-TCCCAAAAGAGCGC 
Exploratory/exten
sion 
 hCV2455646 HLA-DRA 32,44   Exploratory/exten
sion 
rs8084 hCV2455637 HLA-DRA 32,44   Exploratory/exten
sion 
rs7192  HLA-DRA 32,44 TGGGCCTGACTGTGGGTC 
ACCACACCTAACTCACCTCCATG 
FAM-TCATCATCAAGGGATTGCGCAAAAGC 
TET-TCATCATCAAGGGAGTGCGCAAAAGC 
Exploratory-
screen/extension 
rs2213584  HLA-DRA 32,44 AATGGGTAAGGCCAGTCTTCAG 
TGCAGGATTTACATATCAACATCGT 
FAM-TGTCCAATCTCTTTGC 
TET-TGTCCAACCTCTTTG 
Exploratory/exten
sion 
rs2395182  HLA-DRA 32,44 GGTGGTTTCAAGAATCAGTCAGACT 
GGCCTTACCCATTCTGTTAGACATA 
FAM-CGGTAATACAATAGGC 
TET-CTCGGTAATAAAATAGG 
Exploratory/exten
sion 
rs707952  HLA-DQA1 32,62 CATAGAGGTTCCTGAGGTCACA 
TGGTCTCAGAAACACCTTCTGT 
FAM-CTGGGTCAGCCCAACACCCTC 
TET-CTGGGTCAGCCCAACATCCTCA 
Exploratory-
screen/extension 
X66401_G486
29A 
 TAP2 32,80 GGTGGTTTCAGTTGGGCAG 
CTCCATTTCCTGGATGAAGTCA 
FAM-TGTGAGGAACAACATTACTTATGGGCTGCAG 
TET-TGAGGAACAACATTGCTTATGGGCTGC 
Exploratory-
screen 
rs1042337  HLA-DMB 32,91 GCCCAGCCCAATGGAGAC 
CCTAATTCCATCCATCTGCCATAC 
FAM-TGTGTGGTAGAGCACATTGGGGCTCC 
TET-TGTGTGGTAGAGCACACTGGGGCTCC 
Exploratory-
screen 
rs1063478  HLA-DMA 32,92 AAAAGGCCTGGAAGCTGAGTC 
GAGTTTGGCAAGCCCAACAC 
FAM-CTTCCACAGGGATGGAATGATGCTG 
TET-CTTCCACAGGGACGGAATGATGCT 
Exploratory-
screen 
rs3918143  RING3 32,95 GATGCCAGATGAACCACTAGAACC 
CCTCAGAGGAGCTCTCACTGCTAC 
FAM-CCTGGCTTGGCCAAATCGTCTTCAG 
TET-CCCTGGCTTGGTCAAATCGTCTTCAGA 
Exploratory-
screen 
rs2581  HLA-DNA 32,98 TGTGCTGACTTTGAGTGGGATC 
AACACCACCAAAGCATTTAGTGC 
FAM-CCTTCCCATTCAACACACACACACATTC 
TET-CCTTCCCATTCAACACAAACACACATTCTT 
Exploratory-
screen 
rs926424  RXRB 33,16 CTCCTTCTCTTCCACTGATGTGC 
GCACGTGAAGACCTGTGGC 
FAM-CATTGCCTCCTTTTCACACCGATCC 
TET-CATTGCCTCCTTCTCACACCGATCC 
Exploratory-
screen 
rs1547387  HKE4 33,17 AGTGCGGGAGGTGAGGAATAG 
CCCCAAATACACACTCATTGTGTC 
FAM-CCTCACCACTGTGGGAGTGTCCATGT 
TET-CTCACCACTGTGCGAGTGTCCATGTC 
Exploratory-
screen 
rs466384  BING4 33,26 CCTCAGGCTTAGGTGTGTATTAGCA 
TCGTGCCTGTAGAATCTACTGCC 
FAM-CTCTTCCAGGTACTGTGTCTTTATGGAGTCCAG 
TET-TCCAGGTACTGCGTCTTTATGGAGTCCA 
Exploratory-
screen 
rs2071888  TAPBP 33,27 GCATTTGCTGCTTGGGATG 
AGCAAGCTCCAGGGTGACC 
FAM-CTTCTGGCTGCCTAGAGTTCAACCCTTTCA 
TET-TCTGGCTGCCTACAGTTCAACCCTTTCA 
Exploratory-
screen 
rs999942  ITPR3 33,63 CCCTCCATCAGACTGGCACTC 
CGGTCACACAGCCACATGC 
FAM-CAGCAGGAGAGGCTTGCCATGG 
TET-CAGCAGGAGAGCCTTGCCATGG 
Exploratory-
screen 
rs943461  MLN 33,77 CCCCAAGACCCAGAGAGACC 
AGGGATACAGCTCCATGCTGAA 
FAM-CAAGCCCAGATGACGAGGGCTCTG 
TET-CAAGCCCAGATGACCAGGGCTCTG 
Exploratory-
screen 
rs755658  FKBP5 35,55 TTGAAGTCCTGTATCACAGGCATG 
ACCAACAGTGTTAAGACCATGTTACTAGG 
FAM-ACTCGACAGTGAGATGTACGCGCTGC 
TET-TCGGCAGTGAGATGTACGCGCTG 
Exploratory-
screen 
rs992105  FKBP5 35,56 TTCCATCATGACCAAGCTGTAGC 
CAGAGGGAGATAAGGCATGGC 
FAM-ACTCTGGTAAGCACTGCTACAAAGTGCATCTTTAGAA 
TET-CGTACTCTGGTAAGCACTGCTACAAAGTGAATCTTTAGA 
Exploratory-
screen 
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Table 15. Part 4: Primers and probes of SNP assays  
Marker hCV number*  Gene Posit
ion 
(NCBI) 
MB 
Primers: 
Forward 5’-3’ 
Reverse 5’-3’ 
Probes Sample used 
rs1320991  FKBP5 35,56 TGTTGGTATGTTGGAGAATTATGTGAA 
AAACAAGTAAATTCACTGCCTGCAC 
FAM-TAGAAAACCCCTACGTGCTATATATGTGTGTGCGT 
TET-TAGAAAACCCCTACATGCTATATATGTGTGTGCGTATG 
Exploratory-
screen 
rs1326752  SRPK1 35,83 AAAAAAGCCTGTTGTCTTAGGTATGC 
AGAGGTTAATGCTAGGTTGCGC 
FAM-CTGCAGCCAGGTCAGCCCGAA 
TET-CTGCAGCCACGTCAGCCCGA 
Exploratory-
screen 
Z95152_G577
23A 
  36,03 CAGGTGATTGGTCTGTTGGACG 
CCCAAAAAGAGGTGCATGATAGG 
FAM-TGAGTAAATTTTTTGCATTTGCCTTCCTGGTCTA 
TET-TGAGTAAATTTTTTGCGTTTGCCTTCCTGG 
Exploratory-
screen 
Z95152_T587
84G 
  36,08 GGAGAAGAGGGCTAATATATCCTAGAGTAG 
GGCCGCTGTAATTCTCTTATCTG 
FAM-TTCCTTCCTGTCTATGGTACTGATAGCTGTCGACTT 
TET-TCCTTCCTGTCTCTGGTACTGATAGCTGTCGAC 
Exploratory-
screen 
Z95152_T106
861C 
  36,08 GAAGTCATCAGCTTTGTGCCAC 
ACCATGGAGGAAATCTCTGCA 
FAM-AAGGCCTTTTCACGGGAACTCTCCAAA 
TET-AAGGCCTTTTCATGGGAACTCTCCAAATATTC 
Exploratory-
screen 
rs763096  MAPK13 36,10 CTGTGAGGACTGGCAGATGTG 
GCCTTTGCCTGTCAAGTGTG 
FAM-CCAGGCAAGCACTCCACAAAGTCCTT 
TET-CAGGCAAGCACCCCACAAAGTCCT 
Exploratory-
screen 
rs2007683  MAPK13 36,10 CAGCTTCTTCCATCTGCTCA 
ACAGTCGATATTGGGTAGCCA 
FAM-ATGTTGATATCTGAATCAATGCTATCTTACCACATT 
TET-TGTTGATATCTGAATCAATACTATCTTACCACATTCTACA 
Exploratory-
screen 
rs881648  TEL2 36,35 CTAGGCCTCCAACCCAGGAC 
CCCATGGCTTATTTACAGCTAGGA 
FAM-CTCACTTTGGATGCAGAGGAAATGAGACTTC 
TET-CTCACTTTGGATGCAAAGGAAATGAGACTTC 
Exploratory-
screen 
rs881647  TEL2 36,35 TTCAGAACTGGGCTGATATCACAG 
AATGAGGCCATGGTGGTGAC 
FAM-CAAGGGACAACTTGGGAGAATTTTGAGAGG 
TET-AAGGGACAACTTGGGAGAATTCTGAGAGGA 
Exploratory-
screen 
rs916287  TEL2 36,35 AGAAGAAGAGACGCAGGACCG 
CCATTTTCAGAACTGGGATGATA 
FAM-CTCTGAACTGCCTCCTCTCAAAATTCTCCCAA 
TET-CTCTGAACTGCCTCCTCTCAGAATTCTCCCA 
Exploratory-
screen 
rs1885205  TEL2 36,35 CTCCTGACTCACTCTGGCCTTG 
TCCACTCTGAGGACAACCGTG 
FAM-ACCCTCATGGCCATGGACCGG 
TET-CATGGCCATGGACCAGGGATGG 
Exploratory-
screen 
rs2055272  FLJ20337 37,29 CATGGTGGTAATGAATTGTGATTATG 
ATGCTTAAGATTTATGTCATGAGTCCA 
FAM-AGGTAGGTTCGGGCGCTCTTACATTGTCT 
TET-AGGTTCGAGCGCTCTTACATTGTCTCCAC 
Exploratory-
screen 
rs1004279  GLP1R 39,03 AGGAGGCTGAGGTCAAGGC 
GCCATCATGAAACTTATCACTACTGAC 
FAM-TGAGTGGTCCGCCTGCCTTTCC 
TET-AGTGAGTGGTCCACCTGCCTTTCCTG 
Exploratory-
screen 
rs1541816  KCNK5 39,16 AGGCCTCTAGGAATTGGACCA 
GAGCAGGAGGCCAAGTCAGA 
FAM-CCCTCCCGGGTTAGGCTGGGTAC 
TET-CCTCCCGGGTCAGGCTGGG 
Exploratory-
screen 
rs1014737  APOBEC2 41,02 AACACAGAGGGAGGGTAGGTCA 
GTTGTGATTATAAAGCCCTGGACA 
FAM-AGCAATGGATCCTGAAGGGTTAAGTCCACT 
TET-AGCAATGGATCCTGAAGGGATAAGTCCACT 
Exploratory-
screen 
rs2234246  TREM1 41,25 AAAAGGCAGGGAGTTAATAACATGA 
TAGAGGAACGAGGGCAGTGG 
FAM-ATCTGTAATCACCGGCTATTTCTAAAGTCAGCGTCT 
TET-ATCTGTAATCACCAGCTATTTCTAAAGTCAGCGTCTCA 
Exploratory-
screen 
rs1817538  TREM1 41,25 CTGCTTGCATGTCTGCTGATG 
CGAGAAGAATCCACCCGTAGTG 
FAM-CCCAGAAACCTTAGAATCATTTTGCCAAAATCT 
TET-CCCAGAAACCTTAGAATCATTTCGCCAAAAT 
Exploratory-
screen 
rs1351835  TREM1 41,25 ATGTTCCTGCATAGCACTGGC 
AGGAGTGAGGGCACTTGGC 
FAM-CTCTCATCTGCTTGCTTGTCTGCTGATGAA 
TET-TCTCATCTGCTTGCATGTCTGCTGATGA 
Exploratory-
screen 
rs2234237  TREM1 41,25 GAACCCATTCTCTTTCCCTGCT 
AGCGTGTAGTCACATTTCACATCC 
FAM-CTCCGAGCTGCAACTAAATTATCTGAGGAAAAGTATGA 
TET-CTCCGAGCTGCAACTAAATTAACTGAGGAAAAGTATGA 
Exploratory-
screen 
AL391903_C8
8694T 
 TREM1 41,26 ATTTACATTCAAGTATCATTCTCCCTTAGAT 
GACATCAACACAATAATACAGAGACCAA 
FAM-AGGTAATTGTCATTATTACCACAAAAAGGAAAACTGGAG 
TET-AGGTAATTGTCATTATTACCACAGAAAGGAAAACTGGA 
Exploratory-
screen 
rs742735  MDFI 41,62 TCAATTGATGGCTGATGAGGAG 
AGCAGAATAAAATGGTGCCAGG 
FAM-CACATCGGCTGGTTGGGTGTCTG 
TET-CACATCGGCTGGCTGGGTGTCT 
Exploratory-
screen 
rs1410492  CCND3 41,91 GGGCATTGTGGTGTGATGG 
GCAAAGTACTAGTGAGTGTAGACATGCA 
FAM-AGGGGATGCCACTCCTTGCTGGTCT 
TET-AGGGGATGCCACTCCTTCCTGGTCTT 
Exploratory-
screen 
rs1160867  TNRC5 42,90 CCCTAACGGAGGCTCTGG 
TTCCCCACATCTTCCAGCAC 
FAM-ACCAAGACCCGAGGAGAAGAAGCCT 
TET-CAAGACCCGAGAAGAAGCCTGCG 
Exploratory-
screen 
rs9395  SRF 43,15 CCCAGTGAGTGAATCAGGCA 
ACCCCAGAGCCACCGAG 
FAM-ATGCGTGTGTCAGGGATGAGTTGAGGT 
TET-CGTGTGTCAGCGATGAGTTGAGGTGA 
Exploratory-
screen 
rs1418488  CAPN11 44,14 GAAGGACAGTGTGAGAGCCACTG 
AAAGAGCCACAAATTGCTAACAACTA 
FAM-CCCACCAAAGAAATCATGTAAGGTAATTTTTTAAGTCCC 
TET-CCCACCAAAGAAATCATGTAAGCTAATTTTTTAAGTCCC 
Exploratory-
screen 
*-hCV assays were obtained from  ABI “Assay on Demand” database 
(https://www.store.appliedbiosystems.com ). Primer and probe sequences for AoD are not 
available. 
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9.1.2. Sarcoidosis patient phenotypes 
 
Sarcoidosis phenotypes fall into two main categories, namely, acute and chronic sarcoidosis. 
Classification of sarcoidosis patients in this study into a further ten categories involved the  
following criteria: disease location, symptoms, duration and therapy. 30.77% of patients in the 
entire sample have an acute form of sarcoidosis with lung involvement (phenotype groups 1 
plus 2), whereas chronic form has 61.13% of patients (groups 3 to 6).  
 
Table 16. Sarcoidosis phenotypes 
 
Sarcoidosis 
phenotype 
group 
Phenotype description Proportion of 
patients (%) 
1 Acute sarcoidosis (mainly with Loefgren syndrome), without 
systemic Cortison therapy, to complete or large recovery, 
possibly relapse after more than 2 years 
12.08 
2 Acute Sarcoidosis (mainly with Loefgren syndrome), with 
systemic Cortison therapy, to complete or large recovery, 
possibly relapse after more than 2 years 
18.69 
3 Chronic Sarcoidosis (mainly with stealthy beginning), without 
systemic Cortison therapy, to complete or large recovery 
8.44 
4 Chronic Sarcoidosis (mainly with stealthy beginning), with 
systemic Cortison therapy, to complete or large recovery 
14.89 
5 Chronic Sarcoidosis (mainly with stealthy beginning), with 
systemic Cortison therapy, with enduring disease activity 
33.33 
6 Chronic Sarcoidosis (mainly with stealthy beginning), with  
systemic immunosuppressive therapy, lung transplantation 
4.47 
7 Sarcoidosis without lung participation (mainly with skin 
Sarcoidosis) 
0.66 
8 Sarcoidosis in the infancy 0.16 
9 Not classifiable (mainly with missing documents, 
contradictory information) 
3.39 
10 Coincidence findings, no complaints 3.89 
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9.1.3. Structure of 138 sarcoidosis families investigated in the CARD15 study 
 
Table 17. Structure of sarcoidosis families investigated in CARD15 association study 
 
Relationship of patients No. families No. patients  Male  Female  
Affected siblings     
 sister / sister 22 44  44 
 sister / brother 27 54 27 27 
 brother / brother 11 22 22  
 3 siblings 6 18 9 9 
Affected parent / offspring     
 mother / daughter 18 36  36 
 mother / son 8 16 8 8 
 father / daughter 5 10 5 5 
 father / son 10 20 20  
Affected 2 and 3 relatives 19 38 21 17 
Complex families     
 Three patients 7 21 9 12 
 Four patients 3 12 9 3 
 Five patients 1 5 1 4 
 Six patients 1 6 4 2 
Total 138 302 135 167 
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9.1.4. Assays for CARD15 genotyping  
 
Table 18. SNP assays for CARD15 genotyping    
 
Marker Forward primer 
Reverse primer 
Probe 1 
Probe 2 
SNP5 5’-GGAGGACATATACACAGAGAATGTCC  
5’-ATGGCTGGATCCCCGCAGAAGAGCT 
FAM-ATGGCTGGACCCCCGCAGAAGAGT  
TET-ATGGCTGGATCCCCGCAGAAGAGCT 
SNP8 5’-TTCCTGGCAGGGCTGTTGTC 
5’-AGTGGAAGTGCTTGCGGAGG 
FAM-CCTGCTCCGGCGCCAGGC 
TET-CCTGCTCTGGCGCCAGGCC 
SNP12 5’-ACTCACTGACACTGTCTGTTGACTCT 
5’-AGCCACCTCAAGCTCTGGTG 
FAM-TTTTCAGATTCTGGGGCAACAGAGTGGGT 
TET-TTCAGATTCTGGCGCAACAGAGTGGGT 
SNP13 5’-GTCCAATAACTGCATCACCTACCTAG 
5’-CTTACCAGACTTCCAGGATGGTGT 
FAM-CCCTCCTGCAGGCCCTTGAAA 
TET-CCTCCTGCAGGCCCCTTGAAA 
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9.1.5. Reaction conditions for diallelic genotyping assays 
 
Table 19. Part 1: reaction conditions of SNP assays in chromosome 6 and CARD15 
genotyping experiments 
Assay  
 
 
Forward 
primer 
(nmol final 
concentratio
n) 
Reverse 
primer 
(nmol final 
concentratio
n) 
Probe 1 
(nmol final 
concentratio
n) 
Probe 2 
(nmol final 
concentratio
n) 
Annealing 
temperature 
(°C) 
Number of 
cycles 
rs2073528 900 900 200 200 60 45 
rs2072803 900 900 200 200 60 45 
hCV2474907 900 900 200 200 60 45 
hCV2474883 900 900 200 200 60 45 
hCV9804528 900 900 200 200 60 45 
rs3736781 900 900 200 200 60 45 
rs126007 300 300 100 100 62 45 
rs929042 900 900 100 100 62 45 
rs53161 300 300 100 100 62 40 
rs404240 50 900 100 100 62 45 
rs362536 300 900 100 100 60 45 
rs1805057 300 300 100 100 60 45 
rs3130253 900 900 100 100 62 45 
rs1569315 300 300 100 100 64 45 
rs8347 300 300 100 100 62 45 
rs1264457 300 300 100 100 62 45 
rs2074510 300 300 100 100 62 45 
rs3095318 300 50 100 100 60 45 
rs2073721 50 300 100 100 62 45 
rs1050393 300 300 100 100 60 45 
rs1051488 900 900 100 100 60 45 
rs1063630 900 900 200 200 60 45 
rs1063635 300 900 100 100 62 45 
rs3828916 900 900 200 200 60 45 
rs3131639 900 900 200 200 60 45 
rs3134900 300 300 100 100 62 45 
AC006046_G30156A 900 900 200 200 60 45 
rs3130062 900 300 100 100 62 40 
rs1800683 900 900 200 200 60 45 
rs1041981 900 900 100 100 65 40 
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Table 19. Part 2: reaction conditions of SNP assays in chromosome 6 and CARD15 
genotyping experiments 
Assay  
 
 
Forward 
primer 
(nmol final 
concentratio
n) 
Reverse 
primer 
(nmol final 
concentratio
n) 
Probe 1 
(nmol final 
concentratio
n) 
Probe 2 
(nmol final 
concentratio
n) 
Annealing 
temperature 
(°C) 
Number of 
cycles 
rs1799964 300 300 100 100 62 55 
rs1799742 300 300 200 200 60 50 
rs1800629 900 300 100 100 62 40 
rs361525 900 300 100 100 62 40 
rs707916 300 300 100 100 62 45 
rs707926 50 900 100 100 60 45 
rs2075800 300 300 100 100 60 45 
rs539689 50 900 100 100 60 45 
AF019413_C89532G 300 900 100 100 62 45 
rs1035798 50 900 100 100 60 45 
rs2070600 900 900 200 200 60 45 
rs1800624 900 900 200 200 60 45 
rs2071287 900 900 200 200 60 45 
rs384247 900 900 200 200 60 45 
rs915894 900 900 200 200 60 45 
rs436845 900 900 200 200 60 45 
rs560505 900 900 200 200 60 45 
rs485774 900 900 200 200 60 45 
rs552339 900 900 200 200 60 45 
rs761187 900 900 200 200 60 45 
rs2073044 900 900 200 200 60 45 
rs2050190 900 900 200 200 60 45 
rs2073045 900 900 200 200 60 45 
AL034394_T26355G 900 900 200 200 60 45 
AL034394_A26270C 900 900 200 200 60 45 
AL034394_C20283T 900 900 200 200 60 45 
AL034394_C16965T 900 900 200 200 60 45 
hCV2488476 900 900 200 200 60 45 
AL034394_C12339T 900 900 200 200 60 45 
AL034394_T10552C 900 900 200 200 60 45 
BTNL2_E360Amb 900 900 200 200 60 45 
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Table 19. Part 3: reaction conditions of SNP assays in chromosome 6 and CARD15 
genotyping experiments 
Assay  
 
 
Forward 
primer 
(nmol final 
concentratio
n) 
Reverse 
primer 
(nmol final 
concentratio
n) 
Probe 1 
(nmol final 
concentratio
n) 
Probe 2 
(nmol final 
concentratio
n) 
Annealing 
temperature 
(°C) 
Number of 
cycles 
BTNL2_P299Q 900 900 200 200 60 45 
BTNL2_M286I* 900 900 200 200 60 45 
BTNL2_P285L 900 900 200 200 60 45 
rs2076530 900 900 200 200 60 45 
BTNL2_S240L 900 900 200 200 60 45 
rs2076529 900 900 200 200 60 45 
rs2294878 900 900 200 200 60 45 
BTNL2_i4_A239T 900 900 200 200 60 45 
rs2076524 900 900 200 200 60 45 
BTNL2_i3_C1900T  900 900 200 200 60 45 
rs2076523 300 300 100 100 62 45 
BTNL2_i3_A1837G  900 900 200 200 60 45 
BTLIIW94R 900 900 200 200 60 45 
BTLIIH60H  900 900 200 200 60 45 
BTNL2_i1_G1717T  900 900 200 200 60 45 
hCV2455668 900 900 200 200 60 45 
DRAp_231 900 900 200 200 60 45 
DRAp_224 900 900 200 200 60 45 
DRAp_196 900 900 200 200 60 45 
DRAp_127 900 900 200 200 60 45 
rs14004 900 900 200 200 60 45 
hCV2455646 900 900 200 200 60 45 
rs8084 900 900 200 200 60 45 
rs7192 300 300 100 100 62 45 
rs2213584 900 900 200 200 60 45 
rs2395182 900 900 200 200 60 45 
rs707952 300 300 100 100 62 45 
X66401_G48629A 300 300 100 100 62 45 
rs1042337 900 900 100 100 62 45 
rs1063478 300 300 100 100 62 45 
rs3918143 300 300 100 100 64 45 
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Table 19. Part 4: reaction conditions of SNP assays in chromosome 6 and CARD15 
genotyping experiments 
Assay  
 
 
Forward 
primer 
(nmol final 
concentratio
n) 
Reverse 
primer 
(nmol final 
concentratio
n) 
Probe 1 
(nmol final 
concentratio
n) 
Probe 2 
(nmol final 
concentratio
n) 
Annealing 
temperature 
(°C) 
Number of 
cycles 
rs2581 50 300 100 100 62 45 
rs926424 900 50 100 100 60 45 
rs1547387 50 900 100 100 62 45 
rs466384 900 50 100 100 60 45 
rs2071888 300 900 100 100 62 45 
rs999942 50 900 100 100 60 45 
rs943461 50 900 100 100 62 45 
rs755658 300 300 100 100 62 45 
rs992105 300 300 100 100 60 45 
rs1320991 300 300 100 100 62 45 
rs1326752 900 300 100 100 62 45 
Z95152_G57723A 50 300 100 100 62 45 
Z95152_T58784G 300 300 100 100 62 45 
Z95152_T106861C 50 900 100 100 62 45 
rs763096 50 300 100 100 62 45 
rs2007683 300 900 100 100 62 45 
rs881648 300 900 100 100 62 45 
rs881647 900 300 100 100 60 45 
rs916287 50 300 100 100 62 45 
rs1885205 50 300 100 100 62 45 
rs2055272 50 300 100 100 62 45 
rs1004279 50 900 100 100 60 45 
rs1541816 300 900 100 100 62 45 
rs1014737 300 300 100 100 62 45 
rs2234246 300 300 100 100 64 40 
rs1817538 50 300 100 100 60 45 
rs1351835 900 300 100 100 62 45 
rs2234237 50 300 100 100 62 45 
AL391903_C88694T 900 900 100 100 62 45 
rs742735 300 900 100 100 60 45 
rs1410492 50 900 100 100 60 45 
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Table 19. Part 5: reaction conditions of SNP assays in chromosome 6 and CARD15 
genotyping experiments 
Assay  
 
 
Forward 
primer 
(nmol final 
concentratio
n) 
Reverse 
primer 
(nmol final 
concentratio
n) 
Probe 1 
(nmol final 
concentratio
n) 
Probe 2 
(nmol final 
concentratio
n) 
Annealing 
temperature 
(°C) 
Number of 
cycles 
rs1160867 50 900 100 100 58 45 
rs9395 300 300 100 100 60 45 
rs1418488 50 300 100 100 62 45 
NOD2_SNP5 900 900 100 100 60 45 
NOD2_SNP8 400 400 100 100 62 45 
NOD2_SNP12 300 300 100 100 62 45 
NOD2_SNP13 400 400 100 100 62 45 
*-all four probes of the assay had the same 200nmol concentration 
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9.1.6. Mutation detection primers used for chromosome 6 PCR and sequencing 
experiments 
 
Table 20. Part1: mutation detection primers and SNP markers selected for chromosome 6 
high density LD mapping experiment. 
 
Primer Sequence  Ampl
icon 
length 
SNP marker selected for 
genotyping*  
1_For 
1_Rev 
5’-CCTCACACATGCCAATTCCC-3’ 
5’-TTTTGCCTCCCCATCGAC-3’ 
463bp  AL034394_T26355G  
AL034394_A26270C  
2_For 
2_Rev 
5’-CCTCACACATGCCAATTCCC-3’ 
5’-TTTTGCCTCCCCATCGAC-3’ 
359bp
. 
AL034394_C20283T  
3_For 
3_Rev 
5’-CAAACCACCACTCTCTCTTCATTG-3’ 
5’-CTCCCTCTTGTTTTTCTCCATTCT-3’ 
384bp
. 
AL034394_C16965T  
4_For 
4_Rev 
5’-TAAACATTTGTGGAAGAATAATGTGTAGTT -3’ 
5’-TCAAGAAGATAAACTATATGTGGAAGACAG-
3’ 
271bp
. 
AL034394_C12339T  
5_For 
5_Rev 
5’-GAGCTGTGTTTGAAGCCAATGTC-3’ 
5’-GAGCCTCCCTTTTCACAAGTCA-3’ 
540bp
. 
AL034394_T10552C  
BTNL2_e8_For 
BTNL2_e8_Rev 
5’-CTTGTCTTCCTGTTTGGCTGTTAA -3’ 
5’-GGGAAGGTGTAGATAGGGCACTT -3’ 
497bp
. 
 
BTNL2_e7_For 
BTNL2_e7_Rev 
5’-AGCAGGCCAACTGCTTCCT-3’ 
5’-ACTGAGCCTGGATTGCATGAT -3’ 
402bp
. 
 
BTNL2_e6_For 
BTNL2_e6_Rev 
5’-CCTGGCCGAAGTTATTTTGT -3’ 
5’-TAGAATCCCTGGGTGTCCTG-3’ 
738bp
. 
BTNL2_e6_E360Amb 
BTNL2_e6_P299Q 
BTNL2_e6_M286I 
BTNL2_e6_P285L 
BTNL2_e5_For 
BTNL2_e5_Rev 
5’-GGTTTCTAAACTCCAATGGAGCTGTT-3’ 
5’-CAAATGTCAGAGAAATTGTCCAGGA-3’ 
528bp
. 
BTNL2_e5_S240L 
BTNL2_i4_For 
BTNL2_i4_Rev 
5’-GGTAAGTACGAGGTGCTGGCA-3’ 
5’-TTGCTACACTCACAGTATCCCAGG-3’ 
541bp
. 
BTNL2_i4_A239T  
BTNL2_e4_For 
BTNL2_e4_Rev 
5’-GTGACAGCATTTTTGTTGTGCAG-3’ 
5’-GGTGTCCATCTGATGCTCACTG-3’ 
474bp
. 
 
BTNL2_i3_For 
BTNL2_i3_Rev 
5’-CCTCAGACTCCTGAACTCCG-3’ 
5’-GGTGCTATGGTGCAGTCCC-3’ 
469bp
. 
BTNL2_i3_C1900T 
BTNL2_i3_A1837G 
BTNL2_e3_For 
BTNL2_e3_Rev 
5’-CATTTTGACAGGCTGGACACC-3’ 
5’-CCTCAACTGTCACAAAGCTTACCA-3’ 
511bp
. 
BTNL2_e3_W94R  
BTNL2_e3_H60H  
 
 
  
121 
 
Table 20. Part2: mutation detection primers and SNP markers selected for chromosome 6 
high density LD mapping experiment. 
 
Primer Sequence  Ampl
icon 
length 
SNP marker selected for 
genotyping*  
BTNL2_e2_For 
BTNL2_e2_Rev 
5’-CAATGGAAGCCATGGAGTGTG-3’ 
5’-AACGTGGTGCAACCACTGATT -3’ 
489bp
. 
 
BTNL2_i1_For 
BTNL2_i1_Rev 
5’-AAGCCGAACTACATCAACGTTTG -3’ 
5’-CTGCACCAGACAGATTGTAGCC-3’ 
528bp
. 
BTNL2_i1_G1717T 
BTNL2_e1_For 
BTNL2_e1_Rev 
5’-TGTCCTCTAAGGGCAAAACAGC-3’ 
5’-GTTTCCCCCTTTCCAAGAAACTA-3’ 
693bp
. 
 
DRAp_For 
DRAp_Rev 
5’-TAGGTGTTTCCATTGATTCTATTCTCAC-3’ 
5’-TGATAGCCCATGATTCCTGAGC-3’ 
462bp
. 
06DRAp_231 
06DRAp_224 
06DRAp_196 
06DRAp_127 
DRA_5’_For 
DRA_5’_Rev 
5’-CCCAAGCCTAACTCATTTCAACA-3’ 
5’-CCCCAAGGTATGGATCTCAGAAT -3’ 
491bp
. 
rs2213584 
rs2395182 
*- only markers selected for genotyping are represented in the table. Data of other SNPs is not 
shown.  
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9.1.7. Sequence variations detected via sequencing  
 
New sequence variations observed in the mutation detection experiment and selected for the 
further high LD mapping experiment: 
 
AL034394_T26355G  
5'_FLANK:ATCAGGGAAAGAAAATGTCTATGGCAAAGGGCCTAAGATTAGAATC 
OBSERVED:T/G 
3'_FLANK:ACTACGCTCAGCGAAGTTGCACTCTCATCTAAGAAGTTCTTATCTAAA 
 
AL034394_A26270C 
5'_FLANK: AGCCACGTAGGCTTGAGACACAGATTCTGGAACCTGAGGGAAAGAAA 
OBSERVED:A/C 
3'_FLANK:ATGTGTTTGCAGATATAAAATATGGATTTAAAAAAATCATCAGGGAAA 
 
AL034394_C20283T 
5'_FLANK:ATCTGAACTAAGAGATGACAAGAAAGAGGGGTACGGCAGAAATAAG 
OBSERVED:C/T 
3'_FLANK:AATAGCCCTGCCAGTACACAGTGTCTTAAGCTCCTACTTCTTGATTTTT 
 
AL034394_C16965T 
5'_FLANK:CCTTGTCCTTGGTGTGTGGGGGCATCCCAGTTCGGGGAACATTCTC 
OBSERVED:C/T 
3'_FLANK:GTTGAAGAAGTGTATCTTCTACCCTCAGATCGGATGAGGTTGGGATGA 
 
AL034394_C12339T 
5'_FLANK:ACGCTCTGCTGCTCTCCAGGATGGCAGACGTCAGAGGCATCGCGGTCC 
OBSERVED:C/T 
3'_FLANK:ATGCGGATCACTCATGAACAGCACTCTGAACTTGCTCTTCTGGGCCAT  
 
AL034394_T10552C 
5'_FLANK:GTTAGGGAGGCTGTTTTGTGTGCTCTAGAAAGTGCTTCCACTTTAAATTTCTTA 
OBSERVED:T/C 
3'_FLANK:GTCCGTGAAACACTTGTCTTCCTGTTTGGCTGTTAATAGAATGAAATTATATTG 
 
BTNL2_e6_E360Amb 
5'_FLANK:ATCAGCATCCCCTTTTTGGGCGAGGAGAAAATCGCAACTTTTTCTCTCTCA 
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OBSERVED:G/T 
3'_FLANK:GTTGGTGATTCCTTATGTTCCTTCAGGTTTGGAAAATAAATATGAAGACCAACT  
 
BTNL2_e6_P299Q 
5'_FLANK:AGAAATGCAGCCGATGTGCTCTTCAGATGGGTGGTTCCCACAGCCCCACGTGC 
OBSERVED:CA/AG 
3'_FLANK:TGGAGGGACATGGAAGGAAAGACGATACCATCATCTTCCCAGGCCCTGACTC 
 
BTNL2_e6_M286I 
5'_FLANK:CTTCCCCACTGATCACTGTGGAGGGGCAAGAAGATGGAGAAATGCAGCCGAT  
OBSERVED:G/A 
3'_FLANK:TGCTCTTCAGATGGGTGGTTCCCACAGCCCCACGTGCCATGGAGGGACATGGA 
 
BTNL2_e6_P285L 
5'_FLANK:GGTTCTTCCCCACTGATCACTGTGGAGGGGCAAGAAGATGGAGAAATGCAGC 
OBSERVED:C/T 
3'_FLANK:GATGTGCTCTTCAGATGGGTGGTTCCCACAGCCCCACGTGCCATGGAGGGACA 
 
BTNL2_e5_S240L 
5'_FLANK:TGACGCCATTGACGAGGGCAGACTGACCCTGCAGATACTCAGTGCCAGACCTT 
OBSERVED:C/T 
3'_FLANK:GGACGACGGGCAGTACCGCTGCCTTTTTGAAAAAGATGATGTCTACCAGGAGG 
 
BTNL2_i4_A239T 
5'_FLANK:TGTGTTACCTGACACTTTGGGGGCTCATGGAGATTCCAGTGAGCATCAGATGG 
OBSERVED:A/T 
3'_FLANK:CACCTATAGGAAGCATGGCATCATCTCTGTTCTATGTGTTGAGGGGAAAGGGA 
 
BTNL2_i3_C1900T 
5'_FLANK:GCTGCTGGCCGTGTCTGAGCATCGCATCCAAGATAAAGATGGCCTGTTCTATG 
OBSERVED:C/T 
3'_FLANK:GGAAGCCACCCTGGTGGTCAGGAACGCCTCTGCAGAGTCTGTGTCCTGCTTGG 
 
BTNL2_i3_A1837G 
5'_FLANK:GTGCACTGCAAGGGGCTGGTTCCCAGAGCCCCAGGTGTATTGGGAAGACATCC 
OBSERVED:G/A 
3'_FLANK:GGGAGAGAAGCTGCTGGCCGTGTCTGAGCATCGCATCCAAGATAAAGATG 
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BTNL2_e3_W94R 
5'_FLANK:GCACAGGGATGGAGTGGAGGTGACTGAGATGCAGATGGAGGAGTACAGAGGC 
OBSERVED:T/A 
3'_FLANK:GGGTAGAGTGGATAGAGAATGGCATTGCAAAGGGAAATGTGGCACTGAAGAT 
 
BTNL2_e3_H60H 
5'_FLANK:GGGAAGATGCCCTGTTAACCTGCCAGCTACTCCCCAAGAGGACCACAATGCA 
OBSERVED:C/T 
3'_FLANK:GTGGAGGTGAGGTGGTACCGCTCAGAGCCCAGCACACCTGTGTTTGTGCACAG 
 
BTNL2_i1_G1717T 
5'_FLANK:GGATGTGATCAGTAATTGCAGAGAAATGGAGCCAAGCCCATTTCACTGACTGT 
OBSERVED:G/T 
3'_FLANK:CAGGGGTTGATGTGGATTCTCTGCTAAGACTGCATAACCAATGGAAGCCATGG 
 
HLA-DRA-G231C 
5'_FLANK:ACAAACAGGACAACAACGACAACAAATCAAGTATTTAAGACTGTTGGTCAAT  
OBSERVED:G/C 
3'_FLANK:ACGGACAGACTCTTTAACCCCAATCTGAGTTCTAGACAGGGATATACCTGAAG 
 
HLA-DRA-G224A 
5'_FLANK:GTTCTTAAACAAACAGGACAACAACGACAACAAATCAAGTATTTAAGACTGTT  
OBSERVED:G/A 
3'_FLANK:GTCAATGACGGACAGACTCTTTAACCCCAATCTGAGTTCTAGACAGGGATATA 
 
HLA-DRA-G196A 
5'_FLANK:TACTCCGTTCATTGGATAAAGAAGTAAAGTTCTTAAACAAACAGGACAACAAC 
OBSERVED:G/A 
3'_FLANK:ACAACAAATCAAGTATTTAAGACTGTTGGTCAATGACGGACAGACTCTTTAAC 
 
HLA-DRA-G127A 
5'_FLANK:GAAAAATATTTTGAGATGACGCATCTGTTGCTAGGGGAAGGGTTCTTGCAAAG 
OBSERVED:G/A 
3'_FLANK:GTCCAGGACACAAGATACTCCGTTCATTGGATAAAGAAGTAAAGTTCTTAAAC 
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Frequencies of listed variations in control population: 
 
AL034394_T26355G:T=0.93/G=0.07 
AL034394_A26270C:A=0.74/C=0.26 
AL034394_C20283T:C=0.97/T=0.03 
AL034394_C16965T:C=0.85/T=0.15 
AL034394_C12339T:C=0.86/T=0.14 
AL034394_T10552C:T=0.86/C=0.14 
BTNL2_e6_E360Amb:G=0.996/T=0.004 
BTNL2_e6_P299Q:CA=0.85/AG=0.15 
BTNL2_e6_M286I:G=0.85/A=0.15 
BTNL2_e6_P285L:C=0.85/T=0.15 
BTNL2_e5_S240L:C=0.98/T=0.02 
BTNL2_i4_A239T:A=0.97/T=0.03 
BTNL2_i3_C1900T:C=0.92/T=0.08 
BTNL2_i3_A1837G:G=0.92/A=0.08 
BTNL2_e3_W94R:T=0.92/A=0.08 
BTNL2_e3_H60H:C=0.92/T=0.08 
BTNL2_i1_G1717T:G=0.98/T=0.02 
HLA-DRA-G231C:G=0.30/C=0.70 
HLA-DRA-G224A:G=0.30/A=0.70 
HLA-DRA-G196A:G=0.31/A=0.69 
HLA-DRA-G127A:G=0.98/A=0.02 
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9.1.8. Sequence data  
 
Stammers et al. 144 4 initially described BTL-II sequence information. Six separate entries in 
the GenBank corresponded to each exon: AF186588, AF186589, AF186590, AF186591, 
AF186592 and AF186593, all located in the BAC insert AL935032. 
 
The revised structure of the BTNL2 gene comprises 8 exons: 
 
Exon 1 
ACCCTTCAGTCTAAGGGGAGGTGACTGGTAAGTTTCAG 
 
Exon 2 
GGAGGATGGTGGATTTTCCAGGCTACAATCTGTCTGGTGCAGTCGCCTCCTTCCTATTCATCCTGCT
GACAATGAAGCAGTCAG 
 
Exon 3 
AAGACTTTAGAGTCATTGGCCCTGCTCATCCTATCCTGGCCGGGGTTGGGGAAGATGCCCTGTTAA
CCTGCCAGCTACTCCCCAAGAGGACCACAATGCACGTGGAGGTGAGGTGGTACCGCTCAGAGCCC
AGCACACCTGTGTTTGTGCACAGGGATGGAGTGGAGGTGACTGAGATGCAGATGGAGGAGTACAG
AGGCTGGGTAGAGTGGATAGAGAATGGCATTGCAAAGGGAAATGTGGCACTGAAGATACACAACA
TCCAGCCCTCCGACAATGGACAATACTGGTGCCATTTCCAGGATGGGAACTACTGTGGAGAAACAA
GCTTGCTGCTCAAAGTAGCAG  
 
Exon 4 
AGAAACTCCAGACTGAGCTGG 
 
Exon 5 
CTTCTTTAAAAGTGAATGGACCTTCCCAGCCCATCCTCGTCAGAGTGGGAGAAGATATACAGCTAA
CCTGTTACCTGTCCCCCAAGGCGAATGCACAGAGCATGGAGGTGAGGTGGGACCGATCCCACCGTT
ACCCTGCTGTGCATGTGTATATGGATGGGGACCATGTGGCTGGAGAGCAGATGGCAGAGTACAGA
GGGAGGACTGTACTGGTGAGTGACGCCATTGACGAGGGCAGACTGACCCTGCAGATACTCAGTGC
CAGACCTTCGGACGACGGGCAGTACCGCTGCCTTTTTGAAAAAGATGATGTCTACCAGGAGGCCAG
TTTGGATCTGAAGGTGGTAG 
 
Exon 6 
GTCTGGGTTCTTCCCCACTGATCACTGTGGAGGGGCAAGAAGATGGAGAAATGCAGCCGATGTGCT
CTTCAGATGGGTGGTTCCCACAGCCCCACGTGCCATGGAGGGACATGGAAGGAAAGACGATACCA
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TCATCTTCCCAGGCCCTGACTCAAGGCAGCCACGGGCTGTTCCACGTGCAGACATTGCTAAGG
GTCACAAACATCTCCGCTGTGGACGTCACTTGTTCCATCAGCATCCCCTTTTTGGGCGAGGAGAAA
ATCGCAACTTTTTCTCTCTCAG  
 
Exon 7 
AGTCCAGGATGACATTTTTGTGGAAAACACTGCTTGTTTGGGGATTGCTTCTTGCTGTGGCTGTAGG
CCTGCCCAGGAAGAGGAGCTGAAAAGAG 
 
Exon 8 
TGAATGTGACATTGGCTTCAAACACAGCTCACCTGAGACTGATTTCTTCTGAACAGAACAAGCGTG
TGATCCATGGACATTCAGGCAGCCAGATATCCCACAGAGATCTGACTATCTGCTCTATGGGC 
 
 
The protein structure of the revised BTNL2 has two splice variants.  
 
The long splice form of the BTNL2 protein: 
 
MVDFPGYNLSGAVASFLFILLTMKQSEDFRVIGPAHPILAGVGEDALLTCQLLPKRTTMHVEVRWYRSE
PSTPVFVHRDGVEVTEMQMEEYRGWVEWIENGIAKGNVALKIHNIQPSDNGQYWCHFQDGNYCGETS
LLLKVAEKLQTELASLKVNGPSQPILVRVGEDIQLTCYLSPKANAQSMEVRWDRSHRYPAVHVYMDG
DHVAGEQMAEYRGRTVLVSDAIDEGRLTLQILSARPSDDGQYRCLFEKDDVYQEASLDLKVVGLGSSP
LITVEGQEDGEMQPMCSSDGWFPQPHVPWRDMEGKTIPSSSQALTQGSHGLFHVQTLLRVTNISAVDV
TCSISIPFLGEEKIATFSLSESRMTFLWKTLLVWGLLLAVAVGLPRKRS 
 
The short splice for m of the BTNL2 protein: 
 
MVDFPGYNLSGAVASFLFILLTMKQSEDFRVIGPAHPILAGVGEDALLTCQLLPKRTTMHVEVRWYRSE
PSTPVFVHRDGVEVTEMQMEEYRGWVEWIENGIAKGNVALKIHNIQPSDNGQYWCHFQDGNYCGETS
LLLKVAEKLQTELASLKVNGPSQPILVRVGEDIQLTCYLSPKANAQSMEVRWDRSHRYPAVHVYMDG
DHVAGEQMAEYRGRTVLVSDAIDEGRLTLQILSARPSDDGQYRCLFEKDDVYQEASLDLKVVWVLPH 
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9.2. Additional experiments on BTNL2 
 
This chapter includes unpublished (to this date) laboratory experiments performed with 
collaborators: Dr.K.A.Gaede (BAL extraction), Dr.P.Rosenstiel Dr.K.Huse cDNA (cloning 
and expression experiments), Mario Albrecht (in silico  analysis). 
 
9.2.1. Preparation of Bronchoalveolar lavage cell samples  
 
Bronchoalveolar lavage (BAL) cell samples were taken from eight chronic sarcoidosis 
patients with overt disease (average age: 44.8 ± 3.6 years), and four controls (avera ge age: 
32.7 ± 8.2 years). All sarcoidosis patients showed clinical signs of active disease. Four 
patients, who underwent bronchoscopy for evaluation of chronic coughing and were 
retrospectively found to be free of inflammatory or malignant disorder, serve d as additional 
controls. All patients and controls gave written informed consent to the study. The protocol 
was approved by the institutional review board of the institution. BAL was performed as 
previously described 175. Mean recovery was 62.5% and the average cell number/100ml of 
BAL cells was 12.9 ± 3.3x106. The cells were centrifuged at 500 x g and washed three times 
with phosphate buffered saline (PBS) at +4°C. The cell suspensions used in this study 
contained 85.4 ± 5.3% alveolar macrophages. Total cellular RNA was extracted from BAL 
cells using TRIzol reagent® (Invitrogen, Paisley, UK) according to the manufacturer’s 
recommendations. To remove contaminating genomic DNA, total RNA samples were treated 
with deoxyribonuclease I (Boehringer Mannheim, Mannheim, FRG). Reverse transcription 
was performed on equal amounts of total RNA per sample, using 1x First Strand Buffer 
(Invitrogen, Paisley, UK), 2' -deoxynucleotide 5'triphosphate (Invitrogen, Paisley, UK), 
dithiothreitol, oligo (dT)12-18 primer (Invitrogen, Paisley, UK), RNasin, and Superscript RT 
reverse transcriptase (RT) (Invitrogen, Paisley, UK). Prior to addition of the RT, the RT 
mixture was incubated for 5 min at 65°C, followed by an incubation period of 5 min at 37°C. 
After addition of the enzyme, incubation was continued for another 1 h at 37°C. For quality 
control, each RNA sample was subjected to RT-PCR omitting the RT. 
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9.2.2. BTNL2 expression experiment 
 
In order to verify the published BTNL2  gene model, conserved exons were searched in mouse 
and human genomic sequences (Twinscan gene predictions, genome.ucsc.edu) and related to 
predicted splice sites (www.fruitfly.org/seq_tools/splice.html). The predicted exons were 
verified by rt-PCR in a pool of cDNA tissue samples (Human Multip le Tissue cDNA Panels I 
and II, Clontech; data not shown) and by subsequent cloning and sequencing of PCR 
products. Primers for rt-PCR and cDNA cloning are listed in table 21.  
 
Table 21. Primers for rt-PCR and cDNA cloning . The position of the primer sequences in 
the revised BNTL2 transcript refers to the 5’ end for forward primers and to the 3’ end for 
reverse primers. 
 
Primer Sequence Position in cDNA 
BTNL2f1 ACCCTTCAGTCTAAGGGGAG 1 
BTNL2f2 TGGTGGATTTTCCAGGCTAC 45 
BTNL2f3 TTAGAGTCATTGGCCCTGCT 126 
BTNL2r1 CTTCAGTGCCACATTTCCCT 370 
BTNL2r2 CTTCTCCCACTCTGACGAGG 542 
BTNL2f4 CCTGCAGATACTCAGTGCCA 733 
BTNL2r3 CGAAGGTCTGGCACTGAGTA 760 
BTNL2f5 AGTACCGCTGCCTTTTTGAA 771 
BTNL2r4 TTCAAAAAGGCAGCGGTACT 790 
BTNL2f6 TCGTCTTTCCTTCCATGTCC 958 
BTNL2f7 CGGAGATGTTTGTGACCCTT 1042 
BTNL2f8 ACTTGTTCCATCAGCATCCC  1073 
BTNL2r5 TGGATCACACGCTTGTTCTG 1282 
BTNL2r6 GCCCATAGAGCAGATAGTCAG 1337 
 
For expression analysis, nested PCR in THP-1 cells and BALs was performed with primers 
5’-TTAGAGTCATTGGCCCTGCT and 5’ -GCCCATAGAGCAGATAGTCAG for the first, 
and 5’ -AGTACCGCTGCCTTTTTGAA and 5’-TGGATCACACGCTTGTTCTG for the 
second round of amplification.  
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9.2.3. Verification of the splicing effects of rs2076530 
 
Matching pairs of cDNA and DNA from lymphoblastoid cell lines (upper part) and from the 
peripheral blood of normal controls (lower part) were genotyped and the BTNL2 splice forms 
evaluated by rtPCR, cloning and sequencing of PCR products.  
 
Table 22. BTNL2 rs2076530 genotype correlation with two different splicing forms. 
Source rs2076530 genotype  no. samples  no. clones 4 bp present 4 bp deleted 
cell lines GG 4 64 64 0 
 AG 5 98 22 76 
 AA 3 131 0 131 
leucocytes GG 1 36 36 0 
 AG 3 36 9 27 
 AA 3 35 0 35 
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9.2.4. In silico BTNL2 protein analysis 
 
Domain architecture of the BTNL2  gene product was derived computationally. The figure 17 
shows a sequence-structure alignment of BTNL2 to the IgV domain and the following IgC 
domain of B7-1 (PDB identifier 1i8l). Coloured frames embrace the putative N-terminal 
signal peptide (light green), the three immunoglobulin-like domains IgV-IgV-IgC (blue), and 
a potential C-terminal PKA phosphorylation motif (dark green). The DSSP secondary 
structure of 1i8l and the corresponding predictions by the PSIPRED server for BTNL2 are 
depicted on top and below each alignment row, respectively (curled lines: a-helices, 
horizontal arrows: b-strands). The predicted transmembrane helices are annotated at the C-
termini. Blue and yellow boxes highlight identical and conserved residues, respectively. The 
disease-associated sequence truncation of BTNL2 , variants P285L, M286I and P299Q, a 
strictly conserved tryptophan W300, and the adjacent disulfide bond between residues C287 
and C341 are annotated by text labels. Asterisks in the IgV domain of B7-1 indicate residues 
involved in binding to the CTLA-4 receptor; solid circles mark residues participating in the 
dimer interface of B7-1. 
Fig.17. In silico BTNL2 protein alignement to the B7 -1 molecule  
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9.2.5. Computational 3D structure model of the second IgV domain and the following 
IgC domain of the BTNL2 homodimer 
 
3D structure model of the second IgV domain (upper half) and the following IgC domain 
(lower half) of the BTNL2 homodimer were derived computationally. The model was created 
using the B7-1 structure as a template. The location of the C-terminal truncation and of 
sequence variants P285L, M286I and P299Q are annotated. A stabilising disulfide bond 
between residues C287 and C341, which are located adjacent to variants P285L and M286I, is 
highlighted in brown. A strongly conserved tryptophan W300 located close to variant P285L 
and the disulfide bond are highlighted in light green. The putative binding site of BTNL2 to a 
yet unknown receptor is marked in the IgV domain in yellow. This site has been deduced 
from the location of residues interacting with the B7-1 receptor CTLA-4. Residues 
participating in the dimerisation interface of the IgV domain are shown in dark blue. The 
figure also indicates the predicted transmembrane helix and a potential PKA phosphorylation 
site at the C-terminus of BTNL2. 
 
Fig.18. Second IgV domain and the following IgC domain of the BTNL2 homodimer 
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